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Abstract 
 
 
 Mammography is the current standard imaging method for detecting breast cancer by using 
x-rays to produce 2D images of the breast. However, with mammography alone there is 
difficulty determining whether a lesion is benign or malignant and reduced sensitivity to 
detecting lesions in dense breasts. Ultrasound imaging used in conjunction with mammography 
has shown valuable contributions for lesion characterization by differentiating between solid and 
cystic lesions. Conventional breast ultrasound has high false positive rates; however, it has 
shown improved abilities to detect lesions in dense breasts. Breast ultrasound is typically 
performed freehand to produce anterior-to-posterior 2D images in a different geometry (supine) 
than mammography (upright). This difference in geometries is likely responsible for the finding 
that at least 10% of the time lesions found in the ultrasound images do not correspond with 
lesions found in mammograms. To solve this problem additional imaging techniques must be 
investigated to aid a radiologist in identifying corresponding lesions in the two modalities to 
ensure early detection of a potential cancer.  
 This dissertation describes and validates automated deformable mapping methods to register 
and relate corresponding lesions between multi-modality images acquired using 3D 
mammography (Digital Breast Tomosynthesis (DBT) and dedicated breast Computed 
Tomography (bCT)) and 3D ultrasound (Automated Breast Ultrasound (ABUS)). The 
methodology involves the use of finite element modeling and analysis to simulate the differences 
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in compression and breast orientation to better align lesions acquired from images from these 
modalities. Preliminary studies were performed using several multimodality compressible breast 
phantoms to determine breast lesion registrations between: i) cranio-caudal (CC) and 
mediolateral oblique (MLO) DBT views and ABUS, ii) simulated bCT and DBT (CC and MLO 
views), and iii) simulated bCT and ABUS. Distances between the centers of masses, dCOM, of 
corresponding lesions were used to assess the deformable mapping method.  
 These phantom studies showed the potential to apply this technique for real breast lesions 
with mean dCOM registration values as low as 4.9 ± 2.4 mm for DBT (CC view) mapped to 
ABUS, 9.3 ± 2.8 mm for DBT (MLO view) mapped to ABUS, 4.8 ± 2.4 mm for bCT mapped to 
ABUS, 5.0 ± 2.2 mm for bCT mapped to DBT (CC view), and 4.7 ± 2.5 mm for bCT mapped to 
DBT (MLO view). All of the phantom studies showed that using external fiducial markers 
helped improve the registration capability of the deformable mapping algorithm. An IRB-
approved proof-of-concept study was performed with patient volunteers to validate the 
deformable registration method on 5 patient datasets with a total of up to 7 lesions for DBT (CC 
and MLO views) to ABUS registration. Resulting dCOM’s using the deformable method showed 
statistically significant improvements over rigid registration techniques with a mean dCOM of 11.6 
± 5.3 mm for DBT (CC view) mapped to ABUS and a mean dCOM of 12.3 ± 4.8 mm for DBT 
(MLO view) mapped to ABUS.  
 The present work demonstrates the potential for using deformable registration techniques to 
relate corresponding lesions in 3D x-ray and 3D ultrasound images. This methodology should 
improve a radiologists’ characterization of breast lesions which can reduce patient callbacks, 
misdiagnoses, additional patient dose and unnecessary biopsies. Additionally, this technique can 
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save a radiologist time in navigating 3D image volumes and the one-to-one lesion 
correspondence between modalities can aid in the early detection of breast malignancies.   
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Chapter 1  
Introduction 
 
 
1.1 Significance of Work  
 According to the most recent statistics, breast cancer accounts for 30% of all new cancer 
diagnoses in women and 1 in 8 women in the United States will develop breast cancer during 
their lifetime.1 Breast cancer incidence rose in the 1980s. This is largely attributed to the increase 
in breast cancers detected with the increase in mammography screening.1 A decline in breast 
cancer incidence was observed in the early 2000s. This is attributed to the reduction in the use of 
menopausal hormonal therapy, which was associated with an increase in breast cancer risks.2 
Breast cancer incidence has remained stable in the United States over the last decade.1 However, 
breast cancer has the second highest mortality rate behind lung cancer for women in the United 
States. Early detection and screening initiatives have been strongly encouraged in order to detect 
breast cancer while it is localized within the breast and therefore is the most treatable. Based on 
the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) programs 
localized cancers that have not spread beyond the breast have a 99% 5-year relative breast cancer 
survival.3 This relative 5-year survival rate decreases to 85% if the cancer has spread to the 
neighboring lymph nodes. The 5-year relative survival rate decreases to 27% if the cancer cells 
have spread to other parts of the body by metastasis3. Therefore, in an effort to reduce breast
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 cancer mortality it is important to have effective medical diagnostic equipment available to aid 
in early diagnosis.  
 Mammography is the current standard imaging method for breast cancer screening and 
diagnosis. However, the benefits of screening mammography vary by age. Women between the 
ages of 50-69 have the greatest overall benefit of screening mammography for breast cancer 
detection and it was concluded by the U.S. Preventative Services Task Force (USPSTF) that 
mammography every 2 years has approximately the same benefit as mammography every year 
while reducing the associated risk.4 The USPSTF recommends mammography every two years 
for women between the ages of 50-69.5 For women between the ages of 40-49, the overall 
benefit is less than older women as various study findings vary.4,6 Women ages 40-49 have a 
lower overall risk for breast cancer and tend to have dense breast tissue which leads to a rise in 
false positive screening results in comparison to older women.7 For this reason, the USPSTF 
does not recommend routine mammography for women ages 40-49. 5 Instead, the USPSTF and 
the American College of Physicians recommend that women within this age group discuss the 
benefits and risks with their health care providers to make an informed decision regarding the 
start and frequency of mammography screening.5,8 For women over the age of 70, there are few 
studies and no randomized control trials to evaluate the benefits of mammography screening. 
The USPSTF recommends mammography for every 2 years for women between the ages of 70-
74. Currently, there isn’t enough evidence to recommend for or against routine mammography 
above the age of 75.5 Most major health organization, recommend that women over the age of 70 
continue to get screening mammograms on a regular basis as long as they are in good health.5,9 
 However, several studies have raised questions against the recommendations of the USPSTF 
as their recommendations neglect scientific evidence in regard to the mortality benefit of 
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mammography screening.10,11 A study by Hendricks and Helvie examined the evidence 
considered by the USPSTF and their results support mortality benefit to annual screening 
mammography for women over the age of 40, as the potential harms in screening are minor in 
comparison.10 Their study shows a 36.9% mortality reduction from using the annual screening of 
women between the ages of 40-84 which would save 71% more lives that the USPSTF 
recommendation which only had a 23.2% mortality reduction.10 A more recent study by 
Hendricks et al. further supports that screening mammography reduces the mortality rate by 
showing between 284,000-615,500 breast cancer deaths have been averted through the use of 
screening mammography since 1989.12 A study by Kopans also disagrees with the USPSTF 
guidelines and states there is no biological or scientific reason to delay mammography screening 
for women to the age of 50.11  
 Ultrasound imaging does not use ionizing radiation like mammography. Instead ultrasound 
imaging uses sound waves in order to produce images of the breast. Conventional ultrasound 
imaging is performed freehand in a different geometry (supine) than mammography (upright), 
which makes it difficult to relate corresponding images between the two modalities. False 
positive results are a problem when searching for secondary masses and the detection in high risk 
or screening populations with the use of conventional ultrasound. 13,14 A study by Conway found 
that at least 10% of the time, lesions found in ultrasound images do not correspond to those in 
mammography.15  
 Ultrasound imaging used in conjunction with mammography in diagnosis has improved the 
characterization of breast lesions because of its ability to differentiate between solid and cystic 
(fluid-filled) lesions. 16–18 A study by Wilczek et al. found that adding 3D automated breast 
ultrasound (ABUS) imaging as an adjunct to screening mammography has shown an increase in 
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cancer detection for women with extremely dense or heterogeneously dense breast tissue.19 A 
study by V. Giuliano and C. Giuliano found that mammography followed by ABUS in breast 
cancer screening resulted in increased sensitivity (76.0% to 97.7%) and increased specificity 
(98.2% to 99.7%) over screening using mammography alone.20 
 One solution to the problem of lesions found in ultrasound images not corresponding to 
those in mammograms is the development of a combined x-ray/ultrasound system that would 
image the breast in the same mammographic geometry using special modality compression 
paddles. A combined system addresses these problems by first taking a 3D digital x-ray image of 
the breast in the compressed mammography state and then to image using ultrasound by using 
the same compression with the use of high-frequency ultrasonic transducers (ranging from 9 – 15 
MHz) across a specialty dual- modality compression paddle. A dual x-ray/ultrasound system 
creates co-registered 3D x-ray and 3D ultrasound images in the same geometry and allows the 
potential for the use for advanced x-ray and ultrasound modes which provide additional 
information about breast tissues that are not currently available using conventional 
mammography and ultrasound.21–31  
 A study by Padilla et al. showed improved discrimination of malignant lesions when adding 
the 3D ultrasound to 3D x-ray images in an initial reader study using a dual system.26 However, 
there are challenges for automated ultrasound scanning in the mammographic geometry in a 
dual-modality breast imaging systems. These challenges include limited penetration depth and 
difficulty achieving good transducer coupling around the peripheral breast margins. A study by 
Sinha et al. found that an adhesive spray that preserves image quality worked best for coupling 
the breast to a solid TPX plastic compression paddle. This study also showed that this adhesive 
spray minimized motion and that a highly viscous ultrasound gel was most effective for 
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transducer coupling along the breast peripheral margins.21 A study by Li. et al., showed enhanced 
breast to paddle contact and a reduction in gaps along the breast peripheral margins using a gel 
detainment dam with the dual-modality breast imaging system.28 Lecarpentier et al. evaluated the 
ultrasound transmission properties of two dual modality mesh compression paddles.32 They 
found that by all measures, polyester mesh fabrics of 1 and 2 mm spacing outperformed the 
original solid TPX paddle. A study by Larson et al., compared the use of single-sided and dual-
sided ultrasound in the mammographic setup using a breast phantom and reported improvement 
using dual-sided ultrasound in image quality from a mean contrast-to-noise ratio of 57% (single-
sided ultrasound) to 79% (dual-sided ultrasound) and breast volume coverage from 59% (single-
sided ultrasound) to 89% (dual-sided ultrasound).33  
 The disadvantage to the previous methods described above is that all studies to date have not 
completely addressed issues of poor ultrasound transducer coupling along the breast periphery in 
the mammographic geometry. Additionally, a combined 3D x-ray/ultrasound system is not yet 
FDA approved or commercially available. An alternative to the combined system is to image the 
breast using a 3D x-ray modality (e.g. DBT or dedicated breast CT (bCT)) and then image the 
breast using an ABUS modality in their own respective geometries and then use a deformable 
mapping technique to relate corresponding lesions. This has the advantage of better acoustic 
coupling and improved breast coverage with ultrasound. However, this method has greater 
technical difficulty in relating corresponding lesions due to the differences in patient positioning 
and compression during image acquisition.   
 This thesis describes and validates novel automated deformable mapping methods to register 
lesions between 3D mammography (DBT and bCT) and 3D ultrasound (ABUS) breast image 
datasets. This method involves the use of finite element modeling and analysis to simulate the 
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differences in compression and breast orientation to better relate corresponding lesions between 
these modalities. This utilizes imaging equipment that is often already commercially available 
with small changes in current imaging protocols. Such a method should help simplify the time it 
takes a radiologist to review breast images and improve radiologist’s characterizations of breast 
lesions, which in turn should reduce patient callbacks, misdiagnoses, and negative biopsies. This 
method can also be especially beneficial for women with dense breasts or multiple breast lesions.  
1.2 Dissertation Outline 
 This dissertation serves as a detailed investigation of novel deformable mapping techniques 
to relate corresponding lesions between 3D x-ray (DBT, and simulated bCT) and 3D automated 
breast ultrasound images to address issues related to multimodality breast registration. These 
investigations have allowed the development of deformable mapping algorithms using breast test 
objects (phantoms) through extensive simulation using biomechanical modeling. Additionally, 
for DBT to ABUS registration, these algorithms are tested with clinical datasets. The body of 
this dissertational text is organized as follows:  
 Chapter 2: This chapter will provide background information of topics that provide a 
framework to this thesis. It will begin with a discussion of the breast anatomy and understanding 
the importance of breast density. Next, the imaging modalities that are used are further 
described, specifically looking at their differences in patient positioning and the use of 
compression during image acquisition. This chapter also looks at a preliminary study of an 
ultrasound camisole that was designed and tested to be used in ABUS imaging for the patient 
study discussed in Chapter 6. Lastly, this chapter will go over the fundamental principles of the 
FEM which is used as the primary tool for registration between lesions in modalities. 
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 Chapter 3: This chapter describes the development of a deformable mapping algorithm that 
uses the FEM to relate corresponding lesions between the DBT cranio-caudal (CC) view and a 
single ABUS view using two breast phantoms (test objects). This chapter provides the 
framework for all the deformable registration cases analyzed within this thesis. It compares the 
validity of this method using locational information from external fiducial markers to aid in the 
registration process. The results show up to 28% improvement in lesion registration with the use 
of external fiducial markers during registration analysis. 34 
 Chapter 4: This chapter extends upon the work in Chapter 3, by showing results of 
registering CC and medial lateral oblique (MLO) DBT views to an ABUS volume using the 
automated deformable registration algorithm. One compressible breast phantom with 20 
simulated lesions was used for this analysis. The results show improvements in registering 14 to 
17 corresponding lesions from the DBT (CC view) to ABUS and 9 to 17 registered lesions for 
the DBT (MLO view) to ABUS when external fiducial markers were employed in the analysis.35 
 Chapter 5: This chapter describes the development of an automated deformable mapping 
algorithm to register bCT images to DBT (CC and MLO views) and to register bCT images to 
ABUS images. This study uses the same compressible phantom from Chapter 4 that contains 20 
simulated lesions. The algorithm uses FEM to simulate plates that compress the bCT model to 
register to DBT (CC and MLO views) and ABUS views. Using external fiducial markers there 
was improvement up to 49% in the reduction in dCOM for bCT to ABUS registration, 57% 
improvement in the reduction in dCOM for bCT to DBT (CC) registration, and 40% improvement 
in the reduction in dCOM for bCT to DBT (MLO) registration.36 
 Chapter 6: This chapter describes an IRB-approved proof-of-concept validation study with 
patient image datasets containing known masses using the deformable registration techniques 
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described in Chapters 3 and 4. The deformable mapping algorithm is tested on 5 clinical data sets 
for DBT (CC and MLO) registration to ABUS. This study compares the deformable FEM-based 
registration using none or various external marker combinations (specific quantities and 
locations). The deformable results are compared to results from using a rigid registration. Results 
show up to 5 times improvement using the deformable method over rigid registration based on 5 
subjects with 13 total registrations. This study shows the superiority of the deformable 
registration technique to rigid registration and displays how the deformable registration 
algorithm can be translated for clinical use.   
 Chapter 7: This chapter summarizes the major findings, conclusions, and limitations of this 
dissertation. It discusses future works that include registration and stitching of multiple ABUS 
views for improvement in the deformable registration to ABUS images and the potential use of 
ultrasound tomography to DBT lesion registration.  
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Chapter 2  
Breast Imaging Acquisition and Finite Element Methodology 
 
 
 This chapter will give an overview of the breast imaging techniques and registration 
methods used within this thesis.  
2.1 Breast Anatomy and Density 
 
Figure 2.1 Schematic of adult female breast anatomy (figure used with permission from GE Healthcare37) 
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 Familiarity with breast anatomy is important to understand how the breasts’ various 
structural components (e.g. glands, skin, ligaments, fat and ducts) can affect the breasts’ shape 
during imaging positioning and while the breast is under compression. The breasts are located on 
the anterior portion of the chest (over the pectoralis major muscle) and are scientifically known 
as the mammary glands. The female breast is predominately composed of skin, lobules, ducts, 
adipose, and the connective tissue matrix. The glandular lobules and ducts used for milk 
secretion are surrounded by connective tissues. Each breast consists of 15-20 lobes that are 
separated by adipose (fatty) tissue. Each lobe constrains smaller compartments known as lobules. 
The lobules are composed of clusters of milk secretion glands known as alveoli within the 
connective tissue. Milk ducts attach to the glandular lobules. Milk ducts and the glandular 
lobules are typically referred to as fibroglandular tissue. Each breast has a nipple that is a 
pigmented projection on the exterior breast where milk is excreted from the body. The 
suspensory ligaments of the breasts (Cooper’s ligaments) run between the skin and breast fascia 
to add support for each breast. These ligaments tend to become looser as a woman ages. A 
schematic of the breast’s anatomy is shown in Figure 2.137. 
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Figure 2.2 BI-RADS breast density category examples from mammography (figure used with permission from GE 
Healthcare38) 
 Breast density is a measure of the amount of dense (glandular and fibrous) tissue volume to 
the total breast volume as seen on a mammogram.39 To have a higher concentration of 
fibroglandular tissues constitutes a dense breast. Currently, radiologists use the Breast Imaging 
Reporting and Data System, or BI-RADS40, to classify breast density into 4 major categories that 
go from breasts that are almost entirely comprised of fatty tissue to extremely dense breast tissue. 
Examples are shown in Figure 2.2. 38 For women with extremely dense breast the sensitivity of 
mammography is lowest for which an ultrasound examination provides higher sensitivity.  
  Breast density is one of the strongest predictors of breast cancer risk. Research now suggests 
that women with high breast density are 4-5 times more likely to develop breast cancer than 
women with low breast density.41,42 Although the sensitivity of mammography for detecting 
breast cancer is 85%, a study by Kolb et al. showed that for women with dense breast tissue 
mammography sensitivity is reduced to 47.8-64.6%.14 High breast density is very common and 
accounts for 40-50 percent of women in the U.S. population between ages 40-74.43 Dense breasts 
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are more common for younger women and higher breast density is higher among women of 
healthy weight than women who are obese.43 Additionally, cancer developed in women with 
dense breasts are typically associated with more aggressive tumor characteristics such as being 
larger in size, higher in grade, and estrogen receptor negative over breast masses found in fatty 
breasts. 42 
 Unfortunately, to date, there is not a consensus as to whether a specific modality or 
supplementary screening should be used for women with dense breasts. However, a medical 
provider may suggest additional types of breast imaging to be done from a suspicion in a 
screening mammogram. For women with dense breasts, supplementary screening can be 
beneficial for the diagnosis of breast cancer and usually involves using ultrasound. Therefore, a 
method would be needed to relate lesions between the x-ray and ultrasound modalities.  
2.2 Digital Breast Tomosynthesis  
 Digital breast tomosynthesis, DBT, is an advanced form of breast imaging and known as a 
3D form of digital mammography. In mammography, typically two 2D breast images, or 
mammograms, are taken of the breast during a screening exam. The breast is compressed 
between a plastic compression paddle and an imaging detector. There are several compression 
types, the two types that this thesis focuses on are known as the cranial-caudal (CC) and the 
medial lateral oblique (MLO) compressions. For CC compression, the detector and compression 
paddle are parallel to the floor and the compression paddle compresses the breast downward to 
the detector to produce a top-to-bottom view of the breast also known as the CC view. CC 
compression is shown in Figure 2.3(a). For MLO compression, the detector and compression 
paddle are angled to approximately 45º from the vertical and compresses the breast from the 
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medial to lateral breast margins. The MLO view incorporates imaging of the axillary and 
shoulder regions, and the pectoral muscle. MLO compression is shown in Figure 2.3(b).  
 
Figure 2.3 Examples of mammographic compression types of a breast mimicking test device for (a) cranio-caudal 
compression and (b) medial lateral oblique compression Note: The sheer fabric is typically not used on the detector 
plate during breast imaging 
 Breast compression is necessary to produce improved image quality and reduce the dose to 
the patient. However, since in mammography a single 2D image which can cause abnormal 
tissue to be hidden due to the superposition of tissues. In DBT imaging, the x-ray tube takes 
multiple projections while moving across a limited angled arc while the breast is compressed in 
the mammographic geometry. This allows multiple images of each breast to be taken at various 
angles as shown in Figure 2.444. These digital projections are reconstructed using computer 
algorithms to create quasi-3D images of the breast. These projections can help minimize tissue 
superposition and make it easier to distinguish lesions within images. Each reconstructed image 
slice shows a different depth within the breast which will show some breast structures in and out 
of focus. Due to the limited tomographic angle and the limited number of projections, structures 
that are out of focus typically generate artifacts in the axial direction in their neighboring 
reconstructed slices.   
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Figure 2.4 Schematic of image acquisition of a digital breast tomosynthesis imaging system (figure used with 
permission from Rodríguez-Ruiz et al.44) 
 DBT is able to locate cancers that are masked by the digital mammogram. Studies have 
shown a general decrease in recall rate and an increase in cancer detection with the addition of 
DBT to digital mammography.45–47 Additionally, DBT imaging has been shown to reduce recall 
rates and increase cancer detection rates over mammography in both screening and diagnostic 
uses for imaging women with dense breasts.48  
2.3  Dedicated Breast Computed Tomography  
     Dedicated breast computed tomography, bCT, is a new and emerging technology that unlike 
DBT provides complete 360º angle acquisition of the breast using cone-beam CT. In bCT, the 
patient lies prone (face-down on her stomach). One breast is placed through an opening of the 
table and the CT scanner and detector combination rotate 360 around the breast. Each breast is 
scanned separately in the pendant position without compression as shown in Figure 2.549. By 
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using a cone-beam CT, x-rays are taken for many angles and provide a true 3D image using the 
same amount of radiation as mammography.  
 
Figure 2.5 Schematic of image acquisition for dedicated breast CT imaging system (figure used with permission 
from Lindfors et al.49) 
     In comparison to mammography, bCT is only proposed to be utilized for diagnostic purposes 
unlike mammography which is used for screening and diagnostic breast imaging. bCT is superior 
to mammography in several ways. By providing 3D images, bCT eliminates image artifacts due 
to the superposition of tissue due to the overlaying of normal breast structures in comparison to 
2D mammographic images. By eliminating superposition this could potentially be helpful for 
women with dense breasts where breast tissue often masks suspicious lesions. Imaging with bCT 
also eliminates the need for compression with the use of cone-beam CT. In a study comparing 
the visualization of 180 lesions with non-contrast bCT vs. mammography, Lindfors et al. found 
that the conspicuity of masses was superior for bCT, but the conspicuity of calcifications was 
inferior.50 Similarly, in a study of 24 breast lesions, Kuzmiak et al. found that the reader 
visualization confidence scores for the shape and margins of masses were statistically 
significantly greater for bCT compared to digital mammography.51 Also, the reader visualization 
confidence scores for the morphology and distribution of microcalcifications were statistically 
significantly worse for bCT compared to digital mammography.51  
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     bCT has several advantages over DBT. bCT imaging has demonstrated an improved and 
constant slice sensitivity profile which for DBT imaging worsens with increasing object size and 
as a result of a limited tomographic angle.52 Additionally, bCT provides imaging of the breast at 
any desired plane with near isotropic resolution, whereas DBT imaging suffers from poor 
resolution in the axial plane. bCT is superior in the reduction of superposition by imaging with a 
higher number of projections over a complete 360º angle whereas DBT images have artifacts due 
to the limited acquisition angle and a lower number of projections.53 Lastly, bCT imaging does 
not use compression of the breast which increases patient comfort during image acquisition.   
2.4  Automated Breast Ultrasound  
 Conventional ultrasound imaging uses sound waves to produce real-time 2D images of the 
breasts’ internal structures. While a patient lies supine the patient is imaged by ultrasound with a 
transducer probe and ultrasound gel or lotion that is applied directly to the skin. Ultrasound gel 
or lotion is used as a coupling agent to ensure the high-frequency non-ionizing sound waves 
transmitted from the transducer into the breast. The sound signals are reflected and scattered 
back to the transducer and an algorithm uses the returning sound waves to generate a real-time 
2D image of the breast.   
 Ultrasound breast imaging used in complement with mammography has shown large 
improvement in the characterization of breast lesions,16–18 particularly in women with dense 
breasts54. Ultrasound imaging used in combination with mammography has been shown to 
improve the radiologists’ overall characterization of breast lesions by aiding in the determination 
of whether a lesion is solid or cystic.16–18 Ultrasound imaging has also aided in finding breast 
lesions that were not seen in mammography due to dense breast tissue.54 DBT imaging improves 
lesion detection in comparison to mammography alone. However, DBT imaging can still miss 
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cancers that ultrasound can identify based on lesion similarities located within dense tissue 
structures of the breast.55 A recent study by Chouldhery et al. concluded that 98% of DBT 
screen-detected masses can be properly assessed with a diagnostic ultrasound alone without the 
need for diagnostic mammography. This study indicates the potential for avoiding a diagnostic 
mammogram for the evaluation of majority of DBT screening-detected masses.56 A solid lesion 
may be a non-cancerous lesion (e.g. fibroadenomas) or a cancerous tumor. A fluid-filled lesion 
(e.g. cysts) are also non-cancerous and very common. 
 Conventional breast ultrasound imaging is performed freehand and therefore these 2D 
images are often difficult to reproduce due to high operator dependence. Automated breast 
ultrasound, ABUS, visualizes the breast as a 3D image volume by allowing automated 3D 
ultrasound imaging for the entire breast. ABUS technologies have advantages over conventional 
breast ultrasound in terms of reproducibility, operator independence, and acquisition speed.3–5 
Several studies have also shown the addition of ABUS imaging used in conjunction with 
mammography screening for women with dense breasts (ACR3 or ACR4) has significantly 
improved the breast cancer detection rate with an acceptable recall increase.19,57,58 
 However, ABUS has several disadvantages in comparison to conventional handheld 
ultrasound in relation to breast coverage and lesion diameter.59 A study by An et al. showed that 
conventional handheld ultrasound is superior for the conspicuity of lesions over ABUS for 
lesions in the peripheral breast margins, irregular in shape, non-circumscribed margins, and BI-
RADS category 4 or 5.60 Studies by Chang et al.61 and Jeh et al.62 show the mean diameter of a 
lesion is important for lesion detectability in ABUS, as smaller lesions are often missed and the 
rate of lesion detectability increases with size. Some potential rolls for ABUS are follow-up 
analysis for benign lesions, breast density assessment, and potentially molecular subtypes of 
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breast cancer.59 A study by Padilla et al. indicated increased reader confidence using DBT 
imaging for breast screening with automated breast ultrasound as a complement.63 A study by 
Choi et al., shows comparable diagnostic ability between ABUS and conventional ultrasound and 
reports diagnostic accuracies of 96.5% for conventional ultrasound and 97.7% using ABUS.64 A 
study by Kim et al. shows considerable agreement between masses classified using the BI-RADS 
categories 4 and 5 between ABUS and conventional handheld ultrasound.65  
 The work in this thesis uses the GE Invenia ABUS (GE Healthcare, Milwaukee, WI) system 
for all automated 3D ultrasound imaging. When imaged using ABUS, the patient is positioned 
supine and light anterior to posterior compression is applied by the ABUS transducer panel. This 
system is FDA approved and uses a curved 153 mm long motor-driven ultrasound transducer that 
scans the superior to inferior margins of the breast over a mesh compression paddle that is 
positioned over the breast as shown in Figure 2.666.  
 
Figure 2.6 Invenia ABUS imaging system a. shown from operator view b. shown imaging a patient  
(figure used with permission from GE Healthcare66) 
 
     There are three settings on the Invenia ABUS system (high, medium, and low) based on 
imaging depth, which changes the frequency setting of the transducer. Depending on breast size, 
three or more breast image volumes can be acquired to ensure adequate breast coverage during 
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ABUS imaging. The additional views vary the tilt of the transducer device by imaging the medial 
and lateral extents of the breast to ensure complete breast coverage as shown in Figure 2.766. It 
should be noted that additional views not shown in Figure 2.766 can be performed, however, this 
thesis will not consider those other views. The Invenia ABUS reverse curved transducer has a 
bandwidth of 6 to 15 MHZ and can image up to a 50 mm depth. The transducer travels up to 170 
mm across the mesh compression paddle for each scan or view.   
 
Figure 2.7 Illustration of the three different ABUS scans performed on the right breast for an ABUS exam  
(figure used with permission from GE Healthcare66) 
2.5 Breast Camisole for ABUS Imaging 
 An ultrasound camisole was designed (in collaboration with a local seamstress, see Chapter 
6 Section 6.8) and evaluated to ensure sufficient image quality, restriction in breast motion, and 
feasibility with external fiducial markers. Since the breast does not contain any muscles and is 
comprised of mostly adipose and glandular fascia, it moves relatively freely when various forces 
act on it. The extent of this can be magnified based on a woman’s breast density and age. Since 
ABUS scanning requires taking multiple projections/views of the breast (as shown in Figure 
2.766); a camisole that helps restricts breast motion would be helpful to better relate breast 
anatomy between ABUS views. This camisole material should not impede in ultrasound depth of 
penetration, DOP, and also should not obstruct the use of ultrasound coupling gel or lotion. We 
found that using an ultrasound camisole was helpful in the deformable registration for DBT and 
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ABUS images which will be further discussed in Chapter 6. A picture of this camisole is shown 
in Figure 2.8. The front of the camisole is made of a nylon stretchable mesh material and the 
back of the camisole is made of a cotton-based fabric.  
 
Figure 2.8 Camisole used for ABUS imaging 
 The camisole is sized based off a woman’s band size. A band measurement (underneath the 
breasts and around the woman’s torso to include her back) is taken to determine the adequate 
camisole size. An elastic band is used in the design in order to provide flexibility in fitting 
women with various chest diameters. The camisole should be fitted to the breast similar to a 
sports bra, additional binding clipsa can be used to improve the camisole fit. Other camisoles are 
currently being used in industry to reduce breast motion during breast imaging and radiation 
therapy treatments. The company SonoCine (Reno, NV)b uses an ultrasound camisole to reduce 
breast motion for 3D ultrasound imaging of the breast using their 3D whole breast ultrasound 
                                                 
a https://www.staples.com/Staples-Binder-Clips-Medium-1-1-4-Width-5-8-Capacity-
Black/product_103549?cid=PS:GooglePLAs:103549&ci_src=17588969&ci_sku=103549&KPID=103549&gclid=EAIaIQobChMI6c-
Ch8Pm3wIViANpCh0Zxg4LEAQYBCABEgIjSPD_BwE&akamai-feo=off  
b http://www.sonocine.com/how-it-works/  
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system. In breast radiation therapy treatments, the Chabner XRT Radiation brac is used to 
provide breast support and reproducibility during radiation therapy treatments. 
2.5.1 Depth of Penetration Measurements for Breast Camisole 
 Since this study involves the use of the Invenia ABUS system this camisole material has to 
be tested with the Invenia mesh panel material to ensure it can be effectively used in conjunction 
with the Invenia system. Systematic measurements of DOP are among the tests used for 
ultrasound scanners quality control and can be affected by many factors, including attenuation by 
materials/fabrics. In order to reduce operator dependence on these parameters automated 
methods have been used to determine DOP in ultrasound devices. A study by Gorny et al. 
concluded that measurements based on signal-to-noise (SNR) phantom-images is best suited for 
routine QC for the clinically important DOP and tested three automated methods for its 
measurement.67 
 Software developed by Sandra Larson, Ph.D. of the University of Michigan Department of 
Radiology was used to compute the DOP via minor adaptations of the IEC 61391-2.68 
Modifications used in this measurement include the setting of the transmit energy at the 
ultrasound systems highest setting, the positioning of transmit focal distance at the maximum 
relative to the DOP displayed on the screen, and lastly the setting of the overall system gain and 
time gain control (TGC) to a level high enough that electronic noise is easily displayed on the 
ultrasound imaging monitors. In order to calculate the DOP, the uniform section of a tissue-
mimicking ultrasound phantom was employed using the GE Logic ML6-15-D linear ultrasound 
transducer in a water medium. The Invenia ABUS transducer was not used since it is so large in 
comparison to the phantom; the GE Logic ML6-15-D transducer is often used for breast 
                                                 
c http://civcort.com/ro/breast-positioning/treatment-brassiere/Chabner-XRT-Radiation-Bra1.htm  
 22 
examinations and operates at a similar frequency range as the Invenia. The maximum DOP is 
determined from the image SNR ratio vs. depth. The phantom used for this study was the ATS 
Multipurpose Ultrasound Phantom Model 539d and is suitable over most clinical frequencies 
(between 2-20 MHz) for DOP measurements. It has a speed of sound of 1450 m/s and an 
attenuation coefficient of 0.5 dB/cm/MHz. 
 This method first requires collecting a cine loop of ultrasound noise, N. This acquisition is 
taken “in air” therefore showing the ultrasound systemic noise. The “in air” acquisition was 
taken using the same gain and processing settings described previously. Second, a cine loop of 
ultrasound images is acquired using the phantom in a water medium to determine baseline values 
for DOP using the same gain and processing settings. This is repeated several times. First by 
adding the Invenia mesh material wrapped against the transducer. Then with the Invenia Mesh 
material still in use, five commercially available fabrics (nylon or polyester based) were tested 
with the Invenia mesh in the water medium by performing a cine loop with the uniform phantom. 
A region of interest, ROI, which extends from the bottom of the image to transducer face is used 
to average the pixel values over the cine loop, S+N, as shown in Figure 2.9 for all acquired 
images.  
                                                 
d http://www.atslaboratories-phantoms.com/resources/Model-539-Data.pdf 
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Figure 2.9 ROI of image profile used to average pixel values of full cine-loop independent images 
 The digitized pixel values from the image data formed in the rectangular ROI shows the 
mean value, S+N. The relative DOP at an imaging depth, d, which is the distance from the 
transducer face can be determined by plotting the mean pixel value vs the imaging depth. Figure 
2.10, illustrates the comparison of S+N and detector noise, N, for the acquired images using the 
Invenia mesh. The S+N and N are computed horizontally line by line within the ROI (Figure 2.9) 
progressing from the top to bottom of the image to determine the mean pixel value as shown in 
Figure 2.10. 
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Figure 2.10 Signal and Noise pixel profiles used to determine system sensitivity using the tissue-mimicking water 
phantom in a water medium measuring the Invenia mesh. S+N =Averaged Image Signal. N =Electronic Noise 
(acquired from air-only acquisition) 
 From the above plots the SNRIEC68 can be calculated from the graphs shown above for 
distance, d, values where the S+N values are greater than the N values in Eq.( 1. 
                                      
 𝑆𝑁𝑅𝐼𝐸𝐶(𝑑) = √
𝑆𝑁(𝑑)2
𝑁(𝑑)2
− 1 ( 1 ) 
 
     The corresponding SNRIEC (d) is shown in Figure 2.11.  
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Figure 2.11 Resulting SNRIEC values plotted as a function of imaging depth 
The maximum DOP resulting from the SNRIEC is calculated using Eq. 2.   
                                                  
 SNRIEC(𝐷𝑂𝑃) = 1 (2) 
 
 This is done by determining a line of best fit for the descending area after the peak in Figure 
2.11. The equation that determined the best fit is shown in Eq. 3; this equation is only useful for 
the specific transducer used in this study. The coefficients a, b, and c are determined by fitting 
the raw data from Figure 2.11. Once the fit coefficients are determined the substitutions of Eq. 2 
is used to solve for the DOP which is taken at the distance, d, to satisfy Eq. 3.   
                              
 SNRIEC(d)  =  a + b ∙ ln(d − c) (3) 
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 Several potential camisole materials were tested and two were superior. Material 1, Mat1, 
was the 108” Nylon Chiffon Tricot whitee and material 2, Mat2, is the 108” 40 Denier Tricot 
whitef. The DOP-values are recorded in Table 2.1. Other materials tested were Power Meshg and 
Telio Matte Chiffonh. All the tested materials were a nylon base similar to the Invenia mesh 
panel and had 10% or greater stretch across the grain in order to better conform to the mold of a 
woman’s breast.  
Table 2.1 Comparisons of DOP between various testing combinations. P= Phantom Only. Inv= Invenia 
Mesh fabric. Mat 1=108” Nylon Chiffon Tricot, Mat2= 108” 40 Denier Tricot, Mat3= Power Mesh, Mat 
4, Mat5= Telio Matte Chiffon 
Case ID Testing 
Combination 
R2 of fit DOP (mm) 
DOPCase ID/ 
DOPCase ID 2  
1 P only  0.997 58.6 99% 
2 P+Inv  0.996 59.4 100% 
3 P+Inv+Mat1 0.996 58.3 98% 
4 P+Inv+Mat2 0.997 58.9 99% 
5 P+Inv+Mat3 0.997 55.6 94% 
6 P+Inv+Mat4 0.996 54.3 91% 
 
 With the use of the phantom and Invenia mesh only, the DOP increases. This is likely due to 
uncertainty in measurements. It is also possible that the increased penetration with the Invenia 
paddle was due to an incidental reduction in air bubbles and improved impedance matching 
between the transducer and the phantom through the Invenia mesh fabric. Adding the Mat.1 the 
DOP was maintained by 99% and Mat. 2 maintained the DOP by 98%. Due to cost effectiveness, 
Mat1 was chosen as the fabric to use for the camisoles for ABUS imaging.  
                                                 
e https://www.fabric.com/buy/uf-737/nylon-chiffon-tricot-white 
f https://www.fabric.com/buy/uf-733/108-40-denier-tricot-white 
g https://www.fabric.com/buy/0450610/power-mesh-white 
h https://www.fabric.com/buy/0455281/telio-matte-chiffon-mesh-white 
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2.5.2 Efficacy of Breast Camisole for ABUS imaging 
 The breast camisole is designed to include the nylon material in the front and a cotton based 
material in the back similar to a sports bra. The breast imaging camisole is shown in Figure 2.8. 
The camisoles are designed to fit women between dress sizes 0 - 26. An IRB-approved patient 
study was performed on 10 patient volunteers of different ages (25-51) and breast sizes (breast 
cup size B-DDD) to evaluate the efficacy of the breast camisole. The purpose of this study was 
to ensure that the designed camisole was sufficient in restricting breast motion between the 
multiple views acquired in ABUS imaging and ensure that external markers stayed in place 
during ABUS imaging. After ABUS imaging was completed the ultrasound technologist 
evaluated the camisole performance based on completing a check list shown in Figure 2.12. 
 The protocol for this study and the ABUS camisole form is listed in the Appendix. An 
overview of the results for all 10 patient volunteers based on the ABUS camisole evaluation 
form is shown in Figure 2.12. This form is also provided in the Appendix. 
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Figure 2.12 Tallied Evaluation for efficacy of ABUS Camisole 
 Based on these results, we can conclude that the ultrasound camisole is sufficient for 
reducing patient motion. We can also conclude that the external fiducial markers locations that 
are underneath the material are not compromised during ultrasound imaging. Clips can be used 
to further improve the fit of the camisole and were needed for one patient in order to ensure 
proper camisole fit. However, these results also indicate that marker positioning can be 
compromised when the patient initially puts on the ABUS camisole. This can be minimized by 
assisting the patient in putting on the camisole, ensuring that enough time (at least 5 minutes) has 
passed before putting on the camisole after markers are glued, and by marking breast locations 
(e.g. by using a washable marker) prior to attaching the external markers.  
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2.6 External Fiducial Markers 
 External fiducial markers are markers attached to the skin that can be easily recognizable in 
reconstructed image views. These markers should not obscure much, if any, of the breast tissue 
images if they are to be used clinically. This study investigates the use of external fiducial 
markers to help improve the registration between corresponding lesions between 3D x-ray and 
3D ultrasound breast images. Several studies have used external fiducial markers and have found 
improved registration results for MRI/PET breast registration69,70, compressed and uncompressed 
prone breast MRI71, and breast MRI to conventional ultrasound72. For ultrasound imaging, this 
marker cannot cause refraction or other distortion artifacts below the skin in ultrasound imaging 
and should not cause artifacts in 3D x-ray imaging. 
 A study by Cloutier et al., found that glass bead fiducial markers were useful when imaging 
a multimodality vascular phantom with digital subtraction angiography, CT angiography and 
ultrasound.73 We decided to investigate the use of small beads between 0.79 mm - 2 mm in size 
composed of different material (acrylic, polystyrene, nylon, Teflon, and glass). These are 
common materials used in x-ray and ultrasound quality control. A thermoplastic elastomer, TPE, 
gel was melted and degassed in a vacuum oven over each echogenic and x-ray absorbing bead in 
order to create the external fiducial marker. This clear degassed gel allows for the bead target to 
be clearly seen in ultrasound imaging in the absence of voids.  
 Of the bead target combinations, we found that a 1 mm diameter glass bead target within the 
TPE gel worked best in reducing ultrasound artifacts and not being too attenuating in x-ray 
imaging. A detailed procedure of how to make this marker is available in the Appendix.  
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Figure 2.13 Edge artifact of external fiducial marker in ABUS imaging 
 These markers are glued to the breast and ultrasound gel or lotion is placed over the marker 
when the breast is imaged. Although the glass bead combination is easily seen in reconstructed 
ABUS images, we found that edge artifacts are present with these external fiducial markers as 
shown in Figure 2.13. Depending on marker width and thickness these artifacts can be more 
pronounced. To reduce the effect of edge artifacts we recommend that the markers are ≤ 3 mm 
thick and about 3 mm – 5 mm radial diameter surrounding the bead. Adequate ultrasound lotion 
or coupling gel can also reduce these effects. However, these effects may not be eliminated 
entirely due to the impedance and speed of sound differences between the marker and the skin 
and subcutaneous fat.  
2.7 Finite Element Method and Analysis  
 Once images are acquired within this research, the finite element method (FEM) is used to 
model breast deformation from one image modality in order to register lesions to another breast 
imaging modality. FEM was used to simulate the difference in breast compression and shape as 
an effect of the various imaging schemes with this thesis. FEM is a numerical discretization 
method used to compute approximations for physics laws (e.g. law of conservation of energy, 
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law of conservation of mass and law of conservation of momentum) for space and time-
dependent problems that are typically expressed using partial differential equations (PDEs). For 
most geometries and engineering problems, these PDEs are complicated and cannot be solved 
analytically to compute relevant mechanical properties (e.g. stress and strain) to estimate the 
corresponding behavior (e.g. deformation) of a component under specified loading conditions. 
Therefore, FEM is used to compute such approximations for various engineering applications 
such as thermomechanical, biomechanical, electromagnetics etc. Finite element analysis, FEA, is 
the simulation of any physical phenomenon using the FEM to predict how a structure behaves 
under specified conditions.  
 FEM approximates a continuous structure into a mesh of smaller finite elements using 
simple geometric shapes (e.g. triangles or quadrilaterals for surfaces and tetrahedrons or 
hexahedrons for volumes). Any point within the finite element structure can be expressed within 
an element through interpolation of the surrounding mesh nodes through the interpolation of 
shape functions. Any force/load applied to the structure can be approximated as a function on the 
interpolated finite mesh. This results in a finite system of equations based on nodal coordinates 
to approximate the result of the problem. For a more in-depth explanation of the application of 
continuum mechanics and the theory of FEM discretization involved for biomechanical models 
see the text from Maurel et al.74  
 FEA for medical application has become increasingly popular and universal for the 
advancement of biomedical engineering, biomechanics, and clinical research.75 There are many 
studies that have been proposed to model the female breast to simulate deformation for image 
registration. One of the pioneering efforts for using FEM in modeling and analysis for modeling 
breast deformations was performed by Samani et al.76 This group developed a biomechanical 
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model for the breast from MRI data.76 Shortly after, studies by Azar et al., used 3D hexahedral 
FE meshes to estimate the location of a tumor during mammographic compression for needle 
biopsies for three sampled patients.77,78 The FEA can be broken into three main sections:  
1. Description of the Physical Model. 2. FEA Preprocessing 3. FEA Solution and Post-
Processing. Each is described below. 
2.7.1 Description of the Physical Model 
 Before the FEA process can begin a description of the problem must be defined and 
simplified in order to be solved using FEMs. For this application, it requires that 3D image data 
must be acquired and segmented (i.e. a breast mass segmented from glandular and fatty tissue). 
Ensuring accurate geometry is key to successful modeling using FEM and should be defined 
with sufficient detail in spatial resolution in order to differentiate between the various tissue 
structures needed for FEA to simulate deformation.   
 Tissue composition directly contributes to the breast’s mechanical behavior and is important 
to have accurate biomechanical properties of the breast anatomy. As the breast contains a variety 
of anatomical structures (e.g. blood vessels, ducts, ligaments etc.) the segmentation must be 
simplified for FEA. Several experimental studies have measured the mechanical properties of 
breast tissues to determine elasticity, specifically with measurements of fibroglandular and 
adipose tissues.71,79–83 Therefore, biomechanical studies simplify the breast anatomical model to 
include the skin, fibroglandular, adipose, and lesion (if applicable) for FEA. 
 Segmentation of each tissue in the acquired image is the process of identifying tissues and 
differentiating their boundaries from other tissues. Studies have used manual71,76, semi-
automated84,85, and automated86–88 segmentation in FE-based breast deformation modeling 
techniques based on MRI data sets. Within this thesis, large 3D image sets (e.g. ABUS and bCT) 
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are used and can be laborious and time-consuming. Automated and semi-automated methods 
should be investigated in order to minimize the time associated with this task. The specific 
methods used in this text will be discussed in the subsequent chapters but deals with a 
combination of manual and semi-automated techniques. Once segmentation of all necessary 
tissues from the 3D imaging data is completed, the corresponding base FE model can be 
generated.  
2.7.2 Finite Element Analysis Preprocessing  
 Once the simplified physical anatomical structures have been identified and segmented from 
the acquired image data, the next step involves the discretization and mesh creation of the base 
FE model for the image data set. Within this text, each tissue is segmented into separate DICOM 
binary files from which a surface mesh is created of each segmentation. A mesh is a network 
model body that is formed by many elements (discretized smaller units) that are interconnected 
at nodes (FE XYZ-coordinate points that serve as boundaries of the mesh). This provides a 
simulated representation of the outline of the tissue structure in 3D. Surface meshes create up to 
millions of small elements and their corresponding nodes to generate the 3D shape of the tissue 
structure from the segmented DICOM files. There are many meshing schemes (e.g. quadrilateral, 
triangular, pentagonal etc.) that can be used to create the separate elements that discretize the 
surface mesh. These meshes only show the outline of the segmented DICOM files and are 
therefore hollow on the inside. Triangular meshing schemes are used within this thesis and 
examples of the surface meshes or different tissue types are shown in Figure 2.14.  
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Figure 2.14: Surface meshes of the skin (brown), inner gel (yellow), multiple lesions (pink, red, green and blue) 
from a breast phantom for (a) surface meshes created from segmented DICOM (Notice surface meshes are hollow 
on the interior and not filled or connected to one another) (b) tetrameshed model of breast fully connected 
 For breast FEA literature, there has been a plethora of mesh node density values and it is an 
ongoing area of research. No experimental study has concluded an optimal value.89 Breast plate 
compression studies have varied the number of elements by hundreds86,90 to thousands34, and 
even tens of thousands76,84,91. 
 After surface contours are meshed, volumetric meshing is needed to provide a fully 
connected breast FEA model. For volumetric meshing, tetrahedral and hexagonal meshes are 
typically used to mesh within a surface mesh volume and allow connectivity between surface 
components. Most breast studies using FEA have used tetrahedral meshes92, however hexahedral 
meshes have been used in studies by Lee et al.60, and Ruiter et al. 65 The majority of breast FEA 
has been used on tetrahedral meshes89, however there is not a consensus as to which (hexahedral 
or tetrahedral) meshing scheme is superior. These methods rely on a subdivision algorithm of the 
volume. A volumetric mesh is built by triangulating each of the cells of the volumes and may 
slightly change the coordinates of the vertices of the exterior nodes in order to improve mesh 
quality. Tetrahedral meshing schemes are used within this thesis and examples of the surface 
meshes or different tissue types are shown in Figure 2.14b.  
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 Material properties (e.g. Young’s Modulus, Poisson’s Ratio) are assigned to each meshed 
component in the model. The modulus of elasticity, Young’s Modulus (E), is a measure of a 
material’s stiffness and is often calculated from tensile stress (σ) /strain (ε) curves and formulates 
Eq. 4. 
 
 𝐸 =
𝜎
𝜀
 (4) 
 
 Stress can be defined as the force applied to a specific cross-sectional area of an object. 
Strain is a dimensionless parameter that is defined as the amount of deformation of a material 
along the applied force direction divided by the initial length of an object. The Poisson’s ratio (ν) 
is a dimensionless parameter that is defined as the ratio of the transverse strain to longitudinal 
strain in the direction of the stretching force as shown in Eq. 5. Breast tissues are modelled as 
incompressible materials having Poisson’s ratio nearly 0.50.  
 
 ν = −
𝜀𝑡𝑟𝑎𝑛𝑠𝑣𝑒𝑟𝑠𝑒
𝜀𝑙𝑜𝑛𝑔𝑖𝑡𝑢𝑛𝑑𝑖𝑛𝑎𝑙
 (5) 
 
 For the phantom studies within this thesis, the manufacturer provided information for the 
material properties as described in Chapters 3-5. For real breasts, there is high variability in the 
moduli of elasticity, Young’s Modulus, as this is still a current area of research. Studies by Kruse 
et al.83, Sinkus et al.80,94, and McKnight et al.95 used in vivo magnetic resonance elastography in 
order to quantify the elastic modulus for adipose, glandular, and carcinoma breast tumors. A 
study by Gefen et al. showed the Young’s modulus for glandular tissue ranges from 7.5 kPa - 66 
kPa and adipose tissue ranges from 0.5 kPa – 25 kPa.82 A study by Athanasiou et al. used 
supersonic shear wave imaging on 46 women with 48 breast lesions where the mean elasticity 
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values was 146.6 ± 40.05 kPa for malignant lesions and a mean elasticity value of 45.3 ± 41.1 
kPa for benign breast lesions.96 A study by Kellner et al., determined the skin, fat and glandular 
elastic moduli for FEA simulations for bCT plate compressions based on a combination of 
published results.97  
 The physical constraints (or boundary conditions) are defined to approximate the loading of 
the model. These prescribed boundary conditions define the force or nodal displacement needed 
to determine the resulting stress-strain deformation on types of breast tissues based on set 
material characteristics. For example, for a bCT FE model that is compressed to the DBT (CC 
view) imaging model, this involves applying loading on compression plates to simulate CC plate 
compression on an uncompressed bCT breast. For DBT FE deformed to ABUS this involves 
nodal loading displacements that will be described in greater detail in Chapters 3, 4 and 6.  
 Once boundary conditions are defined, specifications of analysis types need to be 
determined as an indicator to the FEA solver as to which types of equations need to be used in 
order to approximate the result of the model. There are many analysis types that can be used 
within FEA (e.g. heat transfer, fatigue, linear buckling). For breast deformation static or quasi-
static (quasi-Newtonian) stress analysis is most commonly used. The difference between static 
and quasi-static is that static analysis neglects a time dependent material response. Both analysis 
types include linear elastic or nonlinear elastic analysis and neglects inertial effects. An elastic 
material is defined a material whose stress is dependent on the materials’ strain.  
 Studies by Tanner et al.84 and Alonzo-Proulx et al.98 used linear elastic models when 
modeling large breast deformation. However, non-linear model analysis is considered more 
accurate for large breast deformations.89 Work involved in this thesis also found non-linear 
 37 
elastic quasi-static analysis yielded more precise results for the applications due to large 
deformation involved in the various modality registration. 
 For linear solutions the basic FEM equation to be solved is Eq. 699 
 
 [𝐾]{𝑢} = {𝐹} (6) 
 
 Where K is the elastic stiffness matrix, u is displacement vector and F is the vectors or loads 
applied to the structure. Eq. 6 is solved for the displacement vector. Thus, creating a set of 
simultaneous algebraic equations at each node within the FE model. Since all elements are 
interconnected through their nodes FEM uses piecewise polynomial interpolation to resolve a set 
of simultaneous equations at each node within the model. Linear solutions assume a homogenous 
deformation and neglect the interdependency of stress and strain.  
 For non-linear solutions Eq. 6 is modified to in Eq. 7.100  
 
 [𝐾(𝑢)]{𝑢} = {𝐹} (7) 
 
 Where, K(u) is the nonlinear stiffness response matrix of the nodal system reactions which is 
a function of, u, is the displacement vector, and F is the total force/loading vector. Non-linear 
solutions are generally history dependent as the solution is obtained in a series of small 
increments. Therefore, the model equilibrium equation is solved for each increment using 
Newton’s method.  
2.7.3 Finite Element Analysis Solutions & Post-Processing 
 Once all these considerations are performed an input file can be generated and a FEA solver 
is used in order to simulate the deformation of the input breast model using FEM. The FEA 
solver solves the set millions of differential equations which approximates the resulting stress, 
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strain, and nodal displacements of the models based off the loading scheme. Implicit FEA is used 
using non-linear quasi-Newton analysis and large displacement theory to determine the 
deformation of the breast within this dissertation.  
 Nonlinear analysis using quasi-Newtonian techniques, by satisfying the equilibrium 
equation at each step while ignoring inertial and momentum effects, allows a dynamic problem 
to be solved as a static problem by simplifying the problem into incremental load steps.101 After 
each increment, the FE breast model geometry changes and therefore the stiffness matrix needs 
to be updated for the sequential increment. For explicit analysis, the incremental procedure is 
done such that the increments are small enough for the results to be accurate. The problem with 
using explicit analysis is that many small increments are needed for accuracy and analysis 
convergence which is time consuming and this method does not enforce equilibrium.102 Implicit 
analysis uses the same incremental procedure however, equilibrium is enforced using Newton’s 
methods. Implicit analysis can handle more sophisticated problems. However, implicit analysis 
can be even more time consuming because the stiffness matrix must be updated and equilibrium 
is checked at the end of each increment.102 All studies in this dissertation used implicit analysis 
with quasi-Newtonian techniques for the non-linear analysis and large displacement theory.  
 The quasi-Newton method is then applied to enforce equilibrium of the internal structures of 
within the simulated breast model based on the external loads being applied to it.  
 Eq. 7 can be rewritten to show the application of the Newton method for a typical iteration, 
i, as follows100,102: 
 
 [𝐾𝑖(𝑢𝑖)]{∆𝑢} = {𝐹} − {𝐹𝑖} (8) 
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 Where, Ki(ui ), is the Jacobian nonlinear stiffness response matrix (the structural stiffness for 
computing element displacements within the model) for current iteration, ∆𝑢 is the change in the 
DOF displacement vector between the previous and current iteration, and Fi is the vector of 
internal force vector determined from elemental stresses in the current iteration. For each 
iteration Ki(ui ) and Fi is evaluated from ui. The next approximation is then made, ui+1, as shown 
in Eq. 9100. 
 
The process repeats until the right hand side of Eq. 8 converges or {𝐹} − {𝐹𝑖} = 0.
100,102  
 Quasi-Newton analysis modifies the above equations when the regular Newton method is 
too difficult or time-consuming to evaluate for Ki(ui ). Instead of obtaining the Ki(ui ) at a single 
point, quasi-Newton methods gradually build up an approximate Ki(ui ) by using gradient 
information from the previous iterations of Ki(ui ). Various quasi-Newton techniques can be used 
depending on the FEA solver system. Quasi-Newton methods were first introduced by Charles 
Broyden103 and he extended upon this works to include a more detail analysis of minimization 
algorithm of the DFP (David- Fletcher- Powell formula) method104 and the Davidson formula in 
1970.105 The work in this thesis incorporates the use of commercial software packages for FEA 
specifically Optistruct (Altair Engineering, Troy, MI) and ABAQUS (Dassault Systèmes 
Americas Corp., Waltham, MA). ABAQUS implements the BFGS (Broyden-Fletcher-Goldfarb-
Shanno) stiffness update that was shown by Matthies and Strang to help simplify systems of 
equations in nonlinear applications where the Jacobian is symmetric and not highly variable from 
one iteration to the next.106 More information about the quasi-Newton methods can be found in 
 {𝑢𝑖+1 } = {∆𝑢} + {𝑢𝑖 } (9) 
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the ABAQUS documentation.i Similar information for Optistruct can be found in its 
documentation.j  
 Commercial, open-source, and in-house codes can be used to solve these systems of 
equations. Commercial FEA solvers typically provide complete tools for FEA through the pre-
processing, post-processing, and visualizations for the model generation and results. Studies by 
Hopp et al.88,107 and Samani et al.76 have used ABAQUS to simulate breast deformations. 
Likewise, studies by Tanner et al.71,84,108, Ruiter et al.90, Unlu et al.70 used the commercial FEM 
package ANSYS for simulating breast deformation. Once the FEA is completed, the deformation 
results can be applied to the base FE model for registration considerations.  
 This thesis shows the implementation of this software by using FEM for breast deformation 
for different registration schemes. Unlike in the previous studies mentioned, nodal displacement 
is used to relate breast lesions from DBT to ABUS views instead of solving for the plate 
compression and decompression between these modalities. The use of nodal displacement in 
FEA for the two compressed states allows for the method to be more transferrable for use in the 
clinic in comparison to modeling plate compression. Nodal displacement was used because 
without uncompressed image data of the breast (e.g. as done in MRI or bCT) there is no way to 
verify a breast in its uncompressed state after DBT compression in the upright geometry and 
before ABUS compression in the supine geometry. These specifics will be further discussed in 
Chapter 3, 4 and 6. For bCT to DBT and bCT to ABUS registration the use of plates was used to 
model the breast deformation and will be further discussed in Chapter 5.
                                                 
ihttps://www.sharcnet.ca/Software/Abaqus610/Documentation/docs/v6.10/books/stm/default.htm?startat=ch02s02at
h15.html  
jhttps://altairhyperworks.com/hwhelp/Altair/2017/help/os/topics/solvers/analysis_nonlinear_quasi_static_c.htm   
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Chapter 3  
Deformable Mapping Technique to Correlate Lesions in Digital 
Breast Tomosynthesis and Automated Breast Ultrasound Imagesk  
 
 
3.1 Abstract 
Purpose: To develop a deformable mapping technique to match corresponding lesions between 
 digital breast tomosynthesis (DBT) and automated breast ultrasound (ABUS) images.  
Methods: External fiducial markers were attached to the surface of two CIRS multi-modality 
compressible breast phantoms (A and B) containing multiple simulated lesions. Both phantoms 
were imaged with DBT (upright positioning with cranial-caudal compression) and ABUS 
(supine positioning with anterior-to-chest wall compression). The lesions and markers were 
manually segmented by three different readers. Reader segmentation similarity and reader 
reproducibility were assessed using Dice similarity coefficients (DSC) and distances between 
centers of mass (dCOM). For deformable mapping between  the modalities each reader’s 
segmented dataset was processed with an automated deformable mapping algorithm as follows: 
First, Morfeus, a finite element (FE) based multi-organ deformable image registration platform, 
                                                 
k This work is published in the Medical Physics Journal: Green CA, Goodsitt MM, Brock KK, et al. Deformable 
mapping technique to correlate lesions in digital breast tomosynthesis and automated breast ultrasound images. Med 
Phys. 2018;45(10):4402-4417. doi:10.1002/mp.13113. Note: Italicized text in this chapter was not included in the 
original publication and is used to provide supplementary information.  
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converted segmentations into triangular surface meshes. Second, Altair HyperMesh, a FE pre-
processor, created base FE models for the ABUS and DBT data sets. All deformation is 
performed on the DBT image data; the ABUS image sets remain fixed throughout the process. 
Deformation  was performed on the external skin contour (DBT image set) to match the external 
skin contour on the ABUS set, and the locations of the external markers were used to morph the 
skin contours to be within a user-defined distance. Third, the base DBT-FE model was deformed 
with the FE analysis solver, Optistruct. Deformed DBT lesions were correlated to matching 
lesions in the base ABUS FE model. Performance (lesion  correlation) was assessed with dCOM 
for all corresponding lesions and lesion overlap. Analysis was performed to determine the 
minimum number of external fiducial markers needed to create the desired correlation and the 
improvement of correlation with the use of external markers.  
Results: Average DSC for reader similarity ranged from 0.88 to 0.91 (ABUS) and 0.57 to 0.83 
(DBT). Corresponding dCOM ranged from 0.20 to 0.36 mm (ABUS) and 0.11 to 1.16 mm  (DBT). 
Lesion correlation is maximized when all corresponding markers are within a maximum distance 
of 5 mm. For deformable mapping of phantom A, without the use of external markers, only 2 out 
of 6 correlated lesions showed overlap with an average lesion  dCOM of 6.8 ± 2.8 mm. With use 
of 3 external fiducial markers, 5 out of 6 lesions overlapped and average dCOM improved to 4.9 ± 
2.4 mm. For deformable mapping of Phantom B  without external markers analysis, 4 lesions 
were correlated out of 7 with overlap between only 1 of 7 lesions, and an average lesion dCOM of 
9.7 ± 3.5 mm. With 3 external markers, all 7 possible lesions were correlated with overlap 
between 4 out of 7 lesions. The average dCOM was 8.5 ± 4.0 mm. 
Conclusion: This work demonstrates the potential for a deformable mapping technique to relate 
corresponding lesions in DBT and ABUS images by showing improved lesion  correspondence 
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and reduced lesion registration errors with the use of external fiducial  markers. The technique 
should improve radiologists’ characterization of breast lesions  which can reduce patient 
callbacks, misdiagnoses and unnecessary biopsies.  
3.2 Introduction 
Ultrasound imaging used in conjunction with mammography has been shown to improve 
characterization of breast lesions.16–18 Conventional ultrasound imaging is performed freehand in 
a different geometry (supine) than mammography (upright). Since the acquisition is freehand, the 
2D ultrasound images are difficult to reproduce. Automated breast ultrasound, ABUS, visualizes 
the breast as a 3D image volume and has advantages in terms of reproducibility, acquisition 
speed and operator independence over conventional breast ultrasound.18,19,57 Likewise, studies 
have also shown the addition of ABUS imaging used in conjunction with mammography 
screening for women with dense breasts (ACR3 or ACR4) has significantly improved the breast 
cancer detection rate with an acceptable recall increase.19,57,58 Digital breast tomosynthesis, DBT, 
provides better detection and characterization of breast lesions over mammography through the 
reduction of tissue superposition. However, DBT has not completely eliminated the need for the 
use of ultrasound.109,110 One problem with the use of ultrasound in conjunction with 
mammography/DBT is that at least 10% of the time, the lesions found in the ultrasound images 
do not correspond to those found in mammograms/DBT.15 
One solution to this problem is to develop a combined x-ray/ultrasound system that images 
the breast in the same upright geometry using a special dual-modality compression 
paddles.21,22,24–30 However, the simpler single-sided combined systems are limited in ultrasound 
depth of penetration, and all studies to date have not completely addressed issues of poor 
ultrasound transducer coupling at the periphery of the breast in the mammographic geometry. 
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Some improvements such as dual sided ultrasound111 for better coverage and resolution have 
been explored but have not yet been implemented into a single combined system. An alternative 
to the combined system is to image the breast with the DBT and ABUS modalities in their own 
separate geometries and then use a deformable mapping technique to relate corresponding 
lesions. This has the advantage of better acoustic coupling and possibly better coverage of the 
breast with ultrasound. It utilizes DBT and ABUS systems that are already commercially 
available and does not require the extra expense of purchasing a special combined system. 
However, a deformable mapping method has the disadvantage of greater technical difficulty in 
relating corresponding lesions. 
To date, there are no deformable registration techniques for detecting corresponding lesions 
between ABUS and DBT breast images. The purpose of the present study is to investigate the 
viability of a deformable mapping method to relate corresponding lesions between DBT and 
ABUS breast images. Such a method should simplify and improve radiologist’s characterizations 
of breast lesions which can reduce patient callbacks, misdiagnoses, and negative biopsies. Using 
finite element analysis, FEA, a biomechanical algorithm can be used to relate regions of interest 
between modalities, so a radiologist can directly verify that a lesion seen in a DBT view is solid 
or cystic as determined from the ABUS image set. 
To produce FE based biomechanical models, segmentation of the entire breast volume is 
required for creation of surface and volumetric meshes. Defining the boundary between breast 
tissue and the pectoral muscle and distinguishing between glandular, connective, and adipose 
tissues poses difficulty for segmentation of breast images. Studies have used manual71,76, semi-
automated84,85, and automated86–88 segmentation in FE-based breast deformation modeling. For 
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large deformations due to breast compressions non-linear models have proven to be more 
effective than linear elastic models.92 
Relating breast images across modalities is a challenging task since the breast is a highly 
deformable entity. Patient positioning in various modalities can change from upright 
(mammography/DBT), prone (MRI, transmission US, and dedicated breast CT), and supine 
(ultrasound/ABUS). Immobilization of the breast with compression plates and paddles adds an 
additional challenge when relating areas of the breast between modalities. A recent study has 
proposed FE based non-linear biomechanical models for correlating breast structures between 
two compressed states for cranio-caudal, CC, to medial lateral oblique, MLO, mammography 
views.112 Several studies, have found favorable results in using FE modeling between MRI to x-
ray registration for CC and/or MLO mammograms.85,86,88,90. A recent study has found favorable 
results in relating lesions in supine breast ultrasound to prone MRI.113 Another correlation study 
showed favorable agreement between ultrasound computed tomography and mammography 
registration. That research group also used ultrasound to determine the distribution in the breast 
of Young’s Modulus from the speed of sound. This distribution was directly used in FE 
deformation modeling.107 
Due to high deformation fields of the breast between modalities and even over time in a 
single modality114 the use of external fiducial markers could provide an added benefit for lesion 
correlation. Several studies have used external fiducial markers and found improved registration 
results. In 2 studies of MRI/PET breast registration, ink was used to mark locations on the breast 
(up to nine in total). MRI visible markers were placed at those locations prior to MR imaging, 
and PET-visible markers were placed at the same locations prior to PET imaging.69,70 In a study 
of registration between compressed and uncompressed prone MRI, four external markers were 
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placed around the breast and on the nipple .71 Finally, using a volume navigation technique a 
study of breast MRI and ultrasound registration, 3 external markers (soft-gel capsules contain 
vitamin E in lipid solution) were used. 72. In the present study, we investigate the use of external 
fiducial markers to improve the registration of breast lesions in upright DBT to supine 
ABUS images.  
3.3 Materials and Methods  
3.3.1 Phantoms 
 Two CIRS Multi-Modality Breast Biopsy and Sonographic phantomsl were used in this 
study. The first, Phantom A, contains a total of 7 lesions: 3 cystic masses and 4 dense masses. 
This phantom also contains 3 calcifications. The lesions were randomly positioned in a Zerdine-
based background gel emulsion and wrapped by a Z-skin membrane material. Z-skin is a 
proprietary self-healing skin-like membrane that reduces phantom desiccation and simulates the 
texture and properties of skin during imaging and biopsy. Zerdine is a patented solid elastic 
water based polyacrylamide tissue mimicking material that’s formulation can be adjusted to 
correspond to a variety of soft-tissue acoustic properties for ultrasound imaging.115 For some 
time, similar polyacrylamides have been described for ultrasound imaging and therapy 
phantoms.116,117 Since it is a water-based material and the density can be controlled it can be used 
for CT and MR imaging as well.115,118 
 The second phantom, Phantom B, contains a total of 12 lesions: 6 cystic masses and 6 dense 
masses. These lesions were randomly positioned in a Zerdine-based background gel, without the 
Z-skin outer membrane. CT images of both phantoms were acquired with a GE Discovery 
                                                 
l Computerized Imaging Reference Systems, Inc., 2428 Almeda Ave, Suite 316 Norfolk, Virginia 23513, 
http://www.cirsinc.com/file/Products/073/073%20DS%20032316.pdf 
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CT750 CT scanner. These images were used solely to identify lesion type and quantity; the CT 
scans have no bearing on the deformation algorithm. Material properties for the phantoms were 
provided by the manufacturer. (See Table 3.1.)  
Table 3.1 Phantom material properties 
 Young’s Modulus (E) Poisson’s Ratio (ν) 
Z-skin Membrane  10 kPa 0.50 
Zerdine background gel  10 kPa 0.50 
Dense lesions  60 kPa 0.50 
Cystic lesions 0 kPa 0.50 
 
 HyperMesh, the finite element pre-processor, cannot utilize the Poisson’s Ratio of 0.50 for 
the materials in Table 3.1 therefore, a Poisson’s ratio of 0.49 was assumed for all materials. For 
this study, based on visual inspection of the phantom before and after DBT and ABUS imaging 
there were no external indications that the phantoms did not fully recover to their original states. 
To better quantify the differences in phantom deformations, measured load-strain curves are 
shown in Figure 3.1. Based on these curves, the elasticities of the phantoms are linear, and 
phantom A is a factor of 1.9 times stiffer than phantom B.  
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Figure 3.1: Load-strain curve comparing elastic properties of Phantom A and Phantom B. Note: Phantom B a 
similar phantom made of same material properties were used for these points as the Phantom had ruptured due to 
the amount of time that had passed as these measurements took place 
3.3.2 External Fiducial Markers  
The present application requires an external marker that does not cause refraction or other 
distortion below the skin in ultrasound imaging and does not cause artifacts in 
mammography/DBT imaging. In previous work, Cloutier et al, found glass bead fiducial markers 
were useful when imaging a multimodality vascular phantom with DSA, CTA, MRA and 
ultrasound.73 We investigated various targets within different background materials as candidates 
for external fiducial markers. The fiducial marker that we found worked best for both DBT and 
ABUS was a 1 mm diameter glass bead target within a clear bubble-free thermoplastic elastomer 
(TPE) gel. To make this marker, thin samples of TPE were placed on top of the 1 mm glass 
beads on a cupcake baking sheet and melted at 130˚ C in a vacuum oven. The vacuum was 
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applied to the TPE as it cooled to eliminate air pockets/bubbles, which can be mistaken for the 
markers in ultrasound images. The fiducial markers have a thickness of approximately 3 mm.  
The markers were placed around the breast, using Nu-Hope Liquid Waterproof Adhesivem. A 
waterproof adhesive is recommended to ensure maintenance of fiducial marker placement with 
use of ultrasound coupling gel or lotion. Six external markers were applied to phantom A as 
show in in Figure 3.2. Results were obtained using all 6 markers as well as using 5 markers 
(positions F, A, B, C, and E), 4 markers (positions F, E, B, and C), 3 markers (position F, A, B), 
and two markers (positions F and B). Results for Phantom A, indicated no statistical difference 
in lesion correlation when using 6 markers and when using a maximum of three markers at 
locations F, A, and B. Therefore, for Phantom B, only 3 markers at those approximate locations 
were used when imaged. 
 
 
Figure 3.2 Phantom A with external fiducial marker locations indicated by A-F 
3.3.3 Data Collection  
     A GE-SenoClaire DBT system (GE Healthcare, Milwaukee, WI) was used to image Phantom 
A in the CC view with a compressive force of 6 daN and compressed breast thickness of 48 mm. 
The maximum uncompressed breast phantom thickness measured 98 mm from reconstructed CT 
                                                 
m (Nu-Hope Laboratories, Inc., P.O. Box 331150 Pacoima, CA 91333-1150, http://nu-hope.com/products.php ). 
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images. Thus, phantom A was compressed 51% for this study. 6 out of the 7 lesions in this 
phantom were identified in the reconstructed DBT images. A GE Senographe Pristina DBT 
system (GE Healthcare, Milwaukee, WI) was used to image Phantom B in the CC view with a 
compressive force of 3 daN and compressed breast thickness of 31 mm. For Phantom B, 7 of the 
12 lesions were identified in the reconstructed DBT images. The maximum uncompressed breast 
phantom thickness measured 97 mm from reconstructed CT images. Thus, phantom B was 
compressed 68% for this study. The reason 1 lesion in Phantom A and 5 lesions in Phantom B 
were not seen in the reconstructed DBT images is that the plastic backing on both phantoms 
restricted the ability to image close to the “chest wall” where those lesions were located.  
Figure 3.3 (a) and Figure 3.3 (b), show DBT images of both phantoms including some of the 
lesions and an external fiducial marker (red arrow).  
 
Figure 3.3 DBT and ABUS acquired images. The red arrows indicate the locations of external fiducial markers 
in:(a) DBT image of Phantom A, (b) DBT image of Phantom B, (c) ABUS image of Phantom A, and (d) ABUS image 
of Phantom B 
     Both phantoms were imaged with a GE Invenia ABUS system119 (GE Healthcare, Milwaukee, 
WI) immediately after DBT imaging. Light AP compression is applied to the phantoms when 
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they are imaged with the Invenia ABUS system. There are three settings on the system (high, 
medium, and low) based on imaging depth. The high setting was used for imaging Phantom A 
and the medium setting was used for imaging Phantom B. The system has a safety stop at 20lbs 
(8 daN) which is lower than the compression used in most mammography exams today. The 
Invenia ABUS reverse curve transducer has a bandwidth of 6 to 15 MHz and can image up to 50 
mm in depth. The transducer has a width of 153 mm and automatically travels approximately 
170 mm across a mesh compression paddle. The breast/phantom was positioned supine with 
anterior-posterior compression applied by the mesh paddle. One ultrasound volume of each 
phantom was taken in the anterior posterior view. Clinical procedures typically include 
acquisitions of three separate volumes per breast to ensure full coverage of the breast and 
axillary region. Raw data from the Invenia ABUS system does not include correction for the 
curved transducer. Therefore, an algorithm was developed and used to correct for transducer 
curvature in ABUS images. Figure 3.3 (c) and Figure 3.3 (d), indicate marker positioning under 
the ABUS imaging for Phantoms A and B with the correction for the transducer curvature. In 
Phantom A, the 3 calcifications were not seen in the reconstructed ABUS images. A 
disadvantage of ultrasound imaging is that microcalificatons are often not seen and even larger 
calcium macrocalcifications deposits can be missed.120 All 12 lesions were seen in the ABUS 
scans of Phantom B.  
3.3.4 Manual segmentation 
All lesions and external markers from the acquired image sets from both modalities were 
manually segmented using a free-hand drawing tool within 3D Slicer121 by three readers (CAG, 
MMG and JHL) using the same window-level settings on the same work station. Readers viewed 
the images together and agreed upon a window-level setting to be used for each image set in 
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order to eliminate window-leveling as a variable in inter-reader concordance of lesion 
segmentation. Since DBT images have poor axial resolution, the lesions were segmented until 
the superior and inferior extents of the lesions exhibited significant blur along the edges. These 
decision points are very subjective so the axial extents of the lesion segmentations in DBT can 
vary significantly between readers.  
 
Figure 3.4 Reader 1’s manual segmentation of a slice in (a) Phantom A – DBT, (b) Phantom B- DBT, (c) Phantom A 
- ABUS (d) Phantom B - ABUS 
Figure 3.4, shows examples of lesion segmentation for Phantom A and B in both DBT and 
ABUS image sets. Dice similarity coefficients (DSC) (twice the overlap of corresponding 
segmented volumes/sum of those volumes) were used to evaluate similarities between lesion and 
marker contours between readers.122 For the DBT and ABUS data sets, one reader manually 
segmented the outer skin layer from the air and the body of breast phantom A and segmented the 
body of breast phantom B from the air. For the ABUS images, that same reader performed these 
same segmentations manually. There was no correction in the segmentations for DBT 
reconstruction artifacts. After segmentations were completed, resampling was used to decrease 
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runtime when converting segmentations into triangular surface meshes. The DBT images were 
resampled from a native voxel size of 0.1 mm width, 0.1 mm length, and 1.0 mm depth to 0.2 
mm width, 0.2 mm length, and 1.0 mm depth. The ABUS images were resampled from a native 
voxel size of 0.082 mm width, 0.2 mm depth, and 0.506 mm length (distance between adjacent 
slices), to 0.2 mm width, 0.2 mm depth, and 0.506 mm length. Image resampling is done using 
the MATLAB imresizen command.  
3.3.5 Deformable mapping algorithm  
 The deformable mapping algorithm is an automated process that integrates the use of 
Morfeus, a commercial FE pre-processor (HyperMesh 2017, Altair Engineering, Troy, MI) and a 
finite element analysis (FEA) solver processor (Optistruct 2017, Altair Engineering, Troy, MI). 
An overview of the process is shown in Figure 3.5. 
                                                 
n https://www.mathworks.com/help/images/ref/imresize.html  
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Figure 3.5 The automated deformable mapping process. Software’s used shown in red.  
 The entire deformable mapping algorithm takes up to approximately 40 minutes to complete 
from start to finish on a Windows 7 Intel® Core™ i7 CPU with a speed of 2500 MHz and 4GB 
RAM. In ABUS imaging, poor acoustic contact with the transducer often occurs around the 
periphery of the breast causing artifacts as shown on the right and left sides of Figure 3.3 © and 
Figure 3.3 (d). These artifacts cause the actual breast size and shape in ABUS imaging to be not 
as well defined in comparison to DBT. An example of the segmentation of the skin layer for both 
phantoms is shown in Figure 3.6.  
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Figure 3.6: Periphery uncertainty from skin segmentation for a slice in ABUS for (a) Phantom A (b) Phantom B. 
 Reader bias can affect the segmentation in the periphery boundary. The use of external 
markers for registration should help to reduce and correct for these differences in lesion 
registration. On the other hand, the breast shape and size are better defined in the DBT images as 
shown in Figure 3.3 (a) and Figure 3.3 (b). Therefore, we chose to have the deformable mapping 
algorithm perform deformation only to the DBT FE model and register the resulting deformation 
to the ABUS image set. The external fiducial markers allow for adjustments to be made since all 
markers observed in the ABUS images had potentially corresponding points in the DBT images. 
More sophisticated registration rules are required if that is not the case. 
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3.3.5.1 Conversion of DICOM segmented images to triangular surface mesh 
 Morfeus, a FE based multi-organ deformable image registration platform, converts all 
DICOM segmented contours into individual triangular surface mesh for use in the FE model pre-
processor.47 Morfeus converts the DICOM image data into mask files for image analysis using 
Interactive Data Language (IDL, Research Systems Inc.). Each mask file is then converted into a 
triangular surface mesh file. Within HyperMesh, the shrinkwrap function is used on the Morfeus 
generated triangular surface element mesh in order to create a triangular “trias” surface mesh for 
further processing and FEA. Prior to FEA, an element quality check is performed to ensure all 
elements in the model are within various specifications (e.g., aspect ratio, Jacobian, warpage 
etc.) in order for the analysis to commence. Therefore, Morfeus uses Laplacian smoothing and a 
decimate function to better ensure the triangular mesh is within element quality specifications by 
smoothing rough or sharp elements to ensure viable mesh integrity while maintain a reasonable 
mesh size to maintain structural features. 
3.3.5.2 Finite element model generation 
 The algorithm uses the FE model pre-processing software, HyperMesh, to build the base FE 
model for the DBT and ABUS image set from the individual mesh triangular surface contours. 
3D four-point tetrahedral FE models are created using the trias surface meshing algorithm within 
HyperMesh from all 3D-triangular surface mesh contours for each modality model which results 
in fully connected tetrameshed base FE ABUS and DBT models. The algorithm takes into 
account the shape of the triangular surface being meshed and uses a defined library of element 
patterns to map them to triangular surfaces for tetrahedral mesh generation. Each reader’s 
segmented dataset includes the resulting base DBT and ABUS models for both phantoms. The 
material properties that were assigned to the 3D tetrahedral model volumes are as noted in Table 
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3.1. Surface interfaces are defined, and boundary conditions are determined using a mesh 
morphing module named HyperMorph. The base DBT model is deformed to match the ABUS 
model since there is higher certainty in the overall breast shape in the DBT model. Since the 
simulated dense and cystic lesions cannot be distinguished in the DBT images, all lesions are 
assumed to have the material property of the dense lesions from Table 3.1. For Phantom A, the 
average number of elements/nodes are 366,000/65,800 for the base DBT model and 
102,000/20,300 for the base ABUS model. For Phantom B the average number of 
nodes/elements are 192,000/35,600 for the base DBT model and 137,000/24,200 for the base 
ABUS model. The DBT model has a larger number of elements/nodes due to smaller element 
size since it is used for FEA and the ABUS model is used as the reference model. 
3.3.5.3  Skin surface transformation of DBT model to match ABUS skin surface 
 The base DBT FE model (Figure 3.7 (a), blue) is translated and rotated to the center of mass, 
COM, of the base ABUS FE model (Figure 3.7 (b), brown). Nodal locations, (x, y, z-coordinate 
locations that define elements in FE model) from the skin surface of the base DBT-FE model are 
automatically moved to best match the outer surface of ABUS FE model along the axial and 
coronal planes by morphing the original mesh, which results in Figure 3.7 (c). This 
transformation reshapes the skin surface mesh and does not use any breast phantom material 
properties. For this transformation, the entire skin surface as the volume is encased in a six-sided 
hexahedron to encompass the entire skin volume. The handles, (68 in total, yellow and red 
spheres shown around the DBT skin mesh in Figure 3.7) are created and encompass the outer 
contour of the DBT skin model at seven equidistant locations along each planar axis. The red 
spheres indicate global handles, which are 8 in total and are generated at the eight corners of the 
hexahedron box surround the skin mesh. Global handles are used for making large scale changes 
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to the mesh. The yellow spheres indicate local handles which make smaller scale changes to 
localized areas of the. There are 60 yellow spheres in total and are used to manipulate a small 
region of the skin mesh by influencing external nodal locations. Influence functions, using the 
HyperMorph feature within the HyperMesh software, relate the movement of the handles to the 
nodes within. There are a number of non-linear algorithms used depending on the size and shape 
of the domains and the number of nodes within. The algorithm enforces symmetry or constrain 
nodal movements in many different patterns to modify the relationship between handle 
movement and node manipulation. The external nodes of the DBT skin model are then related 
along the axial and coronal anatomical planes to the nearest node in the ABUS model based on 
the axes of interest. The external nodes of the DBT skin model are then related along the axial 
and coronal anatomical planes to the nearest node in the ABUS model based on the axes of 
interest.  
   
 
Figure 3.7: Mesh transformation for external DBT breast surface mesh to match shape of ABUS surface mesh. 
Brown: ABUS (unchanged) Yellow:Blue (deformed): (a) COM translation and rotation of DBT to ABUS COM (b) 
Coronal handle manipulation of DBT breast surface mesh (along y axis) (c) Axial handle manipulation of DBT 
breast surface mesh (along z axis)   
 The algorithm computes the differences and manipulates the handles so the DBT volume 
can match the external ABUS shape. Manipulating handles along the coronal plane (Figure 3.7 
(b)) simulates the decompression of the DBT surface mesh. Manipulating handles along the axial 
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plane (Figure 3.7 (c)), simulates AP compression of the DBT surface mesh to match the ABUS 
surface mesh. In other words, the original DBT surface mesh is morphed by changing nodal 
locations to better align with the overall shape of the ABUS surface mesh. The sagittal plane (the 
plane the ultrasound transducer is scanned) is not considered due to poor coupling along the right 
and left sides of the breast during ABUS image acquisition. 
3.3.5.4 External Marker Correlation 
After surface deformation is completed using the outer skin contours between models, the 
algorithm computes COM positions of the external fiducial markers from the morphed DBT 
model and reference ABUS model. The DBT surface mesh is further deformed based off 
external marker correlation as follows: External fiducial markers in the DBT model are matched 
with the base ABUS external fiducial markers by determining the minimum distance between 
the COMs of corresponding markers. This distance will be used to align markers closer together 
and allows for mesh corrections along all anatomical planes (includes correction along the 
scanning plane of the ultrasound transducer).  
Once external markers are matched between the two sets and the resulting distances between 
COMs is determined, the algorithm determines which local handle (yellow spheres shown in 
Figure 3.7 (c)) is needed to adjust nodes within the mesh domain. This handle is determined by 
proximity to handle locations along the x-axis. Once the local handle is determined, the local 
handle is manipulated by half the distances between the COMs of correlated markers for each 
planar axis. This is repeated for all corresponding markers. After all handle manipulation is 
completed the algorithm recalculates the COM distances between markers. If all markers are 
within a user-defined distance, dM (between 1 and 10 mm), the algorithm will begin FEA. If not, 
the algorithm identifies which markers are not within dM and iterates again to manipulate the 
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handles for markers that are not satisfying the dM boundary condition. The algorithm will iterate 
until all markers satisfy the dM boundary condition. Each iteration will only perform handle 
corrections based off the total number of matched markers (i.e. 6 matched markers corresponds 
to a maximum of 6 handle corrections for that iteration).  
To maintain mesh integrity, the DBT FE model is deformed by half the distance between 
correlated markers to ensure that mesh quality is not compromised due to large changes to the 
skin mesh which can halt processing by the FEA solver. Skin deformation per iteration occurs 
only for corresponding markers that are greater than dM. For those markers, deformation by 
further manipulation of the handles, as described in Sec. 3.3.5.3 is performed in that area of the 
DBT model of the breast. A lower bound of 1 mm is used as it is approximately equal to the 
ultrasound point spread function expected for the fiducial markers. If there are no markers 
inferior to the nipple, mesh deformation is assumed symmetric superior and inferior to the 
nipple. The displacement for each node from the surface mesh of the DBT translated model 
(Figure 3.7 (a)) and the deformed DBT surface mesh (Figure 3.7 (c) with the addition of 
external marker corrections) are stored and applied as boundary conditions for FEA deformation 
to begin on the base DBT model. Skin surface deformation is used for the sole purpose of 
creating the boundary conditions needed to begin the FEA.  
3.3.5.5 Finite Element Analysis 
 The constraints or boundary conditions for each external DBT surface mesh are applied to 
the translated base DBT FE model. These boundary conditions are used as input to the FEA 
solver program, Optistruct, to generate and solve the differential equations to describe the model 
deformation based off the defined constraints. The FEA uses the material properties and 
boundary conditions to find the resultant stress and strain of the deformation of the entire breast 
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volume. Due to the high deformation that is needed to match the DBT and ABUS volumes, the 
FEA is performed as a non-linear quasi-static analysis in a single step. Linear static deformation 
would compromise mesh integrity and result in faulty output or inability of FEA to run. 
Therefore, this study does not recommend the use of linear static deformation analysis between 
DBT and ABUS compressions. The FEA was performed on a Windows 7 Intel® Core™ i7 CPU 
speed of 2500 MHz with 4GB RAM with analysis complete in approximately twenty minutes. 
The analysis time will be longer for models with greater complexity. 
3.3.5.6 Lesion correlation  
After FEA is performed, the COM of all lesions from the FEA-DBT model and the base FE 
ABUS model are determined. A correlation algorithm determines which lesions correspond to 
lesions in the other set with the constraint that the difference in COM is within 15 mm. Previous 
studies, for deformable registration from breast MR to mammography CC views have shown 
mean registration errors of 10 - 20 mm.92 Therefore, since those studies were based on real breast 
data these bounds were used loosely as correlation criteria for registration measurement. All 
external nodal locations of each lesion are analyzed to determine overlap of correlated lesions. 
Corresponding lesions from DBT and ABUS sets that have a minimum distance between the 
COMs, dCOM are considered to match. For two lesions in DBT that have the same dCOM with a 
lesion in ABUS, the code checks the dCOM of those two DBT lesions with other ABUS lesions to 
minimize all dCOM and thereby determines the correct lesion matches. The matching process is 
described in pseudo-code in Figure 3.8.  
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Figure 3.8 Pseudo-code for lesion correlation used within deformable mapping algorithm 
 
All corresponding lesions are considered matched between the two modality sets based on 
the criteria in Table 3.2. Since our studies use uniform background phantoms with large numbers 
of lesions, stricter lesion correlation guidelines were employed to reduce the likelihood of 
mismatch. 
Table 3.2 Criteria for lesion correlation between ABUS and DBT model 
 dCOM dO 
Overlapping Lesions dCOM ≤ 10 mm n/a 
Non-overlapping Lesions dCOM ≤ 15 mm dO ≤ 7.5 mm 
 
Therefore, if two corresponding lesions overlap, they are considered a match if dCOM is 
within 10 mm. If lesions correspond but do not overlap the minimum distance to overlap, dO, is 
calculated as shown in Figure 3.9. If the two corresponding lesions are within a dCOM of 15 mm 
and dO is within 7.5 mm, the lesions are matched. The dO is restricted to 7.5 mm to ensure a 
match discrepancy is not made. The results are output into a table and can be used to relate 
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positions from the original ABUS and DBT DICOM data. Calcifications from Phantom A are 
not considered during lesion matching. 
 
Figure 3.9 Lesion correlation metrics for COM distance (dCOM) and minimum distance to overlap (dO) for (a) 
non-overlapping lesions and (b) overlapping lesions. (Blue = ABUS, Yellow = DBT) 
3.3.5.7 Studies performed  
The following studies were performed: 
• Inter-reader concordance of segmented lesions: Inter-reader concordance of all 
segmented lesions was evaluated using DSC and distances between the COM’s of 
corresponding lesions.  
• Inter-reader concordance of locations of fiducial markers: Inter-reader concordance of 
the locations of the fiducial markers was evaluated by measuring the distances between 
the COM’s of each segmented marker for each image set. 
• Reader reproducibility: After segmentation was performed for all lesions, three lesions 
were selected from each image set of each phantom for a study of reader segmentation 
reproducibility. Each reader segmented those three lesions in the DBT and ABUS images 
several days after completing their original segmentations.  
• Accuracy of deformable mapping technique: For Phantom A, results were compared for 
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cases when sufficient iterations were performed to achieve corresponding marker 
separations of ≤ 1 mm vs. ≤ 5 mm This comparison included results when different 
numbers of markers were used. In addition, results were compared with and without the 
use of the markers. For all comparisons, the statistical significance of any differences 
between the average dCOM values for corresponding lesions were determined with paired 
t-tests. The numbers of lesions that overlapped and dO were also compared.  
3.4 Results  
3.4.1 Analysis of inter-reader concordance of segmented lesions in both phantoms 
     Table 3.3 compares the segmentation results between readers for all lesions in both phantoms. 
The DSC for the ABUS data for both phantoms is approximately 0.90. For DBT data for both 
phantoms DSC results are lower, likely due to differences in reader determination of the vertical 
extents of the lesions. The smallest DSC is 0.57 for R2 to R3 for Phantom 2. For this same reader 
correlation, the average distance between COM (dCOM) is 0.81 mm thus illustrating that even 
though the DSC values are low, the central positions of the lesions segmented by the different 
readers are still very close to one another. 
Table 3.3 Average DSC and average COM distance (dCOM) results between readers for corresponding lesions in all 
DBT and ABUS data sets for Phantoms A and B. 
Reader 
correlation 
Phantom A Phantom B 
ABUS DBT ABUS DBT 
DSC dCOM 
(mm) 
DSC dCOM 
(mm) 
DSC dCOM 
(mm) 
DSC dCOM 
(mm) 
R1 to R2 0.89 ± 
0.07 
0.20 ± 
0.03 
0.70 ± 
0.19 
1.06 ± 
0.27 
0.90 ± 
0.05 
0.31 ± 
0.06 
0.62 ± 
0.24 
0.78 ± 
0.08 
R2 to R3 0.88 ± 
0.08 
0.29 ± 
0.01 
0.73 ± 
0.11 
0.59 ± 
0.12 
0.88 ± 
0.09 
0.30 ± 
0.05 
0.57 ± 
0.25 
0.81 ± 
0.17 
R3 to R1  0.89 ± 
0.03 
0.36 ± 
0.01 
0.72 ± 
0.21 
1.16 ± 
0.23 
0.91 ± 
0.04 
0.21 ± 
0.03 
0.83 ± 
0.04 
0.11 ± 
0.02 
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3.4.2 Analysis of inter-reader concordance of fiducial markers locations 
Table 3.4 illustrates the average distances between the COM’s of the fiducial markers segmented 
by the three readers. The largest differences between the COM’s for both DBT and ABUS are 
approximately 2 mm.   
Table 3.4 Average COM distance (dCOM) between external markers among readers in DBT and ABUS data sets for 
Phantoms A and B 
 
dCOM (mm) 
Phantom A Phantom B 
ABUS DBT ABUS DBT 
R1 to R2 1.31 ± 0.37 1.37 ± 0.26 0.45 ± 0.27 1.18 ± 0.26 
R2 to R3 1.33 ± 0.40 0.69 ± 0.08 0.74 ± 0.23 1.38 ± 0.34 
R3 to R1 1.77 ± 0.61 0.97 ± 0.32 0.48 ± 0.27 2.24± 0.72 
 
3.4.3 Reader reproducibility analysis 
     Table 3.5 illustrates the reproducibility of the segmentation results for each individual reader 
for three lesions in Phantom A and Phantom B. The reproducibilities of the DSC for the 
individual readers are in general higher for the lesions in the ABUS images and lower in the 
DBT images. The latter is likely due to differences in reader determination of the vertical extents 
of the lesions in DBT images when the readers repeat the segmentations themselves. However, 
the dCOM values in Table 3.5 are less than 2 mm for both modality images indicating good 
reproducibility of the positions of the lesions. 
Table 3.5 Reproducibility for each reader’s lesion segmentations in DBT and ABUS data sets for Phantoms A and B 
using DSC coefficients and average COM distance (dCOM). 
Reader 
 ID 
Phantom A Phantom B 
ABUS DBT ABUS DBT 
DSC dCOM (mm) DSC dCOM (mm) DSC dCOM (mm) DSC dCOM (mm) 
R1 0.85 ± 0.04 0.50 ± 0.27 0.78 ± 0.09 1.88 ± 1.34 0.89 ± 0.02 0.19 ± 0.03 0.68 ± 0.19 0.59 ± 0.05 
R2 0.86 ± 0.03 0.47 ± 0.34 0.85 ± 0.05 0.60 ± 0.45 0.86 ± 0.01 0.23 ± 0.13 0.66 ± 0.16 0.69 ± 0.05 
R3 0.86 ± 0.01 0.29 ± 0.26 0.78 ± 0.07 1.19 ± 0.92 0.87 ± 0.05 0.16 ± 0.04 0.69 ± 0.07 0.42  0.38 
 
For segmentations by each reader, deformation was successfully performed on the base DBT 
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FE model and correlated to the corresponding ABUS datasets between reader segmented data. In 
every iteration of the algorithm, the average distances between the COMs between the readers of 
the correlated markers decreased as shown in Figure 3.10. After 6 iterations, the average 
correlated difference between all markers is 3.0 mm which corresponds to a dM ≤ 5 mm.  
3.4.4 Accuracy of deformable mapping for different numbers of fiducial markers for 
Phantom A 
Phantom A has 7 lesions, all of which were viewed with ABUS. However, only 6 of the 
lesions were viewed in the DBT images because 1 lesion was too close to the chest wall and 
moved outside the image field of view when the phantom was compressed. Figure 3.10 (a), 
illustrates the resulting lesion dCOM, dO, and overall lesion overlap where no marker analysis was 
used and compares it to various marker combinations described in Sec. 3.3.1 when markers 
within a 1-mm distance (dM ≤ 1 mm). Figure 3.10 (b), illustrates the resulting lesion dCOM, dO, 
and overall lesion overlap fraction that were obtained when no fiducial marker analysis was used 
and compares it to various marker combinations described in Sec. 3.3.1 when all corresponding 
markers were within a 5-mm distance (dM ≤ 5 mm). 
For the 6 marker case, 6 iterations were needed for all of the corresponding external markers 
to be within a 5-mm distance of each other. For all corresponding external markers to be within a 
1-mm distance of each other required 17 iterations. Each iteration can have runtimes of up to 3 
minutes depending on the number of markers used in the analysis. Therefore, a difference of 10 
iterations can increase runtime by about 30 minutes. Although as shown in Figure 3.10, the dCOM 
are slightly greater for markers being within 1 mm vs. 5 mm (likely due to the greater number of 
iterations and corrections made to get all of the markers within the 1 mm distance), the p-value 
for a paired t-test was 0.12. Thus, there was no statistical difference in dCOM when markers were 
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within 1-mm versus a 5-mm distance. Hence a dM of 5 mm is regarded as an acceptable distance 
between correlated markers to ensure acceptable algorithm run time, with the employed, simple 
processor, while maintaining desired lesion correlation. Without the use of markers only 2 out of 
6 lesions overlapped. For both dM cases analyzed, overlap improved to 6 out of 6 lesions with 4 - 
6 marker analysis combinations and improved to 5 out of 6 lesions overlapped for 2 and 3 
marker analyses. The largest improvement in dCOM is shown for 2 and 3 markers vs. 0 markers.  
 
Figure 3.10 Average distances between COMs of corresponding lesions in ABUS and DBT images (dCOM) for all 3 
readers, as well as minimum distance to overlap (dO), and overall lesion overlap ratio (the number of lesions that 
overlapped between DBT and ABUS sets divided by the total number of lesions that were imaged) for Phantom A 
with various number of external fiducial markers. (a) All marker distances were within a distance (dM ≤ 1 mm) 
between readers’ data sets. (b) All marker distances were within a distance (dM ≤ 5 mm) between readers’ data sets. 
Marker combinations from Figure 3.2:6 markers (A-F), 5 Markers (A, B, C, E, and F), 4 markers (F, B, E, and C), 3 
markers (A, B, and F) and two markers (F and B). 
 Figure 3.11 displays the improvement from no marker analysis to that with three marker 
analyses in Phantom A for all correlated lesions for Reader 1 segmented datasets. 
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Figure 3.11 Phantom A lesion correlation for Reader 1 (a) without marker analysis coronal view (b) with marker 
analysis coronal view (c) without marker analysis axial view (d) with marker analysis axial view. All numeric values 
correspond with Lesion ID’s in Table 3.6. (Blue = ABUS, Yellow = DBT) 
 Table 3.6, compares the average distances between the COMs of corresponding individual 
lesions ± the standard deviations of those distances in the deformed DBT and base ABUS images 
for the combined data for all 3 readers for phantom A, without the use of markers and with the 
use of three external markers for lesion correlation. The mean difference in lesion dCOM was 1.9 
mm with 3 marker analyses vs. without. A paired t-test of the mean dCOM values was performed 
and resulted with an overall p-value of 0.01 for the averaged dataset. Therefore, the use of 3 
external markers showed statistically significant improvements in lesion dCOM in comparison to 
the use of no external markers.
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Table 3.6 Lesion correlation for Phantom A when no external markers are used for the deformation (left) vs. three 
external markers used for the deformation (right). 
Without Marker Analysis With 3 Marker Analysis (dM ≤ 0.5 mm) 
Lesion ID dCOM (mm) dO (mm) Overlap Lesion ID dCOM (mm) dO (mm) Overlap 
1 8.2 ± 0.3 3.4 ± 0.4 no 1 4.5 ± 0.2 n/a yes 
2 10.2 ± 0.7 3.6 ± 0.3 no 2 7.1 ± 1.1 n/a yes 
3 5.0 ± 0.3 n/a yes 3 3.9 ± 0.5 n/a yes 
4 8.5 ± 0.1 1.9 ± 0.1 no 4 8.4 ± 0.5 1.1 ± 0.0 no 
5 4.7 ± 0.5 n/a yes 5 2.0 ± 0.5 n/a yes 
6 4.5 ± 0.1 1.5 ± 0.6 no 6 3.6 ± 1.4 n/a yes 
Average 6.8 2.6 Overlap Average 4.9 1.1 Overlap 
σ 2.4 1.1 2/6 σ 2.4 0.0 5/6 
 
3.4.5 Accuracy of deformable mapping technique for phantom B 
Based on the results for Phantom A, Phantom B was only imaged with three markers in the 
positions F, A, and B as illustrated in Figure 3.2. Phantom B has 12 lesions, all of which were 
viewed with ABUS. However, only 7 of the lesions were viewed in the DBT images because 5 
lesions were too close to the chest wall and moved outside the image field of view when the 
phantom was compressed. Without the use of markers analysis, 4 lesions were correlated (within 
15 mm of each other) with only 1 overlapped. As shown in Table 3.7, the average dCOM between 
corresponding ABUS and DBT lesions for the 3 readers was 9.7 ± 3.5 mm and the average lesion 
dO was 2.9 ± 1.8 mm. For the segmented data without marker analysis only one lesion showed 
overlap. These results are tabulated in Table 3.7.  
 Table 3.7, also includes a comparison between the deformable mapping method without 
marker analysis with that for 2 and 3 external markers. Using 2 and 3 marker analyses, the 
average dCOM between corresponding lesions improved by 18% and 27%, respectively, relative 
to the no markers case. For the 4 lesions correlated without marker analysis a paired t-test of the 
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mean dCOM values was performed with the results for 2 and 3 marker analysis combinations and 
both resulted in p-values of 0.01 respectively. Therefore, these 4 lesions on average show 
statistically significant improvement in lesion dCOM with the use of external markers. Figure 3.12 
displays the improvement from no marker analysis to that with three marker analyses in Phantom 
B for all correlated lesions for Reader 1 segmented datasets. 
 
Figure 3.12 Phantom B lesion correlation for Reader 1 (a) without marker analysis in the coronial view (b) with 
three marker analyses in the coronial view (c) without marker analysis in the axial view (d) with three marker 
analyses in the axial view. All numeric values correspond with Lesion ID’s in Table 3.7. Note that for the without 
marker analysis lesions 5, 6, and 7 did not meet the correlation criteria of being within 15 mm of each other (See 
Table 3.7). (Blue = ABUS, Yellow = DBT) 
Table 3.7, shows a comparison between the deformable mapping method without marker 
analysis and with 2 and 3 external markers. The mean dCOM values for 2 and 3 marker analyses 
are 7.6 ± 3.6 mm and 8.5 ± 4.0 mm, respectively. A paired two-sample t-test for means was 
performed on the average dCOM values. The p-value was 0.053 and supports that the difference 
between using 2 markers and 3 markers is not statistically significant. Lesion ID=7 values were 
calculated for only two readers, as that specific lesion was not within bounds for correlation for 
one of the readers as defined in Table 3.2.  
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Table 3.7 Lesion correlation for Phantom B when no external markers are used for the deformation and with the use 
of 3 and 2 marker analysis. Note: Lesion Overlap is defined by the resultant of at least 2 out of 3 readers’ data 
showing overlap for that specific lesion between ABUS and DBT set. +Indicates that lesion 3 in no marker analysis 
showed overlap for 2 out of 3 readers’ datasets. * Indicates that lesion 7 was out of correlation bounds for one 
reader set and therefore the values are averaged based for two readers’ data and not all three. 
Without Marker Analysis With 2 Marker Analysis (dM ≤ 0.5 mm) With 3 Marker Analysis (dM ≤ 0.5 mm) 
Lesion ID dCOM (mm) 
d
O
 
(mm) 
Overlap Lesion ID dCOM (mm) dO (mm) Overlap Lesion ID dCOM (mm) dO (mm) Overlap 
1 13.8 ± 0.4 2.7 ± 0.2 No 1 5.8 ± 2.0 n/a Yes 1 9.1 ± 0.9 n/a Yes 
2 8.1 ± 0.5 2.9 ± 0.4 No 2 3.4 ± 0.9 n/a Yes 2 2.9 ± 1.5 n/a Yes 
3+ 5.8 ± 2.4 0.8 ± 0.0 Yes 3 3.4 ± 0.7 n/a Yes 3 3.3 ± 2.0 n/a Yes 
4 11.1 ± 2.0 5.2 ± 1.3 No 4 6.7 ± 1.5 n/a Yes 4 8.3 ± 1.6 1.1 ± 1.3 No 
5 n/a n/a n/a 5 10.1 ± 1.2 1.0 ± 0.9 No 5 11.5 ± 0.8 1.6 ± 0.5 No 
6 n/a n/a n/a 6 11.1 ± 2.7 4.0 ± 0.4 No 6 11.8 ± 3.7 5.1 ± 1.6 No 
7 n/a n/a n/a 7* 12.7 ± 0.7 5.8 ± 0.1 No 7* 12.8 ± 0.2 6.6 ± 0.8 No 
Average 9.7 2.9 Overlap Average 7.6 3.6 Overlap Average 8.5 3.6 Overlap 
σ 3.5 1.8 1/4 σ 3.6 2.5 4/7 σ 4 2.6 3/7 
3.5 Discussion  
A novel automated deformable mapping algorithm has been described and assessed between 
upright DBT and supine ABUS images. Although this method uses commercially-available 
biomechanical modeling and FEA software, the techniques described can be applied to other 
commercially available software or research algorithms. This study demonstrates that with the 
use of 2-3 external fiducial markers for the deformation results in up to 28% improvement in 
lesion correlation (dCOM) in comparison with not using external markers. An expansion of this 
work will incorporate an interface on a radiologist work station for displaying corresponding 
lesions in the original ABUS and DBT slices as shown Figure 3.13.  
 72 
 
Figure 3.13 Relating corresponding lesion in DBT and ABUS original datasets for Phantom A based on use of 
deformable mapping algorithm results 
Figure 3.10 demonstrates that for Phantom A, as the number of external fiducial markers that 
are used for deformable mapping increase from 4 to 6, the overlap fraction remains the same and 
the average dCOM remains approximately the same. This effect is probably a result of Phantom A 
being a stiff phantom. It should be noted that although, in this study, two different compression 
forces were used, and the phantoms represented two different breast densities, the automated 
deformable mapping algorithm was successful in identifying the majority of the corresponding 
lesions within the two phantom data sets. This supports translation of the deformable mapping 
method to actual patient data where there will be a wide range of compressions used as well as 
differences in breast density and size.  
For Phantom B, without marker analysis only 4 lesions were correlated. Comparative t-tests 
of the means of the dCOM of those lesions without marker analysis to those with 2 and 3 marker 
combinations indicated statistical significance. With the use of 2 and 3 markers all 7 lesions 
came within correlation parameters. However, a statistically insignificant t-test of dCOM between 
the use of 2 and 3 markers indicates no greater improvement in correlation with the use of 3 
markers over 2 in the indicated geometry. Nevertheless, additional markers in the axillary region, 
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which was not simulated in the phantoms for this study could potentially allow better registration 
in patient imaging. This will be investigated in future studies. 
It is difficult to directly compare the results between Phantom A and Phantom B for the 
following reasons: Phantom A used more external markers than Phantom B. Phantom B did not 
contain the Z-skin membrane and all lesions were near the chest wall. Phantom B was easily 
compressed simulating a fatty breast and Phantom A represented a breast with higher glandular 
tissue content. Using only 3 external markers for Phantom B vs. 6 markers for phantom A may 
have biased the results. Using the same number of external markers for both phantoms would 
have allowed for a better direct comparison between the two data sets.  
Overall, the phantoms were easily segmented by readers. The largest differences between 
readers and variance in reader reproducibly were evident in the DBT data sets. Due to poor axial 
resolution in DBT imaging, determining where lesions were blurred or out of focus at the 
superior and inferior extents of the lesions was difficult. Therefore, the use of an automated 
segmentation method would be useful and will be investigated for future work. Drawing the top 
and bottom of the lesions at a distance from the central plane equal to the mean circumference in 
the central plane might prove most effective. After lesions are correlated, their borders in DBT 
might be drawn better based on the ABUS contours.  
When deforming the DBT model to the base ABUS model this study assumes that all lesions 
are homogenous and have the material properties of dense lesions. After correlation has taken 
place, for lesions that correlated to cystic lesions in the ABUS set the algorithm could be rerun 
with the correct cystic material properties. In actual patient data, there will be heterogeneity in 
breast tissue. An expansion of this study could investigate the significance of this heterogeneity 
in the FEA-based registration.  
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The use of 2 or 3 markers for deformable mapping with Phantom A showed improvements 
for dCOM results over the use of 4-6 markers. Based on marker placement in this study, markers 
located inferior to the nipple have direct contact with the breast support plate during DBT 
compression. The inferior part of the phantom flattens initially when the phantom is placed in 
contact with the breast support plate. It is believed that this contact restricts the movement of the 
markers resulting in small displacements of the markers in this region. The contact could also 
cause the markers to stick to the breast support plate during compression and fall off the breast 
eliminating their use in the subsequent ABUS scans and therefore in the deformable registration. 
Conversely, markers located superior to the nipple (Figure 3.2 Positions A, B, and F) did not 
have initial contact with the DBT compression paddle and the marker displacements were not as 
easily compromised between DBT and ABUS imaging. Results from both phantoms indicate that 
a minimum of two or three external markers at the indicated positions provide significant 
improvement in lesion registration. However, we intend to directly quantify the number of 
markers and their respective locations that are the most helpful in an IRB approved proof-of-
concept study with patients. Likewise, an MRI to US breast study also used three external 
markers at those approximate locations and found improvement in lesion registration.72  
Intuitively, one would suspect that more external markers would allow for better correlation. 
However, this study indicates that when modeling large breast compressions, external 
deformation may not be completely indicative of internal breast deformation. The degree to 
which this holds true for real breasts is yet to be determined. We believe that determination of 
optimal external marker positions on the breast could yield better results in lesion correlation, 
which could allow the use of fewer markers. A recent study using external fiducial markers to 
register MR breast images with microwave images found that fewer better placed fiducial 
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markers reduced the effect of skin translation that is associated with movement of internal 
structures in the breast.123 
The multimodality phantoms used in this work have limitations with respect to simulating 
real breasts. Some of these limitations include: 1) they are made of materials that follow a linear 
elastic behavior while under compression; whereas, real breast tissue follows hyperelastic 
behavior20,38,39, 2) they have a homogeneous background; whereas, real breasts have a 
heterogeneous background and 3) they do not simulate attachment to the pectoral structure which 
could also contribute to the linear elastic behavior. Our planned human subject study will 
determine the degree to which these limitations affect the results in patients. To reduce these 
effects, we will use automatic segmentation of the DBT images into glandular and adipose 
tissues and include the elasticity properties of those tissues in our model. Further developments 
are needed to produce physical breast phantoms with materials that better model patient specific 
breast tissue properties and can model the axillary region of the breast. Other deformable breast 
registration studies have proposed the use of patient-specific in vivo parameters to determine 
biomechanical properties.71,85 
During ABUS imaging, up to 3 scans are rendered to image the breast in its entirety. The 
Invenia system scans from the superior to inferior margins of the breast producing axial images. 
The scans are performed in an AP view. For different views of the breast, this process can be 
repeated with parasagittal imaging planes. Multiple ABUS scans allow the ability to estimate the 
patient-specific distribution of elastic properties in the breast. Inclusion of ABUS-based 
elastography or pulse echo segmentation124 could offer great benefits for the deformable 
mapping algorithm and other biomechanical techniques for use in FEA. With more ABUS scans, 
the need for an additional marker near the axilla region of the breast could be helpful in relating 
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ABUS projections. The present study only considers one ABUS volume; whereas, up to three 
volumes can be taken during an ABUS exam of a patient. Stitching or overlaying ABUS views 
into one volume would be helpful and provide better coverage for deformation of the DBT FE 
base algorithm. ABUS stitching or overlay could also allow this technique to deform the base 
ABUS model into the DBT base model. This would allow the correct cystic and dense lesion 
material properties to be assigned before FEA to their respective lesions. A future goal is to 
include correlation between DBT and ABUS sets in the axilla region of the breast.  
     When translating this technique to patients, we intend to use more external markers placed at 
better breast locations and have the patient wear a special camisole for the ABUS acquisitions. 
Currently, this study shows satisfactory results with the use of just three external markers for 
both phantoms. The use of more external markers will allow for full coverage of the breast 
including the axillary region and we can better determine what number of markers and their 
locations render the best results. As shown for the results of Phantom B, it would be better to 
directly determine which marker locations are best for all patient data by using the same number 
of markers at the same locations and then using the algorithm to determine the minimum needed 
for a desired registration result. 
     We expect that with the use of a breast ultrasound camisole, breast movement between 
various scans can be restricted. This restriction should reduce the effect of varying the 
compression between ABUS views. The use of the camisole can also address an additional 
potential problem with the external markers becoming attached to the ultrasound mesh paddle 
between multiple ABUS compressions. This camisole would need to be made of sheer material 
similar to the Invenia mesh membrane that does not affect the ultrasound depth of penetration 
and also does not interfere with coupling to the ultrasound transducer. Ultrasound penetration 
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and coupling of the Invenia mesh material is well understood and in some cases the use of this 
material improves coupling as it holds ultrasound gel in place. The SonoCiné AWBUS system 
(SonoCiné, Inc., Reno, NV)125 is a commercially available system that uses an ultrasound 
camisole that fits similar to a sports bra to reduce breast movement during scanning. By 
restricting breast motion, a breast camisole should allow for improvement in lesion registration 
for the deformable mapping algorithm.  
     Specifically, even if some markers become detached there will still be a sufficient number 
remaining that can be used for registration. This study uses a tight 15 mm bound when 
determining a match between corresponding lesions since the phantoms have a uniform 
background. When translated to real breasts, this bound will likely increase due to breast 
heterogeneity and breast structures (i.e. Cooper’s ligaments) that will not be modeled in the FE 
process. Additionally, we expect to segment glandular tissue from the background adipose tissue 
in the breast of the ABUS43 and DBT images. Several studies, have found successful results in 
determining breast density from DBT breast images.44–46 Although, the poor spatial resolution of 
DBT in the z (depth) direction reduces the accuracy of the dense tissue segmentation in that 
direction, the overall coarse volumetric segmentation should still be of value in providing 
information about the spatial distribution of the glandular and adipose tissues within the breast 
for the deformable mapping. This should assist with the lesion correlation when the method is 
translated to patient images.  
     The process that took the most time in this study was the manual segmentation. In order for 
this technique to be effective in a clinical platform semi-automated and automated segmentation 
techniques will be needed and explored. Once all images are segmented the automated 
deformable mapping algorithm takes about 40 minutes to run on a Windows 7 Intel® Core™ i7 
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CPU with a speed of 2500 MHz and 4GB RAM. The runtime could be improved greatly with a 
computer with more memory and a capable GPU. 
3.6 Conclusions 
This work demonstrates the potential use of deformable mapping techniques to relate lesions 
between DBT and ABUS breast images. The utilization of external fiducial markers has been 
shown to improve the accuracy of this approach. The resulting one-to-one correlation between 
lesions in DBT and ABUS could help improve radiologists’ characterization of breast lesions, 
which can reduce patient callbacks, negative biopsies and false negative biopsies. Future work 
will expand this platform to include an IRB approved study for patient volunteers, and an 
expansion of the deformable mapping technique for use in relating lesions in other breast 
modalities such as MRI, dedicated breast CT and transmission US. 
3.7 Acknowledgements 
This work was supported in-part by a research grant (15-PAF04328) from GE Global 
Research. Crystal A. Green is supported by the Science, Mathematics and Research for 
Transformation (SMART) Scholarship for Service Program (HQ0034-16-C-0008). The authors 
would like to thank Ted Lynch, Ph.D., of CIRS, Inc. for his assistance in phantom development 
and characterization. The authors would like to thank Darius Fadanelli, Eamon Whalen, and John 
P. Kytasty of Altair Engineering Inc. for their assistance in FE modeling and processing.  
 79 
Chapter 4  
Deformable Mapping Technique for lesion registration for Multiple 
Digital Breast Tomosynthesis views to Automated Breast 
Ultrasound Imageso 
 
 
4.1 Abstract 
Purpose: To test an automated deformable mapping method for registering corresponding lesions 
in the craniocaudal (CC) and mediolateral oblique (MLO) digital breast tomosynthesis (DBT)  
views to automated breast ultrasound (ABUS) images with and without the use of external 
fiducial markers. 
Methods: A Computerized Imaging Reference Systems Inc. (CIRS) multi-modality breast 
phantom containing 20 lesions was employed and imaged with DBT (upright positioning with 
CC compression and MLO compression), and ABUS (supine positioning with anterior-to-chest 
wall compression). Eight external fiducial markers (gel pads containing 1-mm glass beads) were 
attached to the surface of the breast phantom prior to the imaging. The reconstructed images 
were segmented using manual (ABUS) and semi-automated (DBT) techniques. An automated 
                                                 
o This chapter is published in the Radiological society of North America 2018 Scientific Assembly and Annual 
Meeting: Green CA, Goodsitt MM, Lau JH, Brock KK, Davis CL, Carson PL. Evaluation of an Automated 
Deformable Mapping Technique with and Without External Fiducial Markers to Relate Corresponding Lesions in 
Digital Breast Tomosynthesis and Automated Breast Ultrasound Images.itle. In: Radiological Society of North 
America 2018 Scientific Assembly and Annual Meeting, November 25 - November 30, 2018, Chicago IL. ; 2018. 
archive.rsna.org/2018/18005292.html.  
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mapping method generates, deforms, and relates the resulting models of the breast for 
registration of lesions between the DBT (CC or MLO) and ABUS image sets. Performance was 
assessed by the number of matched paired lesions and measures of the distances between the 
centers of mass (dCOM) of corresponding lesions. 
Results: The maximum number of lesions that could be matched was 18 because 2 of the 20 
lesions were too close to the chest wall to be visible in the reconstructed DBT images. For 
mapping of DBT (CC) to ABUS without markers, 14 of the 18 lesions were matched and the 
mean dCOM was 13.6 ± 6.3 mm. With markers, 17 of the 18 lesions were matched and the mean 
dCOM was 12.8 ± 6.0 mm. For mapping of DBT (MLO) to ABUS without markers, 8 of the 18 
lesions were matched and the mean dCOM was 9.3 ± 2.8 mm. With markers, 17 of the 18 lesions 
were matched and the mean dCOM was 12.3 ± 5.8 mm.  
Conclusion: This work demonstrates the potential for using this deformable mapping technique 
to identify related lesions between two DBT views and ABUS images. This method shows 
improved lesion correlation with the use of external fiducial markers and extends upon our 
previous work by incorporating registration from the DBT MLO to the ABUS view. This method 
should improve radiologists’ characterization of breast lesions which should reduce patient 
callbacks and unnecessary biopsies. Future work will include an IRB-approved proof of concept 
study with patient data for registration between DBT and ABUS images.  
4.2 Introduction 
 Ultrasound imaging used in adjunct with mammography has been shown to improve the 
characterization of breast lesions.16–18 However, at least 10% of the time lesions found in 
ultrasound images do not correspond to those in mammograms.15 This discrepancy is due to 
several factors. Mammography images the entire breast as a 2D projection which results in the 
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superposition of breast structures. Conventional ultrasound uses sound reflection imaging, 
typically from linear or convex linear arrays, that creates 2D planar images of the specified 
breast area in depth and along the length of the array. Most ultrasound imaging is controlled and 
operated by hand and therefore has high operator dependence. This can cause difficulty in 
reproducing ultrasound images. There is also a difference in patient positioning and a major 
difference in compression applied to the breast between the two modalities. Conventional 
ultrasound imaging is performed in the supine geometry where typically anterior-to-posterior 
(AP) compression is applied by a sonographer using an ultrasound transducer. Mammography 
imaging is performed with the woman upright and with typically, CC or MLO compression 
being applied to the breast between a compression plate and detector panel.  
 Three dimensional forms for ultrasound and mammographic technologies ultrasound exist 
and could be beneficial in relating lesions between these 3D imaging modalities. A 2D 
mammogram only allows localization of a mass to a line through the thickness of the breast. 
Automated breast ultrasound, ABUS, has advantages over conventional breast ultrasound in 
terms of reproducibility and operator independence by visualizing the breast as a 3D image 
volume. Studies have shown the addition of ABUS images with mammography screening have 
significantly improved breast cancer detection rate for women with dense breasts. 19,57,58 Digital 
breast tomosynthesis, DBT, is a quasi-3D form of mammography that provides better detection 
and characterization of breast lesions over mammography through the reduction of tissue 
superposition. However, even with these improvements, DBT has not completely eliminated the 
need for the use of ultrasound as a complement to DBT/mammography.109,110 
 In our previous work34, a deformable mapping method was developed to relate 
corresponding lesions between the DBT (CC view) to ABUS where a significant improvement 
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(p=0.01) was shown using external fiducial markers to aid in the methodology. The purpose of 
the present study is to extend upon this work by evaluating the deformable mapping technique 
using both the CC and MLO DBT views to relate corresponding masses to ABUS. This is 
significant as the MLO view is important for imaging close to the axillary regions of the breast 
which encompasses the upper outer breast quadrant where most cancers are located.126 A study 
by Duffy et al. suggests that using breast density as an indicator of breast cancer risk is enhanced 
by interactive software that uses the CC and MLO view vs a single view.58 Additionally, this 
work also incorporates the use of semi-automated segmentation of the lesions in the DBT 
images; whereas only manual segmentation was used for all modalities in our previous work34. 
4.3 Materials and Methods 
4.3.1 Phantom 
 A CIRS Multi-Modality Breast Biopsy and Sonographic phantom (Computerized Imaging 
Reference Systems, Inc., Norfolk, Virginia)p was used in this study. The phantom contains a total 
of 20 lesions: 10 spherical cystic lesions, 5 spherical dense lesions, and 5 spiculated dense 
lesions. The lesions are randomly located in a background gel, Zerdine, and wrapped in a Z-skin 
membrane material. The lesions are made of the similar Zerdine-based materials; however, the 
cystic lesions have anechoic properties and the dense lesions have hyperechoic properties under 
ultrasound. Material properties phantom components were provided by the manufacturer in 
Table 4.1. For use in the finite element analysis (FEA) solver, a Poisson’s ratio of 0.49 was used 
for convergence stability since the FEA solver cannot run using a Poisson’s ratio of 0.50.  
 
                                                 
p http://www.cirsinc.com/file/Products/073/073%20DS%20110617(3).pdf   
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Table 4.1 Material Properties of CIRS phantom 
 Young’s Modulus (E) Poisson’s Ratio (ν) 
Z-skin Membrane  10 kPa 0.50 
Zerdine background gel  10 kPa 0.50 
Lesions  60 kPa 0.50 
 
4.3.2 External Fiducial Markers 
 The breast phantom was marked with a magic marker to differentiate marker locations. 
Eight external fiducial markers were attached using Jobst “It-Stays” Roll-On Adhesive (BSN 
Medical, Charlotte, NC)q to the breast phantom at the indicated locations as shown in Figure 4.1. 
Each marker contains a solid 1 mm diameter glass bead within a thermoplastic elastomer gel. 
The 1 mm glass bead within the gel can be clearly seen in the reconstructed images and are used 
to aid in the deformable mapping process. A detailed explanation of how these markers are 
created can be found in our previous study34 and in the Appendix. 
 
Figure 4.1 CIRS Multi-modality phantom with 8 external markers attached 
                                                 
q  http://www.jobst-usa.com/product/it-stays-roll-on-adhesive/ 
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 This phantom was imaged using DBT and ABUS techniques, the external fiducial markers 
can be clearly seen in reconstructed DBT and ABUS images as shown by the red arrow in Figure 
4.2.  
 
Figure 4.2: Reconstructed slice indicating external fiducial marker (red arrow) for a slice of (a) DBT 
(CC view) (b) DBT (MLO view) (c) ABUS transverse view (d) ABUS coronal view 
4.3.3 Image Acquisition 
 The GE Senographe Pristina DBT system (GE Healthcare, Milwaukee, WI) was used to 
image the phantom in CC and MLO view. For the CC view, a compressive force of 3 daN 
(decanewton) was used and the phantom was compressed to a thickness of 44.2 mm. For the 
MLO view, a compressive force of 2.5 daN was used and the phantom was compressed to a 
thickness of 48.5 mm. For both image views, only 18 lesions were shown in reconstructed DBT 
images. Two lesions were not seen because they are close to the phantom “chest wall”. The 
phantom backing restricts the ability to image close to that area.  
      Lastly, the phantom was imaged with the GE Invenia ABUS system (GE Healthcare, 
Milwaukee, WI). Light anterior-to-posterior (AP) compression is applied when imaged with the 
Invenia and the medium imaging setting was used. The Invenia ABUS operates between 6-15 
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MHz and can image up to a 50 mm depth. The system contains three settings based on imaging 
depth (high, medium and low). For this study, the medium setting was used which images up to 
40 mm. Clinical procedures can include up to three image sweeps of the breast depending on 
breast size to ensure coverage of the breast and axillary region in its entirety. Due to the absence 
of the axillary region, only one image sweep using ABUS was acquired. All 20 lesions were 
shown in reconstructed ABUS images.  
4.3.4 Segmentation Techniques 
 Lesions in the DBT acquired images were segmented using a semi-automated segmentation 
program called MiViewer.127 For the ABUS images, all dense lesions were segmented using the 
MiViewer program. The 10 cystic lesions in ABUS images were segmented using automated 
nonlinear filtering and segmentation approach by Elawady et al.128 Figure 4.3 shows a 
representation of segmentations of the phantoms.  
 
Figure 4.3: Segmentation of lesions within an image slice of (a) DBT CC (b) DBT MLO (c) ABUS 
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4.3.5 Automated deformable mapping algorithm 
 The deformable mapping algorithm is an automated process that integrates the use of 
Morfeus, a commercial FE pre-processor (HyperMesh 2017, Altair Engineering, Troy, MI) and a 
finite element analysis (FEA) solver processor (Optistruct 2017, Altair Engineering, Troy, MI). 
An overview of the process is shown in Figure 4.4. The entire algorithm takes up to 
approximately 60 minutes to complete from start to finish on a Windows 7 Intel® Core™ i7 
CPU with a speed of 2500 MHz and 4GB RAM. 
 
Figure 4.4 The automated deformable mapping process for DBT to ABUS registration. Software’s used 
are shown in red.  
 In ABUS imaging, poor acoustic contact with the transducer often occurs around the 
periphery of the breast causing artifacts as shown on the right and left sides of Figure 4.2 (c). 
These artifacts cause the actual breast size and shape in ABUS imaging to be unknown. In 
comparison, the breast shape and size are better defined in the DBT (CC or MLO) images as 
shown in Figure 4.2 (a) and Figure 4.2 (b). Therefore, the deformable mapping algorithm 
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performs deformation only to the DBT FE model and registers the resulting deformation to the 
reference ABUS image set.  
 The algorithm begins with a conversion of DICOM segmented images to a triangular surface 
mesh using Morfeus, a finite element based multi-organ deformable image registration platform. 
Morfeus converts the DICOM image data into mask files for image analysis using Interactive 
Data Language (IDL, Research Systems Inc.). A surface mesh is created for each individual 
contour. Morfeus uses Laplacian smoothing and a decimater function in order to maintain a 
reasonable mesh size while maintaining structure features for each mesh.  
 Next, the algorithm uses the FE pre-processing software, HyperMesh, to build the base FE 
models for the DBT (CC and MLO) image sets from the associated mesh surface contours. From 
these contours, 3D four-point tetrahedral FE models are generated for each modality which 
results in fully connected meshed FE base DBT and ABUS models. Material properties are 
assigned to the different models as noted in Table 4.1. The number of elements/nodes is 
577,295/99,684 for the base DBT (MLO) model, 547,426/94,408 for the base DBT (CC) model 
and 231,990/38,021 for the base ABUS model. 
 Skin deformation for the DBT (CC) model to ABUS is explained in Sec. 3.3.5.3. Skin 
deformation for the DBT (MLO) model is slightly different and will be described as follows. For 
the base DBT-MLO model the ABUS, the ABUS model is rotated -45 (Figure 4.5, brown) for 
the left breast and 45 for the right breast. Then the DBT-MLO base model (Figure 4.5 (a), blue) 
is translated and rotated to the COM of the rotated ABUS model as shown in Figure 4.5 (a). Skin 
deformation then performs exactly as described in Sec. 3.3.5.3 by manipulating the handles (red 
and yellow spheres shown in Figure 4.5). First corrections along the axial plane of the breast are 
                                                 
r A decimate function is used to decrease the sampling rate of a signal sequence or continuous function by an integer 
factor 
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made along the y-axis as shown in Figure 4.5 (b) and then corrections along the coronal plane as 
shown in Figure 4.5 (c). Again, there are no corrections along the sagittal axis (x-plane) due to 
poor transducer coupling on the right and left sides of the breasts as shown in Figure 4.2 (c). 
 
Figure 4.5 Skin Mesh transformation for base DBT-MLO model (blue) to ABUS model (brown) (a) 
translation and rotation of DBT-MLO model to COM of ABUS model (b) decompression of skin model 
along the y-axis to match ABUS shape (c) compression in the z direction of the DBT-MLO model 
 Once skin surface deformation is completed, the algorithm computes the COM positions of 
the external marker locations between the two models as described in Chapter 3 Sec. 3.3.5.4. 
Once the marker locations are matched the handles shown in Figure 4.5 are manipulated again so 
that the DBT-MLO model is more aligned with the external markers of the reference ABUS 
model within a user-defined distance, dM. The resulting changes in the displacement of each node 
of the original surface mesh (Figure 4.5 (a)) are applied as boundary conditions for FEA 
deformation. The boundary conditions are applied to the translated base DBT model (Figure 4.5 
(a) for MLO case) that incorporates changes for skin deformation and external marker 
correlation. These boundary conditions are used as input for the FEA solver, Optistruct. 
Optistruct generates and solves the differential equations that describe the model deformation 
and returns the resulting stress and strain due to the deformation of the entire breast volume. The 
FEA was performed on a Windows 10 Intel® Core™ i7 CPU speed of 2500 MHz with 4GB 
RAM with analysis complete in approximately twenty minutes. 
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After FEA is performed the COM of all lesions between the resultant DBT model and the 
reference ABUS model are calculated. The COM of each lesion is computed by exporting the 
nodal (x, y, and z coordinates) from HyperMesh of the lesion exterior surface mesh and taking an 
average of those coordinate values. The algorithm then determines which lesions correspond by 
determining the minimum distance between COMs and ensuring the lesions are within 
correlation guidelines as described in Table 4.2. The dCOM value for this study increased due to 
the softness of this phantom in comparison to the previous study in Chapter 3 Sec. 3.3.5.6. The 
minimum distance to overlap, dO, for non-overlapping lesions is restricted by half of tolerable 
dCOM distance in order to reduce the likelihood of a match discrepancy. The results are exported 
as a table and are used to relate the original position from the ABUS and DBT DICOM data.  
Table 4.2: Lesion correlation criteria between DBT (CC or MLO) and ABUS models 
 dCOM dO 
Overlapping Lesions dCOM ≤ 25 mm n/a 
Non-overlapping Lesions  dCOM ≤ 25 mm dO ≤ 12.5 mm 
 
4.3.6 Studies Performed 
 Studies were undertaken to evaluate the performance of the deformable mapping technique 
for DBT (CC view) to ABUS and DBT (MLO view) to ABUS and are described as follows: 
• Accuracy of the deformable mapping technique for DBT (CC) to ABUS registration: 
Results (dCOM) are compared between using the deformable mapping algorithm (with and 
without marker analysis). T-test and signed Wilcoxon rank tests are used to provide the 
null hypothesis, that there is no improvement using the deformable method with using 
external marker locations in comparison to using the deformable method without external 
marker analysis included. Based off dCOM results further analysis is performed to 
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determine how the dCOM results vary based off lesion locations within the breast (e.g. 
quadrants and depths) and the effect lesion proximity to external markers.  
• Validation of deformable registration of DBT (MLO view) mapped to ABUS images: This 
study was performed just as described previously for the DBT (CC view).  
4.4 Results 
4.4.1 Accuracy of deformable mapping technique for DBT (CC) to ABUS registration 
      An overview of results for lesion registration of the DBT (CC) model to ABUS is illustrated 
in Table 4.3. A maximum of 18 lesions can be related in the reconstructed DBT (CC) images 
since 2 lesions were located too close to the phantom “chest wall” and pushed outside of the 
detector field of view. Without the use of marker analysis (Step 4 is skipped in Figure 4.3), 14 
lesions were matched with an average dCOM of 13.6 ± 6.3 mm. With the use of external markers 
this improves to 17 matched lesions with a mean dCOM was 12.8 ± 6.0 mm. With the use of 
external markers, the total number of matched lesions improved to 17 out of 18. When all 
external markers were within 1-mm distances (dM ≤ 1 mm) the average dCOM was 12.93 ± 6.28 
mm. When the external markers were within 5-mm (dM ≤ 5 mm) the average dCOM was 12.83 ± 
6.03 mm. The mean difference in lesion dCOM was 0.10 mm. A paired t-test was performed on the 
mean dCOM values when markers are within a 1 mm distance (dM ≤ 1 mm) and a 5 mm distance 
(dM ≤ 5 mm) and resulted in a p-value of 0.64. Using a Wilcoxon signed-rank test the p-value 
was calculated to be 0.49. Thus, both statistical tests show that the null hypothesis cannot be 
rejected. 
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Table 4.3: Lesion correlation summary for DBT (CC) registered to ABUS. A maximum of 18 lesions could be 
matched between image sets. 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 14 17 17 
Mean dCOM (mm) 13.6 ± 6.3 12.9 ± 6.3 12.8 ± 6.0 
Mean dO (mm) 5.3 ± 3.6 5.4 ± 3.3 4.9 ± 3.3 
Total Overlapping Lesions 4 6 6 
 
 To assess the effect of deformable mapping with external fiducial marker vs. without 
external fiducial marker analysis, a paired t-test of the dCOM's was performed for the 14 lesions 
that were matched without marker analysis to the same 14 lesions that were matched with marker 
analysis with dM ≤ 1 mm and dM ≤ 5 mm. A summary of the values used for this calculation is 
shown in Table 4.4. Using a paired t-test the resulting p-value for dM ≤ 1 mm and dM ≤ 5 mm was 
0.19 and 0.04. Thus, for those 14 lesions using a dM ≤ 5 mm for the deformable registration 
indicates significant improvement in lesion dCOM with the use of external fiducial markers. Using 
a Wilcoxon signed-rank test the resulting p-value for dM ≤ 1 mm and dM ≤ 5 mm was 0.21 and 
0.06. Thus, both statistical tests show that the null hypothesis cannot be rejected. 
 There were 4 lesions whose correlated dCOM’s worsened using marker analysis (Lesion ID’s 
4, 8, 9, and 10 in Table 4.6) and three of those lesions were in the superior lateral breast margins. 
There were 3 lesions that were not within correlation bounds without using marker analysis but 
became within correlation bounds using marker analysis (Lesion ID’s 6, 11, and 12 in Table 4.6) 
which two of these are in the central lateral breast margin, one is located in central medial breast 
margins and all lesions were posterior in depth. Lesions that showed the greatest improvements  
(dCOM (without markers analysis)- dCOM (with markers analysis) ≥1.12 mm based on the 95% 
confidence interval) are along the medial breast margins (Lesion ID’s 2,3,14 and 17 in Table 4.6) 
and inferior breast margins (Lesion ID’s 3, 5, and 13 in Table 4.6).  
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Table 4.4: Lesion correlation summary for 8 matched lesions between without marker analysis and with marker 
analysis cases for DBT (CC) registered to ABUS. 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 14 14 14 
Mean dCOM (mm) 13.6 ± 6.3 12.7 ± 5.9 12.5 ± 5.8 
Total Overlapping Lesions 4 5 5 
 
 Figure 4.6 visually displays the improvement in lesion correlation between the DBT (CC) to 
ABUS models for several lesions.   
 
 
Figure 4.6 Lesion correlation for DBT-CC (blue) registered to ABUS (yellow) for selected lesions in the coronal 
plane (a) without marker analysis (b) with marker analysis. Note: All lesions could not be shown due to 
superposition. 
 A study was performed to show how dCOM results varied with the distance of the lesions to 
the nearest matched external fiducial marker. This study also was performed to quantify the 
amount of improvement in dCOM when a lesion is closer to the nearest ABUS external marker. 
The distance between the lesion COM and the nearest ABUS external marker is denoted as the 
dCOM-M. Results for this study are shown in Table 4.5. From this table we see that markers that had 
most improvements (negative difference in dCOM using marker analysis vs. no markers used) 
were Lesion ID’s 3, 5 and 13. These lesions were at least 26 mm away from the nearest external 
marker (dCOM-M). The lesions that were closest to an external marker (dCOM-M ≤ 10 mm) were Lesion 
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ID’s 1 and 4. From these two lesions one shows improvement in dCOM while the other does not. Lesion ID 
8 was the furthest away from the nearest marker and had a corresponding dCOM of 6.2 mm using marker 
analysis. Visually, as shown in Figure 4.7, we see that lesions proximity to external markers is 
independent of corresponding dCOM. 
Table 4.5: Effect of dCOM based on lesion COM distance to nearest external marker (dCOM-M.) 
Lesion ID 
Without Marker Analysis With Marker Analysis (dM ≤ 5 mm) Difference in 
dCOM (mm) dCOM (mm) dCOM (mm) dCOM-M  (mm) 
1 12.5 11.5 8.8 -1.0 
2 4.6 3.2 23.0 -1.4 
3 8.0 3.5 33.1 -4.5 
4 8.0 9.3 6.4 1.3 
5 23.3 19.5 26.5 -3.8 
6 n/a 23.9 27.0 n/a 
7 11.3 10.9 29.6 -0.4 
8 5.0 6.2 37.0 1.2 
9 21.2 21.6 23.5 0.4 
10 14.4 15.0 21.2 0.6 
11 n/a 9.5 15.7 n/a 
12 n/a 10.1 18.8 n/a 
13 23.6 19.2 25.5 -4.4 
14 11.1 8.9 21.6 -2.1 
15 14.3 14.1 23.8 -0.2 
16 16.5 15.9 16.7 -0.6 
17 17.3 15.7 32.4 -1.6 
18 n/a n/a 22.8 n/a 
Average 13.6 12.8 23.0 -1.2 
 6.3 6.0 7.9 2.0 
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Figure 4.7: Plot of dCOM (COM distance between corresponding lesions) vs dCOM-M (distance between COM of lesion 
to nearest external marker) for DBT (CC view) to ABUS 
 Figure 4.8 shows a GUI-Viewer for a marked corresponding lesion in the DBT (CC view) to 
ABUS original DICOM image sets. From the view in the ABUS image the suspicious mass can 
be interpreted as a dense spiculated solid lesion. Detailed lesion correlation values are shown in 
Table 4.6. Further information on the GUI viewer can be found in the Appendix. 
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Figure 4.8: GUI representation for marked corresponding lesion (Lesion ID=1 see Table 4.5) in the DBT (CC) to 
ABUS original DICOM image views. From the view in the ABUS image the suspicious mass can be interpreted as a 
dense solid lesion. Detailed corresponding lesion values are shown in Table 4.6. 
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Table 4.6: Lesion correlation results for each lesion with and without marker analysis for DBT (CC) registered to 
ABUS. Location for breast margins abbreviations include I=Inferior S=Superior C=Central A=Anterior 
P=Posterior M=Medial L=Lateral 
Lesion ID 
Lesion Type & 
(Location) 
Without Marker Analysis 
With Marker Analysis 
 (dM ≤ 5 mm) 
dCOM 
(mm) 
dO 
(mm) 
Overlap dCOM (mm) dO (mm) Overlap 
1 Dense (UOQ-A)  12.5 1.2 no 11.5 0.0 yes 
2 Dense (LIQ-A) 4.6 0.0 yes 3.2 0.0 yes 
3 Dense (UIQ-P) 8.0 0.0 yes 3.5 0.0 yes 
4 Dense (UIQ-A) 8.0 1.3 no 9.3 0.0 yes 
5 Dense (UIQ-P) 23.3 10.4 no 19.5 5.8 no 
6 Dense (UOQ-P) n/a n/a n/a 23.9 10.7 no 
7 Cystic (LOQ-P) 11.3 0.0 yes 10.9 0.0 yes 
8 Dense (LOQ-A) 5.0 0.0 yes 6.2 0.3 no 
9 Dense (LOQ-P) 21.2 8.2 no 21.6 8.1 no 
10 Dense (LOQ-P) 14.4 3.2 no 15.0 3.3 no 
11 Cystic (UOQ-P) n/a n/a n/a 9.5 0.0 yes 
12 Cystic (UOQ-P) n/a n/a n/a 10.1 0.7 no 
13 Cystic (UOQ-P) 23.6 11.6 no 19.2 7.4 no 
14 Cystic (UIQ-P) 11.1 4.0 no 8.9 2.7 no 
15 Cystic (LIQ-A) 14.3 2.6 no 14.1 3.8 no 
16 Cystic (LIQ-A) 16.5 5.4 no 15.9 6.2 no 
17 Cystic (LIQ-A) 17.3 5.1 no 15.7 5.4 no 
18 Dense (UIQ-P) n/a n/a n/a n/a n/a n/a 
Mean 13.6 5.3 Overlap 12.8 4.9 Overlap 
 6.3 3.6 4/14 6.0 3.3 6/17 
4.4.2 Accuracy of deformable mapping technique for DBT (MLO) to ABUS registration 
 An overview of results for lesion registration of the DBT (MLO) model to ABUS is 
illustrated in Table 4.7. A maximum of 18 lesions can be related in the reconstructed DBT 
(MLO) images since 2 lesions were located too close to the phantom “chest wall” and pushed 
outside of the detector field of view. Without the use of marker analysis, only 8 out of 18 lesions 
were matched with an average dCOM of 9.3 ± 2.8 mm. When all external markers were within 1-
mm distances (dM ≤ 1 mm) the number of matched lesions improved to 16 and the average dCOM 
was 12.7 ± 6.4 mm. When the external markers were within 5-mm (dM ≤ 5 mm) the number of 
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matched lesions improved to 17 and the average dCOM was 12.3 ± 5.8 mm. A paired t-test was 
performed on the mean dCOM values of the 16 shared lesions when markers are within a 1 mm 
distance (dM ≤ 1 mm) and a 5 mm distance (dM ≤ 5 mm) and resulted in a p-value of 0.30. Using 
the Wilcoxon-signed rank test for when markers are within a 1 mm distance (dM ≤ 1 mm) and a 5 
mm distance (dM ≤ 5 mm) both resulted in a p-value of 0.60. Thus, both statistical tests show that 
the hypothesis claim cannot be rejected. 
Table 4.7: Lesion correlation summary for DBT (MLO) registered to ABUS. A maximum of 18 lesions could be 
matched between image sets. 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 8 16 17 
Mean dCOM (mm) 9.3 ± 2.8 12.7 ± 6.4 12.3 ± 5.8 
Mean dO (mm) 1.9 ± 1.3 6.0 ± 3.7 5.3 ± 3.8 
Total Overlapping 
Lesions 3 6 8 
 
 To assess the effect of deformable mapping with external fiducial marker vs. without 
external fiducial marker analysis, a paired t-test of the dCOM’s was performed for the 8 lesions 
that were matched without marker analysis to the same 8 lesions that were matched with marker 
analysis with dM ≤ 1 mm and dM ≤ 5 mm. A summary of the values used for this calculation is 
shown in Table 4.8. The resulting p-value was 0.65 using a paired t-test and the p-value was 0.95 
using a Wilcoxon signed-rank test. This indicates that the hypothesis claim cannot be rejected. 
However, with the use of markers the number of matching lesions increased from 8 to 17, 
therefore showing improvement in lesion correlation.   
 There were 9 lesions that were not within correlation bounds without using marker analysis 
but became within correlation bounds using marker analysis (Lesion ID’s 2, 5, 6, 7, 9, 10, 12, 13, 
and 15 in Table 4.10). These lesions are within various breast locations and depth of the breast. 
However, there were 4 lesions whose correlated dCOM’s worsened using marker analysis (Lesion 
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ID’s 4, 8, 11, and 18 in Table 4.10) and two of those lesions were within the upper outer 
quadrants (Lesion ID 8) and central lateral breast region (Lesion ID 11 see Table 4.10) The other 
two lesions were along the lower inner breast quadrants (Lesion ID 4 and 18 see Table 4.10). All 
of these lesions are posterior in depth and were either the most medial or most lateral lesions 
within the breast. Lesions that showed an improvement in registration using marker analysis 
were located in the upper inner quadrants (Lesion ID’s 14, 16 and 17 see Table 4.10) and one 
lesions was in the lower central breast region (Lesion ID 1 see Table 4.10).  
Table 4.8: Lesion correlation summary of 8 matched lesions between without marker analysis and with marker 
analysis cases for DBT (MLO) registered to ABUS 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 8 8 8 
Mean dCOM (mm) 9.3 ± 2.8 9.8 ± 4.2 9.8 ± 3.6 
Total Overlapping 
Lesions 3 4 4 
 
 Figure 4.9 visually displays the improvement in lesion correlation between the DBT (CC) to 
ABUS models for several lesions.   
 
Figure 4.9: Lesion correlation for DBT (MLO view) (red) registered to ABUS (yellow) for selected lesions in the 
coronal plane (a) without marker analysis (b) with marker analysis. Note: All lesions could not be shown due to 
superposition. 
 A study was performed to show how dCOM results varied with the distance of the lesions to 
the nearest matched external fiducial markers. This study also was performed to quantify the 
 99 
amount of improvement in dCOM when a lesion is closer to an external marker. Results for this 
study are shown in Table 4.9. The markers observed to have the most improvements (negative 
difference in dCOM using marker analysis vs. no markers used) were Lesion ID’s 1, 16 and 17. 
These lesions were at least 14 mm away from the nearest external marker (dCOM-M). The lesions 
that were closest to an external marker (dCOM-M ≤ 15 mm) were Lesion ID’s 11, 12 and 16. From these 
two lesions two showed improvement in dCOM while the other does not. Lesion ID 8 was the furthest away 
from the nearest marker and had a corresponding dCOM of 10.3 mm using marker analysis and without 
marker analysis was not within correlation bounds. Visually as shown in Figure 4.10, we see that 
lesions proximity to external markers is independent of corresponding dCOM. 
Table 4.9: Effect of dCOM based on lesion COM distance to nearest external marker (dCOM-M.) 
Lesion ID 
Without Marker Analysis With Marker Analysis (dM ≤ 5 mm) Difference 
 in dCOM (mm) dCOM (mm) dCOM (mm) dCOM-M (mm) 
1 11.3 8.9 20.2 -2.4 
2 n/a 7.9 17.1 n/a 
3 n/a n/a 22.7 n/a 
4 5.9 6.1 17.7 0.2 
5 n/a 11.4 22.4 n/a 
6 n/a 19.5 26.8 n/a 
7 n/a 21.9 23.2 n/a 
8 11.1 16.9 28.1 5.8 
9 n/a 21.9 14.8 n/a 
10 n/a 21.3 22.8 n/a 
11 7.9 9.9 14.4 2 
12 n/a 9.9 11.7 n/a 
13 n/a 10.3 30.9 n/a 
14 6.4 5.9 16.2 -0.5 
15 n/a 6.1 19.5 n/a 
16 13.9 12.5 14.0 -1.4 
17 10.5 8.6 27.0 -1.9 
18 7.5 9.2 25.9 1.7 
Average 9.3 12.3 20.9 0.4 
 2.8 8.9 5.6 2.7 
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Figure 4.10: Plot of dCOM (COM distance between corresponding lesions) vs dCOM-M (distance between COM of 
lesion to nearest external marker) for DBT (MLO view) to ABUS 
 Figure 4.11 shows a GUI-Viewer for a marked corresponding lesion in the DBT (MLO 
view) to ABUS original DICOM image sets. From the view in the ABUS image, the suspicious 
mass can be interpreted as a dense spiculated solid lesion. Detailed lesion correlation values are 
shown in Table 4.11. Further information on the GUI viewer can be found in the Appendix.  
 
Figure 4.11: GUI representation from original DICOM images for a lesion (Lesion ID=11 see ) left shows a slice 
from DBT (MLO) data, upper right shows the ABUS coronal view, and lower right shows the ABUS transverse view
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Table 4.10: Lesion correlation results for each lesion with and without marker analysis for DBT (MLO) registered 
to ABUS. Location for breast margins abbreviations include I=Inferior S=Superior C=Central A=Anterior 
P=Posterior M=Medial L=Lateral 
Lesion ID 
Lesion Type & 
(Location) 
Without Marker Analysis 
With Marker Analysis 
 (dM ≤ 5 mm) 
dCOM 
(mm) 
dO (mm) Overlap dCOM (mm) dO (mm) Overlap 
1 Dense (UOQ-A)  11.3 0.00 yes 8.9 0.0 yes 
2 Dense (LIQ-A) n/a n/a n/a 7.9 0.0 yes 
3 Dense (UIQ-P) n/a n/a n/a n/a n/a n/a 
4 Dense (UIQ-A) 5.9 0.00 yes 6.1 0.0 yes 
5 Dense (UIQ-P) n/a n/a n/a 11.4 1.5 no 
6 Dense (UOQ-P) n/a n/a n/a 19.5 7.2 no 
7 Cystic (LOQ-P) n/a n/a n/a 21.9 11.6 no 
8 Dense (LOQ-A) 11.1 3.3 no 16.9 7.3 no 
9 Dense (LOQ-P) n/a n/a n/a 21.9 0.0 yes 
10 Dense (LOQ-P) n/a n/a n/a 21.3 10.0 no 
11 Cystic (UOQ-P) 7.9 1.2 no 9.9 0.0 yes 
12 Cystic (UOQ-P) n/a n/a n/a 9.9 2.3 no 
13 Cystic (UOQ-P) n/a n/a n/a 10.3 0.0 yes 
14 Cystic (UIQ-P) 6.4 1.6 no 5.9 1.9 no 
15 Cystic (LIQ-A) n/a n/a n/a 6.1 0.0 yes 
16 Cystic (LIQ-A) 13.9 3.1 no 12.5 2.2 no 
17 Cystic (LIQ-A) 10.5 0.4 no 8.6 0.0 yes 
18 Dense (UIQ-P) 7.5 0.00 yes 9.2 3.3 no 
Mean 9.3 1.9 Overlap 12.3 5.3 Overlap 
 2.8 1.3 3/8 5.8 3.8 8/17 
4.5 Discussion  
 A novel deformable registration method has been described and assessed for identifying 
corresponding lesions between two common DBT views (CC and MLO) to ABUS images. For 
both analyzed cases there was improvement in the number of matched lesions with the use of 
external fiducial markers. This study extends upon previous work by expanding this technique to 
relate corresponding lesions in the DBT-MLO view and ABUS and by the use of semi-
automated segmentation techniques for the lesions in DBT and ABUS images. The use of 
automated segmentation techniques will allow this technique to quickly translate to the clinic.  
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 Similar to our previous work, this study also showed improvement in lesion correlation 
when all corresponding markers for ABUS registration are within a 5-mm vs 1-mm distance. 
This is likely because larger mesh corrections take place to get all markers closer in distance and 
can also indicate that external deformation is not entirely indicative of internal deformation. For 
the deformable mapping of DBT (CC view) to ABUS, for the 14 lesions that were within the 
defined correlation bounds with and without using marker analysis cases there was a statistical 
improvement in lesion dCOM using a paired t-test. For the deformable mapping of DBT (MLO 
view) to ABUS, for the 8 lesions that were within the defined correlation bounds with and 
without using marker analysis there was no statistical improvement in lesion dCOM. However, in 
the MLO view the number of matched lesions increased from 8 to 17 as set by our correlation 
bounds. The correlation criteria described in this chapter is larger range than shown in our 
previous work in Chapter 3. This may be an effect of using automated segmentation where the 
method segments to higher and lower extents of a lesion that may be viewed out-of-focus due to 
DBT’s limited angle acquisition and poor axial resolution.  
 Lesion location was also analyzed in regard to its effect on improvement in dCOM when 
using external markers vs. not using external markers in the deformable registration algorithm. 
For DBT (CC) to ABUS registration we see the largest improvement for lesions along the medial 
and inferior breast margins. Lesion registration seems to worsen for lesions in the upper outer 
breast quadrant using marker analysis. However, the resulting dCOM correlation is still within the 
specified correlation bounds. However, since this phantom does not have a pectoral/axillary 
attachment the deformable registration algorithm cannot thoroughly assess improvements in 
lesion registration for lesions in the superior lateral breast margins. Additionally, in Table 4.5 
and Table 4.9 we see that resulting improvement dCOM is independent of lesion proximity to 
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external markers. In one case we actually see that using marker analysis causes the dCOM to 
worsen (Lesion ID 4) for a lesion that is very close in proximity to an external fiducial marker. 
Therefore, a proof-of-concept study will need to be performed with patient volunteers to better 
quantify if there are improvements using the technique with markers. 
 For DBT (MLO view) to ABUS registration we see a decrease in lesion registration using 
marker analysis for those lesions that are on the lateral or medial most margins of the breast 
which is likely a direct result of the MLO compression. However, using marker analysis for 
lesions in all areas of the breast there seems to be a significant improvement as the number of 
matched markers improved from 8 to 17. This will also have to be further analyzed with a patient 
study since there is no axillary attachment on the breast phantom.  
 Lesions in this study are given the material property of dense lesion during FEA since in all 
x-ray based breast imaging solid and cystic lesions are not differentiable. This study also 
assumes that all lesions are homogenous in material. In actual patient data, there will be 
heterogeneity in breast tissue and a study could be performed to determine the differences in 
registration that makes in FE-based techniques. Unlike our previous study, this phantom contains 
simulated dense and cystic lesions that use the same Zerdine- based material. This material 
exhibits different ultrasound properties (anechoic for cystic lesions and if dense have 
hyperechoic). Therefore, when applied to patients, it is expected to see a larger difference in 
dCOM for cystic masses. After correlation has taken place, for lesions that correlated to cystic 
lesions in the ABUS set the algorithm could be rerun with the correct cystic material properties. 
However, this could lead to an increase in algorithm runtime. 
 A large limitation to this study is the fact that this is a phantom study that uses very 
homogenous materials. In a real breast there will be much heterogeneity within tissues and a real 
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breast will contain structures that will not be modeled during FEA. Breast studies that using FE-
based registration techniques typically only segment the breast skin, adipose, glandular tissue, 
and breast mass for modeling breast deformation.89 When translating this technique to patients 
segmentation of these structures will be given. However, due to DBT poor axial resolution there 
will still be high variability in determining the slices for these structures and high variability in 
the elastic properties to be used. 
4.6 Conclusions 
This work demonstrates the potential to use this deformable mapping technique to relate 
lesions between DBT (CC and MLO views) and ABUS breast images. This study extended upon 
previous works by incorporating the MLO view for relating corresponding lesions between DBT 
and ABUS modalities. This is significant as the MLO view is important for imaging close to the 
axillary regions of the breast where most cancers are located. The utilization of external fiducial 
markers has been shown to improve the accuracy of this approach. The resulting one-to-one 
correlation between lesions in DBT and ABUS could help improve radiologists’ characterization 
of breast lesions, which can reduce patient callbacks, negative biopsies, and false negative 
biopsies. Future work will expand this platform to include an IRB approved study for patient 
volunteers to test the viability of this technique with real breast lesions. 
4.7 Acknowledgements 
The authors would like to thank Ted Lynch of CIRS, Inc. for providing the TPE that is used 
to create the external fiducial markers within this study and also for providing the dual-modality 
breast phantom used within this study. 
 105 
Chapter 5  
Deformable Mapping Method to Relate Lesions in Dedicated Breast 
CT Images to those in Automated Breast Ultrasound and Digital 
Breast Tomosynthesiss 
 
 
5.1 Abstract 
 This work demonstrates potential for using a deformable mapping method to register lesions 
between dedicated breast CT (bCT) and both automated breast ultrasound (ABUS) and digital 
breast tomosynthesis (DBT craniocaudal, CC, and mediolateral oblique, MLO, views) images. A 
multi-modality breast phantom with external fiducial markers attached was imaged by the three 
modalities. Then the automated deformable mapping algorithm uses biomechanical modeling to 
determine corresponding lesions based on distances between their centers of mass (dCOM) in the 
deformed bCT model and the reference model (DBT or ABUS). For bCT to ABUS, the mean 
dCOM was 4.8 ± 2.4 mm. For bCT to DBT (CC), the mean dCOM was 5.0 ± 2.2 mm. For bCT to 
DBT (MLO), the mean dCOM was 4.7 ± 2.5 mm. This application could help improve a 
radiologist’s efficiency and accuracy in characterization of breast lesions when imaged with 
multiple modalities.
                                                 
s This chapter has been submitted to a journal for publication 
 106 
5.2 Introduction 
     Mammography is currently the gold standard for early breast cancer detection during 
screenings. One limitation of mammography is reduced sensitivity and increased false-negative 
examinations for women with dense breasts due to reduced lesion conspicuity as a result of 
superposition of breast tissue. Digital breast tomosynthesis, DBT, which uses limited angle 
tomography with breast compression in the mammographic geometry is one approach used to 
improve performance due to the reduction of tissue superposition. The addition of DBT for 
screenings and diagnostic purposes has shown increased cancer detection rate and reduction in 
the recall rate in comparison to digital mammography 48.These gains are largely seen for women 
with heterogeneously dense breasts 129. Mammography and DBT have the advantage of superior 
resolution in the x-y dimensions compared to dedicated breast CT (bCT). However, DBT 
imaging has poor axial resolution, which is due to the limited angle of the tomographic 
acquisition.  
     Breast CT is an emerging technology that, unlike DBT, provides complete 360º angle 
acquisition of the breast using cone-beam CT. In bCT, the patient lies prone and each breast is 
scanned separately in the pendant position without compression. Currently, the Koning breast CT 
(KBCT) system is the only FDA approved and commercially available system in the United 
States 130. In a study comparing visualization of 180 lesions with non-contrast bCT vs. 
mammography, Lindfors et al.50 found that the conspicuity of masses was superior for bCT, but 
the conspicuity of calcifications was inferior. Similarly, in a study of 24 breast lesions, Kuzmiak 
et al. (2016) found that the reader visualization confidence scores for the shape and margins of 
masses were statistically significantly greater for bCT compared to digital mammography. 
However, the reader visualization confidence scores for the morphology and distribution of 
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microcalcifications were statistically significantly worse for bCT compared to digital 
mammography. 
     Breast CT has major advantages over DBT. For angular acquisitions of 180o and above in 
bCT, the slice sensitivity profile (SSP) axial line spread function approaches an ideal delta 
function. On the other hand for DBT with its limited angle acquisition the SSP is considerably 
worse than that of bCT and it worsens with increasing lateral object size, which is not observed 
with bCT for 180o and above acquisitions 52. As a result of the wider acquisition angle and 
greater number of projection views, the resolution of bCT is nearly isotropic. This reduces  
superposition artifacts and volume averaging compared to DBT 53. Lastly, bCT imaging does not 
use compression of the breast which increases patient comfort. This last advantage, however, 
requires a longer path length through the breast for bCT. The maximum path length in a breast is 
typically approximately 10-18 cm in bCT and 2-8 cm in DBT. Thus, higher x-ray energies are 
required for bCT, with reduced differences in tissue attenuation coefficients. For 
microcalcifications, this loss in contrast is probably not compensated by the increase resulting 
from fully-sampled projections over 360º.   
     Similar to mammography and DBT, there is still difficulty in differentiating between 
malignant and benign lesions in bCT images 49,53. Ultrasound imaging used in combination with 
mammography has been shown to improve the radiologists’ overall characterization of breast 
lesions by aiding in the determination of whether a lesion is solid or cystic 16–18. Therefore, bCT 
imaging in conjunction with ultrasound would likely improve lesion characterization and this 
may especially be significant for women with dense breasts. 2D ultrasound images are often 
difficult to reproduce due to freehand acquisition and operator dependence. Automated breast 
ultrasound systems (ABUS) images the breast as a 3D volume and has advantages in terms of 
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reproducibility and operator independence over conventional breast ultrasound. Studies have also 
shown a significant improvement in breast cancer detection rate with an accompanying 
acceptable recall increase for ABUS imaging used in conjunction with mammography for 
women with dense breasts 19,57,58. 
     With the promise shown by bCT as an imaging modality it will become important to relate 
lesions found with bCT to those in other widely used breast imaging modalities. Several studies 
have used finite element modeling, FEM, modeling on bCT data to measure breast density 98, 
peripheral breast thickness 131, and simulate the effect of gravity and compression (craniocaudal, 
CC, or mediolateral oblique, MLO) to generate simulated mammograms for multi-modality 
applications 132. A non-rigid registration technique was used to relate bCT and PET/CT images 
that does not involve FEM 133. FEM or biomechanical modeling has also been used to validate 
conventional registration methods as shown by Tanner et al. (2007) and Hill et al. (2009) for 
dynamic contrast-enhanced MR breast images however these studies do not involve high 
deformation. FEM has proven to be useful for lesion registration when modeling large 
deformations that can occur due to the changes of the direction of gravity and compression plate 
deformation in comparison to conventional registration method (i.e. intensity-based, with B-
splines) 92. A study by Dmitriev et al. (2013) used a conventional B-splines method for 
registration of MRI and PET-CT tumor registration and indicated that the lack of biomechanical 
modeling was a limitation to their approach. To date there has not been a study dedicated to 
registering lesions from bCT to other breast imaging modalities and this study will help address 
that using FEM techniques.  
     Breast MR and transmission US tomography (Delphinus Medical Technologies, Inc., 
Plymouth, MI and QT Ultrasound, Novato, CA) images are acquired in the same prone geometry 
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as bCT, with the modest exception that the breast is suspended in water, rather than air, for 
transmission US tomography. While registration of bCT to breast MR, or even transmission US 
tomography, will be much simpler, there will remain considerable need for registration between 
imaging modes without and with various compressions. Several studies have used FE models of 
breast MRI to simulate breast compression 137 and register breast MRI to CC and/or MLO 
mammograms 81,85,86,88,90. Likewise, other breast MR studies have shown external fiducial 
markers could be beneficial for registration and lesion correlation in breast MRI and PET 69,70, 
compressed and uncompressed prone breast MRI 71, and breast MRI and ultrasound 72.  
     In our previous work, we developed a novel deformable mapping method to relate 
corresponding lesions in DBT (CC-view only) and ABUS with and without the use of external 
fiducial markers 34. This method did not simulate the compression plates involved in DBT and 
ABUS imaging. Instead it used a mesh morphing feature to morph the DBT model to match the 
ABUS and used nodal displacement for the finite element analysis, FEA. Here, we extend this 
work to the problems of relating lesions in bCT to ABUS and DBT. To distort the bCT image 
volume of the freely-dependent breast into the shape predicted for a DBT or ABUS view, 
compression plates were added to the bCT biomechanical model to simulate DBT plate 
compression (CC and MLO with compression paddle and breast support plate) and ABUS mesh 
plate compression (supine anterior to posterior). The resulting bCT biomechanical models were 
then registered to the DBT or ABUS image volumes, respectively. We also used semi-automatic 
segmentation of all lesions in all modalities for this work; whereas, only manual segmentation 
was used for all modalities in our previous work.  
 This study incorporates the use of commercial FE-processing and FEA packages to match 
lesions between bCT to DBT and bCT to ABUS modalities. This is done by using semi-
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automated software in order to segment all phantom components. A commercial FE pre-
processor is used to create base FE models for the bCT and reference modalities (i.e. ABUS or 
DBT). Plate deformation is performed on the bCT FE model to simulate DBT or ABUS 
compression using a commercial FEA solver. Next, the deformed bCT data is registered to the 
center of mass (COM) of the reference modality data set (DBT or ABUS) and modifies the 
resulting deformed data mesh set to align external markers between the bCT and the reference 
modality model (DBT or ABUS). Lastly, the algorithm determines corresponding matching 
lesions between the image sets using measures of distances between COMs (dCOM) and lesion 
overlap. Although commercial software is incorporated into this work, the automated algorithm 
shows a novel use of the commercial technology by relating corresponding lesions between 
breast imaging modalities with very different geometries and degrees of breast compression. 
 Identifying corresponding lesions between modalities does not pose as large a difficulty for 
lesions that are easily identifiable. A benefit to this technique is that for women with dense 
breasts, a radiologist could indicate a region of interest, ROI, within the bCT image set and this 
technique can help a radiologist determine with higher confidence if that is the same region 
within the corresponding ABUS or DBT data set. This can directly influence lesion 
characterization and reduce negative biopsies. Using a deformable registration algorithm can 
decrease review time so that a radiologist can quickly determine corresponding regions 
especially for large datasets in these 3D modalities.  
5.3 Materials and Methods 
5.3.1 Phantom Information 
     A CIRS Multi-Modality Breast Biopsy and Sonographic phantom 138 was used in this study. 
The phantom contains a total of 20 lesions: 10 spherical cystic lesions, 5 spherical dense lesions, 
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and 5 spiculated dense lesions. The lesions are randomly located in a background gel, Zerdine, 
and wrapped in a Z-skin membrane material. The self-healing Z-skin membrane simulates the 
texture and properties of skin during imaging and biopsy. Zerdine is a patented solid elastic 
water based polyacrylamide tissue mimicking material the formulation of which can be adjusted 
to correspond to a variety of soft-tissue acoustic properties for ultrasound imaging 115. Since it is 
a water-based material and the density can be controlled it can be used for CT and MR imaging 
as well 115,118. All lesions in the phantom are made of Zerdine formulations and are 5-10 mm in 
diameter. They have average CT numbers at 80 kVp ranging from 337-430 HU on a GE 
Discovery CT750 HD CT scanner (GE Healthcare, Milwaukee, WI); however, the cystic lesions 
have anechoic properties and the dense lesions have hyperechoic properties in ultrasound 
images. Elastic material properties of the substances in our phantoms provided by the 
manufacturer are listed in Table 5.1.  
Table 5.1: Phantom Material Properties 
 Young’s Modulus (E) Poisson’s Ratio (ν) 
Z-skin Membrane  10 kPa 0.50 
Zerdine background gel  10 kPa 0.50 
Dense lesions  60 kPa 0.50 
 
 For use in the finite element analysis solver, a Poisson’s ratio of 0.49 was used since a ratio 
of 0.50 will not allow the FEA solver to converge. Measurements of the phantom uncompressed 
thickness were taken before and after compression to ensure that the phantoms recovered to their 
original state before imaging with a different modality. A measured load-strain curve for this 
phantom is shown in Figure 5.1. Based on this curve, the elastic modulus of the phantom appears 
to be linear.  
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Figure 5.1: Load Strain curve showing elastic nature of breast phantom. 
5.3.2 External fiducial markers 
     In our previous work, we found that the use of external markers were helpful in relating 
corresponding lesions between DBT and ABUS modalities and the manufacturing method is 
discussed in our previous paper 34. The same markers were created and used in this study. Each 
marker contains a 1 mm diameter solid glass bead within a thermoplastic elastomer (TPE) gel 
and is about 3 mm thick.  
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Figure 5.2: (a) CIRS Multi-modality breast phantom with external fiducial markers attached. Segmented lesion 
Images acquired with (b) DBT (c) simulated bCT, and (d) ABUS. Red arrow shows external fiducial marker 
locations 
     The multi-modality breast phantom was marked with a magic marker with an ‘x’ at eight 
locations. Eight external markers were attached to the phantom, using Jobst “It-Stays” Roll-On 
Adhesive (BSN Medical, Charlotte, NC). (See Figure 5.2). The red arrows in Figure 5.2 show 
the location of a fiducial marker in simulated bCT, DBT, and ABUS reconstructed images.  
5.3.3 Imaging Methods 
     Conventional CT images of the phantom were acquired with a GE Discovery CT750 HD 
scanner (GE Healthcare, Milwaukee, WI). The phantom placed supine within the scanner. Due to 
the softness of the phantom material and the weight of the phantom backing we found we could 
not support the phantom in the upright position to simulate the coronal slice acquisition that is 
performed with dedicated breast CT scanners. The CT settings were 80 kVp, 200 mA, 1 second, 
helical acquisition, 0.969:1 pitch, 20 cm field of view, 30% ASiR, 0.625 mm slice, 0.625 mm 
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slice increment. The voxel dimensions were 0.39 mm x 0.39 mm x 0.625 mm. All 20 lesions 
were seen in the reconstructed simulated bCT images. The maximum uncompressed breast 
phantom thickness (superior to inferior breast margins) measured 106 mm from reconstructed 
simulated bCT images. 
     DBT images were acquired in both CC and MLO views with a GE Senographe Pristina DBT 
system (GE Healthcare, Milwaukee, WI). For the CC view, a compressive force of 3 daN was 
used and the phantom was compressed to a thickness of 44.2 mm. Thus, the phantom was 
compressed by 58%. For the MLO view, a compressive force of 2.5 daN was used and the 
phantom was compressed 54% to a thickness of 48.5 mm. The standard automatic optimization 
parameter (AOP) mode was used in each case and the resulting technique factors were CC: Rh 
target, Ag filter, 34 kVp, 29.7 mAs with a displayed summed average glandular dose of 1.11 
mGy; and MLO: Rh target, Ag filter, 34 kVp, 36.9 mAs, with a displayed average glandular dose 
of 1.29 mGy. The (x, y, depth) voxel dimensions were 0.1 mm x 0.1 mm x 1 mm. Forward 
pressure on the back detector plate was maintained by tightly taping the phantom casing to the 
detector plate while under compression. However, for both image views only 18 lesions were 
shown in reconstructed DBT images. Two lesions were not imaged because they were close to 
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the phantom “chest wall” and moved back outside the imaging field-of-view when the phantom 
was compressed.  
 
 
Figure 5.3: ABUS image acquisition setup on uncompressed phantom 
     Lastly, the phantom was imaged with the GE Invenia ABUS system (GE Healthcare, 
Milwaukee, WI). This system consists of a curved 153 mm long ultrasound transducer that scans 
over a mesh compression paddle that is positioned over the breast. The breast is covered with an 
acoustic coupling lotion or gel prior to application of the paddle to the breast. A picture of the 
uncompressed phantom ABUS setup is shown in Figure 5.3. The paddle is lightly pressed down 
for good contact between the paddle/transducer and the breast, and the transducer scans across 
the breast to generate the 3D ABUS image volume. The Invenia ABUS reversed-curve 
transducer operates between 6-15 MHz and can image up to a 50 mm depth. When imaged the 
phantom is placed supine and the transducer travels approximately 170 mm across a mesh 
compression paddle from the superior to inferior margins of the breast. The system contains 
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three settings based on desired imaging depth (high, medium and low). The medium setting was 
used which images acquired to a depth of 40 mm. Clinical procedures typically include several 
transducer sweeps of the breast depending on breast size to ensure coverage of the breast and 
axillary region. Due to the absence of an axillary area of the phantom only one image sweep was 
acquired. Correction for the reverse-curve of the transducer is not included in the raw DICOM 
images, therefore an algorithm was used to correct for transducer curvature. The ABUS images 
were resampled from a native voxel size of 0.082 mm width, 0.2 mm depth, and 0.506 mm 
length (distance between adjacent slices), to 0.2 mm width, 0.2 mm depth, and 0.506 mm length. 
Image resampling is done using the MATLAB imresizet command. Resampling is needed to 
increase speed in surface mesh creation since ABUS images contain 330 image slices with small 
voxel size for the skin and body phantom layers. All 20 lesions were seen in reconstructed 
ABUS images.  
5.3.4 Segmentation Methods 
     Lesions in the DBT acquired images were segmented using a semi-automatic segmentation 
program MiViewer. MiViewer is an in-house interface used for computer aided diagnosis for the 
detection and segmentation of breast masses in breast tomosynthesis 139–141. For the ABUS 
images, all dense lesions were segmented using the MiViewer program. The 10 cystic lesions in 
ABUS images were segmented using automated nonlinear filtering and segmentation approach 
by Elawady et al.128. The external fiducial markers were manually segmented using 3D Slicer for 
ABUS and DBT images. Thresholding techniques were used within 3D Slicer to segment the 
lesions, external markers, background gel material, and skin layer for the bCT image set 142. 
                                                 
t https://www.mathworks.com/help/images/ref/imresize.html  
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Examples of the segmentations of the lesions in the images of each modality are shown in Figure 
5.2.  
5.3.5 Automated deformable mapping algorithm  
 
Figure 5.4: The automated deformable mapping process. Software’s used shown in red.  
     The deformable mapping algorithm leverages the model creation capabilities in Morfeus, a 
FE based multi-organ deformable image registration platform 143, which utilizes a commercial 
pre-processor (HyperMesh version 2017.2, Altair Engineering, Troy, MI) with a commercial 
finite element analysis (FEA) solver (ABAQUS version 2017x, Dassault Systèmes Americas 
Corp., Waltham, MA). In this process the base bCT model is deformed to register the lesions in 
bCT to those in each of the two views in DBT and to the lesions in ultrasound. For registration 
the voxel sizing of the reference model data set (either DBT or ABUS) is used for lesion 
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correlation. An overview of the process is shown in Figure 5.4. Since the breast is in an 
uncompressed state when imaged in bCT, the bCT base model is being deformed to match the 
reference models for DBT and ABUS imaging. 
5.3.5.1 Surface Mesh Creation  
     All segmented contours are converted into triangular surface meshes using the shrinkwrap 
tool in the FE pre-processor, HyperMesh. The compilation of surface meshes are used to build 
the base model. A 1 mm element size was used for all lesions and 5 to 10 mm element sizes were 
used for the other phantom areas (phantom skin and background gel) due to the larger volume in 
comparison to the lesions. Each surface mesh is based off the original voxel sizes. The 
HyperMesh FE pre-processor uses a widely accepted proprietary meshing technology that 
ensures to high accuracy that created elements have a proper aspect ratio suitable for FEA. If the 
elements are outside the aspect ratio the user is notified of a mesh error.  
5.3.5.2 Finite element model generation  
     Once all segmentations are converted into surface mesh files. The deformable mapping 
algorithm uses the FE pre-processing software, HyperMesh, to generate the base FE model for 
the bCT image set and the reference image sets (e.g. base DBT (CC), base DBT (MLO), and 
base ABUS). 3D four point fully meshed tetrahedral models are created from the mesh contours 
for each modality model being used for registration. The material properties are assigned for the 
various model volumes as described in Table 5.1. Two plates are added to the bCT model to 
simulate DBT compression (top compression plate and bottom breast support plate) and one 
compression plate is added to the bCT model for the case of ABUS compression as shown in 
Figure 5.5. For simulating DBT compression the model assumes no flexure in the compression 
plate. The plate used in ABUS compression is flat, representing the ABUS mesh paddle. The 
 119 
curvature of the transducer is not modeled for the simulation of ABUS compression. Contact 
interfaces are defined between the face of the plate model in contact with the skin of the phantom 
and the skin of the base bCT model. A study by Han et al. (2012) used frictionless contact to 
simulate plate compression. Additionally, a study by Mertzanidou et al. (2014) found negligible 
difference when introducing friction into a model vs. using a frictionless plate model for lesion 
registration. Other studies, have used a friction coefficient of 0.1 between breast skin and 
compression plates 98,144,145. As a compromise, we chose to use a coefficient of friction between 
the skin and plate contact interfaces of 0.05, which is the median between the 0.1 and frictionless 
coefficients. Each plate is initially positioned to clear 1 mm from the breast surface. For DBT 
compression the bottom plate is fixed, and compression is only performed with the top plate. For 
DBT-MLO compression the plates are rotated 45º. The back of the phantom or “chest wall” 
region restricts motion along the x-axis for DBT compression as shown in Figure 5.5(a) and (b), 
and this “chest wall” restricts motion in the along the y-axis for ABUS compression as shown in 
Figure 5.5(c) and (d). In bCT it is often difficult to distinguish between solid and cystic lesions 
49,53, which is even more true from this phantom since all lesions are made of the same material 
they just have difference in ultrasound properties. Therefore, all lesions in the bCT model has the 
material properties of dense lesions as shown in Table 5.1. 
 
Figure 5.5: Plate deformation (a). bCT in DBT (CC) setup no compression applied (b) resulting CC compression to 
bCT model (c) bCT to ABUS setup no compression applied (d) resulting ABUS compression to bCT model 
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 Correction for gravity was not made in this model as it is a minor effect in comparison to the 
high deformation induced by the compression plates in both DBT and ABUS. The effect of 
gravity is likely accounted for with the use of the external fiducial marker corrections involved in 
this study. Other research groups have ignored the initial stress present from gravity with the 
breast in the prone geometry and believe its effect would not be significant in most cases 132,146. 
However, other studies have found the effect of gravity loading significant for biomechanical 
models for prone and supine MRI 147,148 and directly relating prone to supine breast MRI 149. For 
those studies’ gravity needed to be modeled as there are no other external or compressive forces 
acting on the breast unlike in ABUS and DBT imaging. 
     The amount of plate compression is determined by the difference between the face of the 
compression plate and the compressed thickness of the reference model. For the DBT (CC view), 
to match the experimental conditions, the compressed thickness that was used was 44.2 mm and 
for the MLO view it was 48.5 mm. For ABUS imaging, the imaging depth 40 mm was used as 
the compressed thickness. The number of elements/nodes are 698,768/118,730 for the base bCT 
model, 577,295/99,684 for the base DBT (MLO) model, 547,426/94,408 for the base DBT (CC) 
model and 231,990/38,021 for the base ABUS model. 
5.3.5.3 Finite Element Analysis  
     The FEA solver, ABAQUS, is used to implement FE methodologies to solve the partial 
differential equations to simulate the plate compression and outputs the resulting stress and strain 
of the deformation applied to the bCT breast volume. The resultant breast compression by the 
plate, as shown in Figure 5.5(b) and (d), to the breast is performed using a non-linear quasi-static 
analysis and large displacement theory in two steps. The first step is to ensure adequate contact 
between the breast surface and plates. In the first step the breast is compressed to half the total 
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compression distance. The second step continues the compression until the boundary condition is 
satisfied by compressing the plate on the bCT model to ensure an axial compression depth of 
approximately 40 mm for ABUS compression (ABUS imaging depth), 44 mm for DBT-CC 
compression and 49 mm for DBT-MLO compression (compressed breast thicknesses from the 
DICOM headers).  
5.3.5.4 External fiducial marker correlation  
     After the FEA is completed, the deformed bCT model is loaded back into HyperMesh and the 
model is translated and rotated to the COM of the reference DBT or ABUS breast model. Then 
the algorithm determines the COM locations of all the corresponding external fiducial markers 
between the two models. Using HyperMorph, a mesh-morphing feature within HyperMesh, 
handles are generated at seven equidistant locations along each coordinate axis that encompasses 
the entire deformed bCT volume. Global handles (8 in total) and are generated at the 8 corners 
surrounding the skin mesh, they are used to make large scale changes to the mesh. Local handles 
(60 in total) are positioned on each plane between the global handles which can make smaller 
scale manipulations to skin nodes of that region. This allows modifications to be made to the 
deformed bCT model so that markers can be registered to the markers in the reference model 
(DBT or ABUS) within a user-defined distance, dM. The algorithm determines which local 
handle from the deformed bCT model is needed in order to be better aligned with the 
corresponding marker from the reference model (DBT or ABUS). To create the changes to the 
nodes within the morphed volume, HyperMorph, takes the handle information to create 
proprietary non-linear influence functions that relate the movement of the handles to the 
morphed volume. The algorithm only manipulates handles in areas of the breast where the 
distances between the corresponding external fiducial markers are greater than dM. Once all 
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marker corrections take place, the algorithm determines if there are still marker distances greater 
than dM. If so, the algorithm will iterate until all markers satisfy the dM boundary condition only 
performing handle corrections for the markers that do not satisfy the dM boundary condition. The 
maximum number of handle corrections for each iteration is the same as the total number of 
matched markers. More information on this process can be found in our previous paper.34 
5.3.5.5 Matching Corresponding Lesions 
     Once all external fiducial markers are within dM the COMs of all lesions from the external 
markers, the FEA deformed bCT model and the reference model are determined. A matching 
algorithm is then used to determine the lesion matches between the two models by finding the 
minimum distances, dCOM, between each possible pair of COMs. Two corresponding lesions are 
considered matched if the minimum dCOM between the FEA bCT lesion and the reference model 
is ≤ 15 mm and the lesions overlap as shown in Figure 5.6 (a). If the lesions do not overlap the 
minimum dCOM is still restricted to being ≤ 15 mm. A second parameter known as the minimum 
distance to overlap, dO, is calculated and is restricted to 7.5 mm to ensure a match discrepancy is 
not created. Figure 5.6 (b) shows two corresponding lesions that are considered matched but do 
not show overlap. The results are output into a table and are used to relate corresponding lesions 
in the original sets of DICOM images in a graphical-user-interface (GUI) viewer application.  
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Figure 5.6: Matching corresponding lesions showing a. overlapping lesions b. non-overlapping lesions. dCOM is 
restricted to 15 mm (dCOM ≤ 15 mm) for both and dO is restricted to 7.5 mm (dO ≤ 7.5 mm) for non-overlapping 
corresponding lesions. 
5.3.6 Studies Performed 
     Studies were undertaken to evaluate the performance of the deformable mapping technique 
for bCT registered to ABUS, bCT registered to DBT (CC) and bCT registered to DBT (MLO). 
Lesion correlation results (total matched lesions, dCOM, number of lesions that overlap, and dO) 
were compared with and without the use of external fiducial marker correlation and the statistical 
significance (p < 0.05) of the differences were quantified using paired t-test of the average dCOM 
values. For each registered set, results also included comparisons of lesion correlation results 
when external fiducial markers were within dM ≤ 5 mm vs. within dM ≤ 1 mm.  
5.4 Results 
5.4.1 Performance of deformable mapping technique for bCT registered to ABUS 
     An overview of the results for registration of the bCT model to ABUS is illustrated in Table 
5.2. All 20 lesions were visible in the bCT and ABUS reconstructed images. Without the use of 
marker analysis 13 out of 20 lesions were matched with an average dCOM of 8.6 ± 3.0 mm. With 
the use of external markers, the total number of matched lesions improved to 20 out of 20. When 
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all external markers were within 1-mm distances (dM ≤ 1 mm) the average dCOM was 5.3 ± 1.8 
mm. When the external markers were within 5-mm (dM ≤ 5 mm) the average dCOM was 4.8 ± 2.4 
mm. The mean difference in lesion dCOM for dM ≤ 1 mm vs. dM ≤ 5 mm was 0.41 mm and 
resulted with a p-value of 0.02. Thus, there is a statistically significant improvement in lesion 
dCOM when the markers are within a dM ≤ 5 mm.  
Table 5.2: Lesion Correlation summary for bCT registered to ABUS. A maximum of 20 lesions could be matched 
between image sets. (dCOM = distance between centers of masses of corresponding lesions in the two modalities, dO 
= minimum distance for overlap of corresponding lesions, dM = distance between external fiducial markers). 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 13 20 20 
Mean dCOM (mm) 8.6 ± 3.0 5.3 ± 1.8 4.8 ± 2.4 
Mean dO (mm) 5.2 ± 4.1 3.0 ± 2.8 2.4 ± 2.0 
Total Overlapping Lesions 5 14 14 
 
     A paired t-test of the dCOM’s was performed for the 13 lesions that were matched in the 
without marker analysis case to the same 13 lesions that were matched with marker analysis 
cases with dM ≤ 1 mm and dM ≤ 5 mm, a summary of the values used for this calculation are 
shown in Table 5.3. For dM ≤ 1 mm and dM ≤ 5 mm, the resulting differences in the average dCOM 
between without marker vs. with marker analysis were 5.3 mm and 4.8 mm, respectively, with p-
values of 0.01 and 0.005, indicating significant improvement in average lesion dCOM with the use 
of external fiducial markers.  
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Table 5.3: Lesion correlation summary of 14 matched lesions between without marker analysis and with marker 
analysis cases for bCT registered to ABUS (dCOM = distance between centers of masses of corresponding lesions 
in the two modalities, dO = minimum distance 
  
Without Marker 
Analysis 
With Marker Analysis  
With Marker 
Analysis  
(dM ≤ 1 mm) (dM ≤ 5 mm) 
Total Matched Lesions 13 13 13 
Mean dCOM (mm) 8.6 ± 3.0 5.3 ± 1.8 4.8 ± 1.9 
Mean dO (mm) 5.2 ± 4.1 2.3 ± 1.5  2.5 ± 1.3 
Total Overlapping Lesions 5 9 10 
 
     Figure 5.7 (a) and Figure 5.7 (b) display the improvement in lesion correlation between the 
bCT and ABUS models for all 20 lesions. Figure 5.7 (c) shows a GUI-Viewer display of 
corresponding marked lesions in the original bCT and ABUS images. The dCOM values for each 
pair of corresponding lesions are listed in Table 5.4. 
 
Figure 5.7: Lesion correlation for bCT (blue) registered to ABUS (yellow) (a) coronal view without marker analysis 
(b) coronal view with marker analysis (c) GUI representation from a lesion in original DICOM images of bCT 
(left), coronal view ABUS (upper-right), and transverse ABUS (lower-right) for a lesion (Lesion ID= 8). Numbers 
correspond to lesion ID’s and correlation values in Table 5.4).
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Table 5.4: Lesion matching results for each lesion with and without marker analysis for bCT registered to ABUS 
Lesion ID 
Lesion 
type 
Without Marker Analysis With Marker Analysis (dM ≤ 5 mm) 
dCOM 
(mm) 
dO 
(mm) 
Overlap 
dCOM 
(mm) 
dO 
(mm) 
Overlap 
1 dense n/a n/a no 11.1 5.6 no 
2 dense n/a n/a n/a 3.3 0.0 yes 
3 dense 5.6 0.0 yes 6.9 0.0 yes 
4 dense 4.5 0.0 yes 7.0 1.8 no 
5 dense 8.9 3.5 no 2.3 0.00 yes 
6 dense 7.4 0.00 yes 7.6 0.9 no 
7 cystic n/a n/a n/a 6.1 0.0 yes 
8 dense n/a n/a n/a 3.6 0.0 yes 
9 dense 6.8 0.00 yes 5.1 0.0 yes 
10 dense n/a n/a n/a 2.7 0.0 yes 
11 cystic 9.8 6.1 no 2.9 0.0 yes 
12 cystic n/a n/a n/a 0.5 0.0 yes 
13 cystic 11.5 5.5 no 2.2 0.0 yes 
14 cystic 13.7 7.8 no 4.0 0.0 yes 
15 cystic 11.1 5.2 no 5.1 0.0 yes 
16 cystic 12.3 5.5 no 3.7 0.0 yes 
17 cystic 9.0 6.3 no 4.7 1.7 no 
18 dense 6.4 0.00 yes 5.2 0.0 yes 
19 cystic 4.5 0.8 no 7.4 4.0 no 
20 cystic n/a n/a n/a 4.3 0.4 no 
Mean 9.00 5.51 Overlap* 4.8 2.4 Overlap* 
σ 3.12 1.97 5/14 2.4 1.2 14/20 
 
5.4.2 Performance of deformable mapping technique for bCT registered to DBT (CC) 
     An overview of the results for registration of the bCT model to DBT-CC is illustrated in 
Table 5.5. As explained previously, only 18 lesions were viewed in the reconstructed DBT-CC 
images because 2 lesions were too close to the chest wall. Therefore, the maximum number of 
possible lesion matches is 18. Without the use of external fiducial marker analysis only 9 out of 
18 lesions were matched with an average dCOM of 11.6 ± 2.0 mm. With the use of external 
markers, the total number of matched improved to 18 out of 18. When all external markers were 
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within 1 mm (dM ≤ 1 mm) the average dCOM was 5.0 ± 2.2 mm. When the external markers were 
within 5 mm (dM ≤ 5 mm) the average dCOM was 5.1 ± 2.2 mm. The mean difference in lesion 
dCOM for dM ≤ 1 mm vs. dM ≤ 5 mm was 0.12 mm with a p-value of 0.11 indicating no statistical 
difference in lesion dCOM when the external fiducial markers are closer in distance.  
Table 5.5: Lesion Correlation summary for bCT registered to DBT (CC). A maximum of 18 lesions could be 
matched between image sets (dCOM = distance between centers of masses of corresponding lesions in the two 
modalities, dO = minimum distance for overlap of corresponding lesions, dM = distance between external fiducial 
markers). 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 9 18 18 
Mean dCOM (mm) 11.6 ± 2.0 5.0 ± 2.2 5.1 ± 2.2 
Mean dO (mm) 2.7 ± 1.9 0.5 ± 0.3 0.3 ± 0.1 
Total Overlapping Lesions 2 16 16 
 
 A paired t-test of the dCOM’s was performed for the 9 lesions that were matched in the 
without marker analysis case to the same 9 lesions that were matched with marker analysis cases 
with dM ≤ 1 mm and dM ≤ 5 mm, a summary of the values used for this calculation are shown in 
Table 5.6. For dM ≤ 1 mm, and dM ≤ 5 mm the resulting differences in the average dCOM were 8.1 
mm and 8.2 mm, respectively, with p-values of 0.00001 and 0.000008 indicating significant 
improvement in average lesion dCOM with the use of external fiducial markers.  
Table 5.6: Lesion correlation summary of 9 matched lesions between without marker analysis and with marker 
analysis cases for bCT registered to DBT (CC). (dCOM = distance between centers of masses of corresponding 
lesions in the two modalities, dO = minimum distance for overlap of corresponding lesions, dM = distance between 
external fiducial markers). 
  Without Marker 
Analysis 
With Marker Analysis  With Marker Analysis  
(dM ≤ 1 mm) (dM ≤ 5 mm) 
Total Matched Lesions 9 9 9 
Mean dCOM (mm) 11.6 ± 2.0 3.5 ± 1.6 3.4 ± 1.4 
Mean dO (mm) 2.7 ± 1.9 0.0 ± 0.0 0.0 ± 0.0 
Total Overlapping Lesions 2 9 9 
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     Figure 5.8 (a) and Figure 5.8 (b) visually display the improvement in lesion correlation 
between the bCT and DBT (CC) models for several lesions. Figure 5.8 (c) shows a GUI-Viewer 
for a marked corresponding lesion in the bCT and DBT (CC) original image sets. The dCOM and 
dO values for each pair of corresponding lesions are listed in Table 5.7. 
 
Figure 5.8: Lesion correlation bCT (blue) registered to DBT (CC view) (red) (a) axial view without marker analysis 
(b) axial view with marker analysis (c) GUI representation from original DICOM images for lesion (Lesion ID= 8). 
Numbers correspond to lesion ID’s and correlation values in Table 5.7. Note: All lesions are not visually 
represented in this figure due to superposition of the 2D representation
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Table 5.7: Lesion matching results for each lesion with and without marker analysis for bCT registered to DBT 
(CC) 
Lesion ID Lesion type 
Without Marker Analysis With Marker Analysis (dM ≤ 1 mm) 
dCOM (mm) dO (mm)  Overlap dCOM (mm) dO (mm) Overlap 
1 dense n/a n/a n/a 8.2 0.0 yes 
2 dense n/a n/a n/a 8.4 0.3 no 
3 dense 14.6 1.1 no 2.7 0.0 yes 
4 dense 13.2 5.4 no 3.5 0.0 yes 
5 dense 9.4 1.2 no 6.4 0.0 yes 
6 dense n/a n/a n/a 5.5 0.0 yes 
7 cystic n/a n/a n/a 6.0 0.0 yes 
8 dense n/a n/a n/a 8.0 0.0 yes 
9 dense n/a n/a n/a 5.4 0.0 yes 
10 dense n/a n/a n/a 5.2 0.0 yes 
11 cystic 10.1 2.1 no 2.2 0.0 yes 
12 cystic 11.6 3.7 no 5.0 0.0 yes 
13 cystic 11.0 0.7 no 1.0 0.0 yes 
14 cystic n/a n/a n/a 7.4 0.7 no 
15 cystic 9.3 0.0 yes 4.2 0.0 yes 
16 cystic 14.1 4.6 no 3.7 0.0 yes 
17 cystic n/a n/a n/a 3.7 0.0 yes 
18 dense 11.6 0.0 yes 2.9 0.0 yes 
19 cystic n/a n/a n/a n/a n/a n/a 
20 cystic n/a n/a n/a n/a n/a n/a 
Mean 11.6 2.7 Overlap* 5.0 0.5 Overlap* 
σ 2.0 1.9 2 2.2 0.3 16 
 
5.4.3 Performance of deformable mapping technique for bCT registered to DBT (MLO) 
     An overview of the results for registration of the bCT model to DBT (MLO) is illustrated in 
Table 5.8. As with the CC view, only 18 lesions were viewed in the reconstructed DBT (MLO) 
images because 2 lesions were too close to the chest wall. Therefore, the maximum number of 
lesions matches for this set is 18. Without the use of marker analysis only 9 out of 18 lesions 
were matched with an average dCOM of 8.2 ± 3.1 mm. With the use of external markers, the total 
number of matches improved to 18 out of 18. When all external markers were within 1 mm the 
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average dCOM was 4.7 ± 2.5 mm. When the external markers were within 5 mm the average dCOM 
was 5.4 ± 2.9 mm. lesion dCOM for dM ≤ 1 mm vs. dM ≤ 5 mm was 0.6 mm with a p-value of 0.09, 
indicating no statistical difference in lesion dCOM when the external fiducial markers are closer in 
distance. However, more lesions overlapped when the markers were closer together.  
Table 5.8: Lesion Correlation summary for bCT registered to DBT (MLO). A maximum of 18 lesions could be 
matched between image sets. (dCOM = distance between centers of masses of corresponding lesions in the two 
modalities, dO = minimum distance for overlap of corresponding lesions, dM = distance between external fiducial 
markers). 
 
Without Marker 
Analysis 
With Marker Analysis  
(dM ≤ 1 mm) 
With Marker Analysis  
(dM ≤ 5 mm) 
Total Matched Lesions 9 18 18 
Mean dCOM (mm) 8.2 ± 3.1 4.7 ± 2.5 5.4 ± 2.9 
Mean dO (mm) 1.9 ±1.5 1.4 ± 1.6 1.2 ± 1.0 
Total Overlapping Lesions 4 16 13 
 
     A paired t-test of the dCOM’s was performed for the 9 lesions that were matched in the without 
marker analysis case to the same 9 lesions that were matched with marker analysis cases with dM 
≤ 1 mm and dM ≤ 5 mm, summary of the values used for this calculation are shown in Table 5.9. 
For dM ≤ 1 mm and dM ≤ 5 mm the resulting differences in the average dCOM were 4.7 mm and 
4.3 mm, respectively with p-values of 0.002 and 0.001 indicating significant improvement in 
average lesion dCOM with the use of external fiducial markers. 
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Table 5.9: Lesion correlation summary of 9 matched lesions between without marker analysis and with marker 
analysis cases for bCT registered to DBT (MLO). (dCOM = distance between centers of masses of corresponding 
lesions in the two modalities, dO = minimum distance for overlap of corresponding lesions, dM = distance between 
external fiducial markers). 
  
Without Marker 
Analysis 
With Marker Analysis  With Marker Analysis  
(dM ≤ 1 mm) (dM ≤ 5 mm) 
Total Matched Lesions 9 9 9 
Mean dCOM (mm) 8.2 ± 3.1 3.6 ± 1.6 4.0 ± 1.5 
Mean dO (mm) 1.9 ± 1.5 0.0 ± 0.0 0.0 ± 0.0 
Total Overlapping 
Lesions 
4 9 9 
 
     Figure 5.9 (a) and Figure 5.9 (b) display the improvement in lesion correlation between the 
bCT and DBT (MLO) models for several lesions. Figure 5.9 (c) shows a GUI-Viewer display for 
a marked corresponding lesion in the bCT and DBT (MLO) original image sets. The dCOM, lesion 
overlap, and dO values for each pair of corresponding lesions are listed in Table 5.10. 
 
Figure 5.9: Lesion correlation bCT (blue) registered to DBT (MLO view) (green) (a) axial view without marker 
analysis (b) axial view with marker analysis (c) GUI representation from original DICOM images for a lesion. 
Numbers correspond to lesion ID’s and correlation values in Table 5.10. Note: All lesions are not visually 
represented in this figure due to superposition of the 2D representation. 
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Table 5.10: Lesion matching results for each lesion with and without marker analysis for bCT registered to DBT 
(MLO) 
Lesion ID 
Lesion 
type 
Without Marker Analysis With Marker Analysis (dM ≤ 1 mm) 
dCOM (mm) 
dO 
(mm)  Overlap dCOM (mm) 
dO 
(mm) Overlap 
1 dense n/a n/a n/a 7.5 0.2 no  
2 dense n/a n/a n/a 7.0 0.0 yes 
3 dense 6.5 0.00 yes 4.0 0.0 yes 
4 dense 4.0 0.00 yes 5.5 0.0 yes 
5 dense 8.4 0.8 no  3.5 0.0 yes 
6 dense 11.9 0.00 yes 3.25 0.0 yes 
7 cystic n/a n/a n/a 11.1 2.5 no  
8 dense 12.0 1.4 no  6.0 0.0 yes 
9 dense 7.3 0.00 yes 0.6 0.0 yes 
10 dense 9.6 1.4 no  2.7 0.0 yes 
11 cystic 0.00 n/a n/a 8.0 0.0 yes 
12 cystic 10.5 4.2 no  2.9 0.0 yes 
13 cystic 0.00 n/a n/a 6.0 0.0 yes 
14 cystic 0.00 n/a n/a 3.8 0.0 yes 
15 cystic 0.00 n/a n/a 3.8 0.0 yes 
16 cystic 0.00 n/a n/a 3.4 0.0 yes 
17 cystic 0.00 n/a n/a 2.7 0.0 yes 
18 dense 3.9 0.00 yes 3.7 0.0 yes 
19 cystic n/a n/a n/a n/a n/a n/a 
20 cystic n/a n/a n/a n/a n/a n/a 
Mean 8.2 1.9 Overlap* 4.7 1.4 Overlap* 
σ 3.1 1.5 5/9 2.5 1.6 16/18 
 
5.5 Conclusions  
     This work demonstrates and evaluates the potential for use of a deformable mapping 
technique to relate lesions in bCT images to ABUS images and to match lesions in bCT to DBT 
images. To our knowledge, this is the first study involving the use of deformable registration of 
bCT images to ABUS or DBT views. Segmentations for each model were used to create a 3D 
tetrahedral finite element breast model where plate deformations were performed on the bCT 
model to simulate DBT and ABUS compression. The rate of correlation between the lesions in 
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the two different modality images increased with the use of external fiducial markers with this 
method. With the use of external marker corrections, the mean dCOM values decreased by 49% 
for bCT to ABUS registration, 57% for bCT to DBT (CC) registration, and 40% for bCT to DBT 
(MLO) registration. Additionally, the maximum number of corresponding lesions was achieved 
with the use of external marker corrections, where the mean marker dM values were within 1-mm 
and 5-mm distances for all analyzed cases. Thus, this study showed that external marker analysis 
could potentially correct for discrepancies that may be influenced by mesh density, friction, and 
elasticity properties of various tissue types. Implementation of this methodology could 
significantly improve radiologist’s characterizations of breast lesions. In the case for dense 
breasts where a lesion is not easily identifiable, this method can allow a radiologist to indicate an 
ROI within the bCT image to determine with higher confidence the ROI location is a match to a 
better defined region in DBT or ABUS. However, some sort of optimization for patient specific 
material properties must be considered when applying this technique in the clinic. The results 
obtained in this work are preliminary and an expansion of this work is planned to quantify the 
effectiveness of this technique on actual patient data analyzed in an IRB-approved patient study.  
5.6 Discussion 
 A novel deformable registration technique has been described and assessed for identifying 
related lesions in bCT and ABUS images and in bCT and CC and MLO DBT images. For all 
analyzed cases there was statistically significant improvement in lesion correlation with the use 
of external fiducial markers.  
 This study is to our knowledge the first to show lesion registration between bCT and ABUS 
breast images. The use of this technique with bCT in conjunction with ultrasound could likely 
lead to valuable contributions for breast characterizations as it has for mammography 16–18. This 
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study does not show a significant variation in lesion dCOM for cystic lesions in comparison to 
dense lesions. All lesions in this study are given the material property of dense lesion during 
FEA since in all x-ray based breast imaging of this phantom, the solid and cystic lesions are not 
differentiable. The t-test results indicated no difference in lesion correlation based on lesion type. 
This result is expected since both the simulated dense and cystic lesions use the same Zerdine- 
based material and just exhibit different ultrasound properties (anechoic for cystic lesions and if 
dense have hyperechoic). Therefore, when applied to patients, there may be a difference in lesion 
correlation (dCOM) for cystic masses since the algorithm does not use cystic properties during 
FEA.   
 This study also indicated a significant difference lesion dCOM when the external markers 
were further apart (dM ≤ 5 mm) vs. (dM ≤ 1 mm) for the bCT to ABUS case. When all markers 
are aligned to be closer together larger iterations take place which may be over compensating for 
some areas of the breast. For instance, in one iteration a set of markers could have first been 
within correlation bounds and then fall outside the specified correlation bounds, due to shifts 
from movements of other neighboring corresponding markers within correlation bounds. Thus, 
this marker set must be readjusted in the next iteration. This over-correction feature may be the 
cause of the better results with a less strict marker distance (dM ≤ 5 mm). This effect was also 
noted in our previous work for DBT to ABUS registration 34. Additionally, this can be an 
indications that although the external fiducial markers are helpful in registration their use is not 
completely indicative of internal deformation caused by compression. Currently in ABUS 
imaging, there is not a distinct way to determine the compressive force used on the breast. In this 
study, the imaging depth was used to determine ultrasound compression. However, using the 
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imaging depth is not completely accurate since the transducer for the ABUS system has a reverse 
curvature so the depth varies with lateral position.  
 Additionally, this study did not model the reverse curvature of the ABUS transducer during 
FEA analysis. Due to this curvature, the lateral ends of the transducer can experience 
approximately an additional 6 mm of compression (See Figure 5.10). We believe the effect of the 
curvature is not very significant based on the high degree of lesion correlation found in our 
study. The degree to which this is true for real breasts can be better determined through an IRB-
approved patient study. For translation of this technique to patients, the present limited depth of 
ultrasound penetration of 5 cm may make this technique unsuitable for patients with larger 
breasts. From our previous DBT to ABUS study, we found larger dCOM correlation values than 
with the present bCT to ABUS study. That is largely because the previous study did not simulate 
plate compression since the breast is compressed during the DBT and ABUS acquisitions. 
 
Figure 5.10: Measurement of lateral compression difference from Invenia Reverse curve transducer during ABUS 
imaging. 
     For the DBT studies analyzed, there was no statistical difference between results obtained 
with the use of different external fiducial marker spacing, at a distance of ≤ 5 mm vs. ≤ 1 mm 
apart. This is likely due to better compression modeling of the compression plates because of the 
knowledge of the compressive force and compressed breast thickness. However, for the MLO 
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case there was an increase in lesion overlap for 3 lesions when external markers were closer 
together (dM ≤ 1 mm). Two lesions were not visualized in reconstructed DBT images as they are 
too close to the phantom back plate or “chest wall” and were not imaged. In a real breast this 
would should not be an issue with proper technologist positioning.  
 We expect results for patients will likely be worse than those that were obtained in the 
phantom study. The phantom used in our study is made of viscoelastically homogenous material 
whereas there will be much more heterogeneity even within the same material in a real breast. A 
real breast also will include glandular tissue, adipose tissue, blood vessels, Cooper’s ligaments, 
ducts, etc. that can have an effect on the performance of the deformable registration. Breast 
studies that use FE-based techniques typically segment the breast skin, adipose tissue, 
fibroglandular tissue and the lesion (if applicable) for biomechanical modeling 89. These might or 
might not include the effects of ligaments with their primary function of shape control.  
Another limitation to this study is that only one phantom was used. Further developments are 
still needed to produce physical multi-modal breast phantoms that show hyperelastic behaviors.  
The phantom used within this study exhibits linear elastic behavior, whereas real breast tissue 
follows hyperelastic behavior under compression 76,150,151. Although, other research groups such 
as Chung et al.152 have designed and used phantoms with non-linear properties for breast 
biomechanical modeling, these phantoms are not currently commercially available There is a 
rigid posterior wall in the phantom. This causes extreme deformation at the posterior edge of the 
paddle (Figure 5.2 (b)). The gradient in the deformation might, in fact be greater than that in the 
human breast as there are ligaments in the breast that would tend to minimize that deformation 
by pulling down more skin and subcutaneous tissues than in the phantom. Therefore, when 
translating this technique to patients, segmentation of the dense fibroglandular breast tissue from 
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adipose tissue in bCT images and the use of corresponding elastic properties of those tissues will 
be critical. A proof of concept study would be needed to determine the effect these limitations 
have on lesion registration results in patients. 
 There is still high variability in the moduli of elasticity for breast tissues. A study by Gefen 
and Dilmoney82 the Young’s modulus for glandular tissue ranges from 7.5 kPa- 66 kPa and 
adipose tissue ranges from 0.5 kPa – 25 kPa. A study by Athanasiou et al.96 used supersonic 
shear wave imaging on 46 women with 48 breast lesions where the mean elasticity values was 
146.6 ± 40.05 kPa for malignant lesions and a mean elasticity value of 45.3 ± 41.1 kPa for 
benign breast lesions When applying this technique to patients consideration for what material 
properties will need to be used in order to make the model patient-specific. Kellner et al.97 used 
average values found from several in vitro and in vivo elastic coefficients for the skin, fat and 
glandular breast tissue to arbitrarily assign to a model. Contrarily, Han et al.71 used a material 
property optimization algorithm to change the material property based on maximizing the 
similarity between the predicted deformed MR breast images. However, this type of technique 
could lead to huge runtimes with the use of commercial FE packages. Other differences between, 
the work of Han et al.71 and this work is that they used a GPU-based explicit dynamic FEA 
solver153,154 where in this work we use commercial non-linear quasi-static FEA. Due to the high 
runtimes observed in this study we will likely need to explore ways to optimize the results while 
decreasing runtime when applying this technique to patients.  
 When using FEA to simulate application of plate compression to breast models generated 
from bCT images of actual patients’ breasts, a study by Hsu et al.146 found that small alterations 
in the biomechanical properties of the tissues can result in significantly different representations 
of the resulting DBT breast models in the simulations. Hsu et al.146 found that these differences 
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are largely influenced by mesh density, friction coefficient between plates and skin, and relative 
stiffness of the various tissue types which can change the breast tissue distribution during 
simulated compression up to 1 cm. However, other studies have shown the use of external 
fiducial markers can be very helpful and potentially could partially correct for these 
discrepancies and increase confidence in lesion registration 69–72. 
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Chapter 6  
Proof-of-Concept patient validation study of Deformable Mapping 
Technique to relate lesions between DBT and ABUS images 
 
 
6.1 Abstract 
Purpose: This work investigates the application of a deformable localization/mapping method to 
register lesions between the digital breast tomosynthesis (DBT) craniocaudal (CC) and 
mediolateral oblique (MLO) views and automated breast ultrasound (ABUS) images based on 
five patient data sets and up to 7 lesions. This method was initially validated using compressible 
breast phantoms.  
Methods: The automated deformable mapping algorithm uses finite element modeling and 
analysis to determine corresponding lesions based on distances between centers of mass (dCOM) 
in the deformed DBT model and the reference ABUS model.  
Results: This technique has found that using several combinations of external fiducial markers 
can be helpful to improve lesion registration. However, use of external markers are not required 
for deformable registration results described by this methodology. For DBT (CC view) mapped 
to ABUS, the mean dCOM was 11.0 ± 4.9 mm based on 7 lesions. For DBT (MLO view) mapped 
to ABUS, the mean dCOM was 12.3 ± 4.8 mm based on 6 lesions. Both DBT views registered to 
ABUS lesions showed statistically significant improvements (p  0.05) in registration using
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the deformable technique in comparison to a rigid registration.  
Conclusion: Application of this methodology could help improve a radiologist’s timing, 
efficiency, characterization and accuracy in relating corresponding lesions between DBT and 
ABUS image datasets, especially for cases of high breast densities and multiple masses. 
6.2 Introduction 
 Conventional handheld ultrasound (HHUS) imaging is often used as a complement to 
mammography and has shown large improvements in the characterization of breast lesions by 
aiding in differentiating between solid and cystic lesions.16–18 HHUS has a higher sensitivity than 
mammography for lesions in women with dense breasts.54 HHUS produces 2D images and is 
performed freehand in a different geometry (supine) than mammography (upright). In HHUS, the 
image acquisition is freehand and therefore there is difficulty in reproducing images due to high 
operator dependence.  Automated breast ultrasound (ABUS) creates a 3D image volume and has 
advantages in terms of reproducibility, faster image acquisition speed, and operator 
independence over conventional HHUS for breast examinations.18,19,57 As demonstrated by 
D’Orsi et al.40, using ABUS in conjunction with mammography screening for women with dense 
breasts (BI-RADS ACR3 or ACR4) increases the rate in breast cancer detection. Additionally, 
several other studies have shown that ABUS significantly improves the breast cancer detection 
rate with an acceptable recall increase.19,57,58 However, several studies concluded that HHUS is 
superior to ABUS for breast lesion that are smaller in size/diameter, irregular in shape, non-
circumscribed margins, and for breast coverage in peripheral margins.59–62  
 Currently, mammography is the gold standard for detecting breast cancer and is the only 
screening test proven to reduce the breast cancer mortality rate in women.155 However, 
mammography has reduced sensitivity and increased false-negative examinations for women 
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with dense breasts due to the superposition of breast tissues from the single 2D image projection. 
Digital breast tomosynthesis (DBT) mammography’s quasi-3D counterpart, uses limited angle 
tomography in the mammographic geometry and can help locate breast masses that are masked 
in mammography due to superposition of breast tissues. Studies have shown DBT to have an 
increased cancer detection rate and reduced recall rate in comparison with digital 
mammography.45–47 Gains using DBT are largely seen for women with dense breasts, where 
DBT outperforms mammography in both screening and diagnostic uses.129 However, like 
mammography, DBT still has difficulty in distinguishing between solid and cystic breast lesions. 
Thus, there remains a need for supplementary ultrasound imaging.109,110   
  Considering that the breast is highly deformable, and the breast is imaged in different 
geometries and compression for mammography and ultrasound, it can be difficult to relate 
lesions between mammography and ultrasound images. Additionally, at least 10% of the time 
lesions found in ultrasound images do not correspond to those found in mammography/DBT.15 
There are two potential solutions to this problem: (1) The development of a combined x-
ray/ultrasound system that images the breast in the same mammographic geometry using special 
modality paddles or (2) The development of a deformable registration technique to detect and 
relate corresponding lesions between the x-ray and ultrasound modalities in their respective 
geometries. This study will investigate the latter proposed solution.  
 Several groups have evaluated the performance of a combined x-ray/ultrasound system that 
images the breast in the same mammographic geometry using special modality 
paddles.21,22,24,25,27–30,63 Since the images are acquired in the same geometry there is a direct 
localization for lesion registration between the 3D ultrasound to the DBT. However, the singled-
sided ultrasound transducer combined systems have limitations in terms of ultrasound 
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penetration depth and poor ultrasound transducer coupling along the peripheral breast regions in 
the mammographic geometry. To address these issues, Larson et al.33 explored using dual-sided 
ultrasound, however their work has not been implemented into a combined system using x-rays. 
Additionally, a combined x-ray ultrasound system is very expensive and not yet commercially 
available.  
 An alternative solution to using a combined system is to image the breast using DBT and 
ABUS modalities in their respective geometries and then use a deformable registration method to 
relate the corresponding lesions. Using a deformable registration method has advantages of 
improved transducer coupling while imaging with ABUS and it will utilize commercial systems 
that are likely already in the clinic. The main disadvantage of using a deformable registration 
method is that there is greater technical difficulty in relating corresponding masses due to the 
differences in patient positioning and compression between the DBT and ABUS modalities.  
 Our previous work involved the development of a deformable mapping method for lesions 
in DBT (CC-view) and ABUS on a breast phantom with increased improvement using external 
markers and finite element methods (FEM).34 To our knowledge, that study was the first to show 
the direct registration of lesions between DBT and ABUS modalities. We extended that work to 
include registration of DBT (CC and MLO views) and ABUS using a compressible breast 
phantom with multiple lesions.35 Additionally, we extended upon that work to include the 
registration of simulated dedicated breast CT to DBT (CC and MLO views and ABUS using a 
compressible breast phantom with multiple lesions.36 Like other studies, we found the use of 
FEM and external fiducial markers helpful in improving lesion registration.  
 Several studies have used FEM-based methods to register lesions between uncompressed 
MRI (prone positioning) to CC and/or MLO mammograms 85,86,88,90 and between CC and MLO 
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views in mammography.112 Segmentation of the entire breast is required to used FEM 
biomechanical breast models and studies have used manual 71,76, semi-automated 84,85, and 
automated 86–88 segmentation techniques for the development of FEM breast models. 
Additionally, studies have found that using external fiducial markers were helpful to improve 
registration results for MRI/PET registration 69,70, compressed to uncompressed prone MRI 
registration71, and breast MRI to ultrasound registration72.  
 In this chapter, we present modifications and validate our automated deformable registration 
method to relate lesions between DBT (CC and MLO views) and ABUS using FEM. We 
evaluate the improvement in registration by using various numbers of external fiducial markers. 
This study validates the performance of a deformable mapping method based on 5 patient data 
sets to register up to 7 lesions. The validated algorithm can be used to relate regions of interests 
(ROIs) between these two modalities such that a radiologist can directly view corresponding 
lesions in DBT and ABUS images. Implementation of this method can save a radiologist time in 
navigating through the 3D image volumes. This will be especially beneficial for the more 
difficult cases such as women with dense breast tissue or women with multiple breast masses.  
6.3 Materials and Methods 
6.3.1 Experimental Procedures 
 In order to determine the efficacy of our deformable registration technique, we collected 
patient data as part of an IRB-approved study. Inclusion criteria for patient volunteers is defined 
as follows: 1) Women who were scheduled for a biopsy procedure within the Breast Imaging 
clinic at the University of Michigan Cancer Center and 2) have a breast mass 5 mm or greater in 
size that is visible on ultrasound and not located in the axillary breast region. A detailed 
description of the imaging procedures is provided in the Appendix.  
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 In order to help restrict breast motion during ABUS imaging and between ABUS scans, the 
patient volunteer was first fitted by one of the research staff members for an ultrasound camisole. 
The camisole, shown in Figure 6.1 (a), fits on the patient similar to a sports bra. The camisole is 
made in various sizes (women’s dress sizes 0-26). Each camisole is made of a sheer stretchable 
nylon mesh fabric in the front and a stiff cotton fabric in the back. This camisole was tested to 
ensure that penetration ability of ultrasound is not compromised. Additionally, the camisole was 
tested on 10 normal volunteers to ensure that breast motion was restricted, and the locations of 
the external fiducial markers located beneath the camisole were not compromised. The camisole 
was not worn during the x-ray portion of the exam. After being fitted for the camisole the patient 
takes off the camisole and then a research staff member denotes areas of the breast for placement 
of external fiducial markers with a washable magic marker (See Figure 6.1 (b)). Seven external 
fiducial markers were then attached to the breast at the indicated locations using Jobst “It-Stays” 
Roll-On Adhesive (BSN Medical, Charlotte, NC)u. 
                                                 
u  http://www.jobst-usa.com/product/it-stays-roll-on-adhesive/ 
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Figure 6.1 (a) Ultrasound camisole for ABUS imaging (b) External fiducial marker locations (denoted by A-G) 
shown for marker placements on the left breast 
 One marker was placed at the center of each breast quadrants (labeled as A, C, E and G in 
Figure 6.1 (b)), one marker was placed superior and one marker was placed inferior to the nipple 
(labeled as B and F Figure 6.1 (b)). An additional marker was placed more lateral in the upper 
outer quadrant due to this quadrant being the most common quadrant for breast malignancies 
(labeled as D in Figure 6.1 (b)).Various marker combinations can be analyzed using the 
deformable mapping algorithm. Results in this study are obtained using the following 
combinations with letter designation in Figure 6.1 (b): all 7 markers, 6 markers (located at 
positions A-C and E-G), 4 Markers (located at positions A-D), and 3 markers (positions A-C), 
and 1 marker analysis (dependent on the marker closest to the specified lesion). If a lesion is in 
the retroareolar region of the breast the 1 marker analysis is not run. 
 Each external fiducial marker contains a 1 mm glass bead in a bubble-free thermoplastic 
elastomer gel. The glass bead can be easily seen in the DBT and ABUS reconstructed images as 
shown in Figure 6.2. To ensure that the adhesive holding the fiducial markers to the breast has 
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enough time to cure, we waited a minimum of 5 minutes before initiating x-ray imaging. As a 
precaution TomoSpot bandagesv (with the x-ray target removed) were placed over each marker 
to ensure that the external markers remained in place during x-ray imaging.  
 
Figure 6.2: Red Arrow indicates glass bead of an external fiducial marker in (a) DBT (CC view) (b) DBT (MLO 
view) and (c) ABUS AP view. Yellow arrow shows length x for (a) the medial to lateral breast margins in DBT (CC 
view) needed for DBT surface skin transformation (b) nipple to posterior breast length in DBT (MLO view) 
 After patient preparation, DBT images were acquired in both CC and MLO (at 45° angles) 
views by x-ray technologists using the GE Senographe Pristina DBT system (GE Healthcare, 
Milwaukee, WI). The voxel width and length of the DBT images are 0.1 mm and the slice 
thickness (image depth) was 1 mm. Next, the patient was brought to an adjacent ultrasound room 
and positioned supine. The TomoSpot bandages were removed from the breast while the external 
markers remain attached. Prior to ABUS imaging, the patient puts on the ultrasound camisole 
with assistance from a research staff member. The markers may move in this process in which 
case the magic marker locations indicate where the markers need to be reapplied. Ultrasound 
lotion was then applied over the camisole and light AP compression was applied to the patients’ 
                                                 
v https://www.beekley.com/product-details/tomospot-for-marking-nipples-781 
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breast as she was imaged with the GE Invenia ABUS system (GE Healthcare, Milwaukee, WI). 
Three images were acquired during the ABUS exam (AP View, Lateral View, and Medial View) 
to ensure adequate breast coverage. Depending on patient breast size, the low, medium, or high 
setting could be used to image the desired depth. The 153 mm length reversed-curved transducer 
can image up to a 50 mm depth and scanned the breast through a mesh compression paddle. 
Correction for the reverse-curvature of the transducer is not included in the resulting DICOM 
images, therefore a MATLAB program was created to correct for the transducer curvature.  
 Within this curvature correction program, the ABUS images are resampled from a native 
voxel size of 0.082 mm in depth, 0.2 mm in width, and 0.506-0.511 mm in length (distance 
between adjacent slices dependent on exam setting), to 0.082 mm width, 0.082 mm depth, and 
0.506-0.511 mm in length (depending on the imaging depth setting). This algorithm takes about 
1 hour to complete the resampling and curvature corrections. Methods used within the Invenia 
ABUS workstation software could allow for this curvature processing to be done instantly.  
 The curvature-corrected ABUS images are then resampled from the 0.082 mm in depth, 
0.082 mm in width, and 0.506-0.511 mm in length (distance between adjacent slices dependent 
on exam setting), to 0.2 mm in width, 0.2 mm in depth, and 0.506-0.511 mm length (dependent 
on imaging depth setting). Since each ABUS view generates 330 slices, resampling was needed 
to increase the speed of surface mesh creation for the base FE ABUS model generation. Image 
resampling is done using the MATLAB imresizew command. 
6.3.2 Segmentation Methods 
 All lesions in the acquired patient-specific images in DBT and ABUS were segmented using 
MiViewer, a semi-automated segmentation program based on using 3D level set segmentations 
                                                 
w https://www.mathworks.com/help/images/ref/imresize.html  
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from the University of Michigan CAD Laboratory 140,141. In the MiViewer, program the user 
specifies the best slice, the first slice, and the last slice that the lesion is seen in the 3D image set. 
Then the user places a small box to occupy the lesion in the best view of the image slice. We 
found using window level/width settings that provided more contrast and noise (as shown in 
Figure 3(a)-(c)) provided best visualization of the lesions for box placement to occupy the lesion 
in MiViewer. In the publication from Street et al., the MiViewer segmentation is described, “Our 
computer segmentation system consists of three stages. In the first stage, we apply preprocessing 
techniques to the original CT images in the 3D volume in order to obtain a set of smoothed 
images and a set of gradient images. In the second stage, an initial segmentation contour from the 
pre-processed images is extracted. In the last stage, a serial bank of level sets is propagated from 
the initial segmentation toward the final segmentation.”140  
 MiViewer allows for adjusting many parameters in the level set segmentation. We found 
that two sets of parametric settings (e.g. level-set time sets, sample radius, blur kernel etc.) gave 
best segmentations with minimal adjustments needed. These are listed in the Appendix. Minor 
modifications can be made after segmentation. Further information of the MiViewer program 
can be found in the work by Street et al.140 and Hadjiiski et al.141 If a lesion was unable to be 
sufficiently segmented using MiViewer then manual segmentation was performed. All lesion 
segmentations were checked and verified by a radiologist. Examples of a lesion segmented using 
MiViewer software are shown in Figure 6.3 (a) and Figure 6.3 (b) for DBT images and Figure 
6.3 (c) for ABUS images. 
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Figure 6.3: MiViewer lesion segmentation for (a) DBT (CC view) image slice (b) DBT (MLO view) image slice  (c) 
ABUS (AP view) image slice (sagittal) (d) 3D Slicer skin segmentation of ABUS (AP view) (coronal) 
 Segmentation of the glandular/dense tissue from the breast mask of the DBT images was 
performed using LIBRA, an open-source software package developed by the Computational 
Breast Imaging Group at the University of Pennsylvania.156 The LIBRA software was developed 
to quantitatively determine breast density of mammograms, by segmenting the dense breast 
regions from the breasts as shown in Figure 6.4. We found that it was sufficient for also 
segmenting the dense/breast masked from slices in DBT. Using the LIBRA executable, all DBT 
slices are housed in one directory. This is so that the executable is run using “Batch Processing” 
and also to save the additional intermediate files, which are produced for each image slice within 
the directory. The intermediate files contain the segmentations of the breast mask and the dense 
mask which are used for the patient-specific DBT FEM base model construction.  
 Since DBT has poor axial resolution the first 5 and last 5 image segmentation slices (which 
represents the top 5 and bottom 5 sections of the breast) for the glandular tissue are avoided 
during surface mesh creation. These are excluded from classification as dense tissue since the 
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voxels are likely skin. Five slices were used as it was the maximum number of slices that the 1 
mm glass bead from the external fiducial markers is seen in reconstructed DBT views which is 
on the breast skin surface. An example of the resulting segmentation of the dense mask from a 
DBT image slice using the LIBRA executable is shown in green in Figure 6.4(c). 
 The breast was segmented from the background also using LIBRA to generate the breast 
(shown in red from an image slice in Figure 6.4(c)) mask for the skin. Breast skin thickness can 
range between 0.7 to 3.0 mm as reported by Huang et al.157 from breast CT data. The breast mask 
segmentation (shown in red from an image slice in Figure 6.4(c)) is shrunken by 3 mm for each 
image slice in the x-y plane, to create the inner skin mask which accounts for skin thickness. 
This is done by using the MATLAB bwmorphx function. The inner skin mask rejects the first 
and last 3 image slices to account for the 3 mm skin thickness in the z-plane. The area between 
the glandular tissue and the inner skin mask is fatty/adipose tissue for FEM. An example of the 
resulting segmentation of the breast mask from a DBT image slice using the LIBRA executable 
is shown in red in Figure 6.4(c). 
                                                 
x https://www.mathworks.com/help/images/ref/bwmorph.html  
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Figure 6.4: (a) Original DBT DICOM slice (b) LIBRA-generated color map of dense breast regions (c) Breast mask 
segmentation (red) and dense mask segmentation (green) of DBT slice 
 Since ABUS is the reference model, segmentations are only required for the markers, 
lesions, and outer skin layer. The skin layer is segmented using semi-automated techniques using 
3D Slicer.142 This is done by manually segmenting various slices along the coronal ABUS view 
and using the “Fill between Slices” technique under the Segmentation module to segment the 
peripheral breast margins where there was not substantial scatter or signal drop out artifacts.142 
 The first 4-6 slices in the coronal view (see Figure 6.3 (d)) were manually segmented by 
visual inspection. The last slice is segmented based on the manual segmentation of a slice before 
the ribs appear in the breast data. Several intermediate slices should also be segmented to achieve 
more improved results. A resulting segmentation of a slice of the breast image volume for the 
skin outline in ABUS is shown in Figure 6.3 (d). 
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6.3.3 Studies Performed 
The studies undertaken to evaluate the performance of the deformable mapping technique for 
DBT (CC view) mapped to ABUS and DBT (MLO view) mapped to ABUS and are described as 
follows: 
• Validation of deformable registration of the DBT (CC view) mapped to ABUS images: 
Results (dCOM) are compared using the deformable mapping algorithm (with and without 
marker analysis). Those results are then compared to a rigid registration of the DBT (CC 
view) and ABUS image volumes. Various marker combinations are also compared using 
the deformable mapping algorithm. T-test and signed Wilcoxon rank tests are used to 
provide the null hypothesis, that there is no improvement using the deformable method 
for lesion registration over that of rigid registration.  
• Validation of deformable registration of DBT (MLO view) mapped to ABUS images: This 
study was performed similarly to the previous case for DBT (CC view) to ABUS 
registration.  
• Elastic Modulus Sensitivity Analysis: Modifications to the Young’s moduli for adipose, 
glandular and lesions tissues are run on all patient data sets using the deformable 
mapping algorithm without marker analysis. The minimum and maximum elastic moduli 
values that were used are described in Table 6.2. The resulting dCOM values are compared 
to the default dCOM results on all patient datasets using the default/base Young’s moduli 
parameters (see Table 6.1) within the deformable mapping algorithm. The comparison is 
done in order to show the effect that varying the elastic parameters has on the registration 
results (dCOM) using the deformable mapping method. 
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• Algorithm Optimization Study: Results increasing the resampling size to 0.3 mm length, 
0.3 mm width, and 1 mm depth are performed for the subject with the largest breast 
volume in order to determine the effect it on algorithm run time and dCOM. Additionally, 
reducing mesh coarseness of the skin, fat, and glandular tissues is performed for this 
same subject’s image data in order to determine its effect in algorithm run time and 
overall resulting dCOM.  
6.4 Calculations 
 The deformable mapping algorithm is an automated process that leverages a commercial 
pre-processor (HyperMesh version 2017.2, Altair Engineering, Troy, MI) for meshing model 
generation and a commercial FEA solver (HyperMesh version 2017.2, Altair Engineering, Troy, 
MI). An overview of this process is shown in Figure 6.5. This algorithm provides deformation 
results using, or without using, location information provided by external fiducial markers. The 
entire process can take between 30-60 minutes (depending on model/breast size) to complete 
using a Windows 10 Intel® Core™ i7 CPU with a speed of 2500 MHz and 8GB RAM.  
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Figure 6.5: Overview of the Automated Deformable Mapping Process. Software’s used are shown in red. 
6.4.1 Base Finite Element Model Generation 
     The segmented contours are converted into triangular surface meshes using Morfeus, which 
uses the shrinkwrap tool in the finite element (FE) pre-processor, HyperMesh 143. The 
compilation of surface meshes are used to build each base model for the DBT (CC or MLO) and 
ABUS modality. More information on how to generate the base FE model can be found in the 
Appendix. A 1 mm element size was used for all lesions and 5 to 10 mm element sizes were used 
for the glandular, adipose, and skin volumes based on their larger volume and patient 
dependency. The triangular surface meshes are meshed using 3D four-point fully meshed 
tetrahedral models for each modality model being used for registration. This study employs the 
use of a four-compartment model (skin, adipose, glandular, and lesion). The material properties 
assigned for the various model volumes are described in Table 6.1. The skin, adipose, and 
glandular material properties were attributed from work by Kellner et al.158 which has been used 
in other FEM-based breast models 159. Each lesion by default is given the property of a benign 
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lesion based on average reported values by Tozaki and Fukuma160. If specified the algorithm can 
be run so that the mechanical properties of a malignant lesion are used (Tozaki and Fukuma160).   
Table 6.1: Mechanical properties used for biomechanical modeling. By default, a lesion is assigned the properties of 
benign lesion. 
Tissue Type  Young’s Modulus (E) Poisson’s Ratio (ν) 
Skin 88 kPa 0.49 
Adipose Tissue 1 kPa 0.49 
Glandular Tissue 10 kPa 0.49 
Lesion (Benign) 42 kPa 0.49 
Lesion (Malignant) 146 kPa 0.49 
 
 Table 6.2 shows the range of the material properties tested for the sensitivity analysis study 
further discussed in the 6.5 Results section.  
Table 6.2: Minimum and Maximum Young’s Moduli of adipose, glandular and lesion tissue for sensitivity analysis 
 Young’s Modulus (E) 
Tissue Type Minimum (kPa) Maximum (kPa) 
Adipose Tissue  0.5 1.5 
Glandular Tissue 1 20 
Lesion (Benign)  6.3 96 
Lesion (Malignant) 7.1 299 
6.4.2 DBT Skin Deformation 
 Once the base FEM models for the DBT and ABUS models are created the DBT model is 
registered to the center of mass (COM) of the ABUS model. Details of this registration will be 
addressed in the following text for DBT (CC view) to ABUS and DBT (MLO view) to ABUS.  
6.4.2.1 DBT (CC view) mapped to ABUS 
 For DBT (CC view) mapped to ABUS, the base DBT model is rigidly registered to the 
COM of the ABUS base model, as shown in Figure 6.6(a). A check is performed to ensure that 
the nipple is within a 2 cm distance in both the x and y dimensions. If this is exceeded the model 
is rigidly registered to the nipple. This nipple registration check helps correct for proper 
alignment in the case where the nipple was not adequately positioned during ABUS image 
acquisition due to the shape or size of the breast, or improper positioning by a technologist. The 
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nipple correction only corrects in the x and y planes. Skin deformation is performed on the base 
DBT model using the HyperMorph feature, which creates local (yellow) and global (red) handles 
around the DBT FE volume. The handles are manipulated to morph the mesh to be a similar 
shape as the ABUS model in all anatomical directions. Our previous work described the detailed 
process of how skin deformation takes place.34 This method was slightly modified in order to 
account for axillary attachment, breast size, and improper positioning during ABUS imaging. 
The modifications are explained below, and the process is summarized in Figure 6.6.  
 In our previous work, the skin deformation was based on a phantom that did not have an 
axillary attachment, therefore the method deformed the skin based on the shape of the phantom. 
This modification is necessary because real breasts are attached to the body. Since our previous 
method does not account for this attachment this could cause the breast to be deformed too great 
for smaller breasts in which the axillary and upper thoracic regions are included in the ABUS AP 
view. Similarly, it could cause for larger breasts to not be deformed enough, where the ABUS 
AP volume contains more breast tissue and not the upper thoracic and axillary breast regions. 
Therefore, this study employs the use of standardized parabolic shape corrections shown by Eq. 
(10 for skin deformation based on a measure of the medial to lateral breast skin length (denoted 
by L) in Figure 6.2 (a) indicated by the yellow arrow. The patient breast data was fit using the 
parabola equation to determine breast deformation based on L.  
 𝑦 = 𝑎𝑥2 + 𝑏𝑥 + 𝑐 (10) 
 Each handle controls deformation of the DBT breast volume based on influence functions 
that control those areas of the mesh model. There are 68 handles along the exterior of the breast 
in all planes. The handles along the x-plane are manipulated based on their location to the center 
of mass (COM) of the breast DBT FEM model (e.g. superior/inferior or anterior/posterior). Each 
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handle is equidistant, L/6, from the neighboring handle along the x-axis. The length from the left 
side of the breast to the handle is used as the variable “x” in Eq. (10 to calculate the proper y-
distance needed for handle manipulation. The coefficients that were found to show the best fit  
based on location and the length L are defined in Table 6.3. Handle manipulations based on these 
parabolic dimensions are shown in Figure 6.6(b). All resulting R2 values based on these fits were 
over 0.98.  
Table 6.3: Coefficients for Equation 1 based on different lengths, L, as described in Figure 6.2. SA= Superior 
Anterior. SP= Superior Posterior. IA= Interior Anterior. IP=Interior Posterior. 
 
 After corrections are made along the y-axis, the anterior handles are then manipulated to 
show AP compression which results in Figure 6.6 (c).   
 
Figure 6.6: Handle manipulation for external skin DBT mesh. Blue=ABUS (unchanged). Brown= deformed DBT 
(CC view) (a) original DBT mesh registered to COM of ABUS (b) morphed DBT mesh following parabolic 
deformation for nodes along x-axis (c) resulting morphed DBT model after compression along z-axis. The handles 
(red and yellow spheres) are used to manipulate the DBT mesh model to match similar shape of the ABUS model. 
 
 
 Coefficients for Equation 1 
Nodal 
Location 
L < 18.0 cm 18.0 cm < L < 20 cm L > 20 cm 
a b c a b c a b c 
SA -3.65 3.65 1.49 -7.31 7.31 1.48 -4.73 4.73 0.77 
SP -3.65 3.65 1.49 -7.31 7.31 3.48 -4.73 4.73 1.52 
IA 2.57 -2.57 -1.46 2.57 -2.57 0.04 3.65 -3.65 -0.99 
IP 2.57 -2.57 -2.96 2.57 -2.57 -1.46 3.65 -3.65 -1.99 
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6.4.2.2 DBT (MLO view to ABUS) 
 For MLO to ABUS registration, first the base ABUS model is rotated +/- 45° in the x-y 
plane (depending on breast laterality such that the lateral side of the DBT breast is superior and 
the medial side of the DBT breast is inferior as shown in Figure 6.7 (a) in comparison to its 
position in Figure 6.6 (a)). For the right breast the ABUS model is rotated 45° (shown in Figure 
6.7) and for the left breast, the ABUS model is rotated -45°. It should be noted that all analyzed 
cases in this study were acquired at a 45° angle for the MLO view. DBT (MLO) base FEM 
model is then rigidly registered to the COM of the ABUS model shown in Figure 6.7 (a). A 
nipple correction is made by rigidly registering the nipple of base DBT model to the nipple of the 
ABUS model to ensure alignment across all planes, as shown in Figure 6.7 (b). Skin deformation 
is performed by manipulating the handles as similarly described in our previous works.34,35 The 
deformation is performed on the DBT (MLO) model to transform the DBT mesh volume to 
match the outer shape of the breast in the ABUS model. This is done by manipulating handles 
along the x and y planes as shown in Figure 6.7 (c). Posterior nodes are compressed in the 
positive z direction based on the length L (see Figure 6.2 (b)), subtracted from the depth of the 
ABUS 3D volume to correct for depth. Since the MLO view contains the axillary tail there is no 
correction for that area as shown in Figure 6.7(c). The axillary tail which is located on the right 
in the brown DBT MLO model does not correspond to any areas on the blue ABUS model; 
therefore, no skin deformation is made in that region.  
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Figure 6.7: Handle manipulation for external skin DBT mesh. Blue=ABUS (unchanged). Brown= deformed DBT 
(MLO view) (a) original DBT mesh registered to COM of ABUS (b) original DBT mesh registered to the nipple of 
the ABUS model (c) skin morphing performed by handle perturbations to allow DBT MLO model to match similar 
shape of ABUS model. The handles (red and yellow spheres) are used to manipulate the DBT mesh model to match 
similar shape of the ABUS model. 
6.4.3 External Marker Relation (Optional Step)  
 After skin deformation is completed, the algorithm computes the COM positions of the 
external fiducial markers between the morphed DBT and ABUS model. The external markers are 
matched using a matching algorithm that was described in greater detail in our previous work 34. 
We’ve found that allowing the algorithm to search for corresponding markers clockwise (right 
breast) and counter-clockwise (left breast) beginning with the marker located in the lower inner 
breast quadrant was the most helpful to ensure proper marker matching. Once the algorithm 
determines which external markers are matched between the two models and further manipulates 
the handles of the deformed DBT mesh as described in Figure 6.6 and Figure 6.7 to ensure are 
markers are within a 5 mm distance. We’ve found that high iterations (>10 iterations) of the 
algorithm can cause mesh distortions. Therefore, it is recommended that the external marker 
correlation does not iterate more than 10 iterations for both DBT (CC view) to ABUS 
registration and DBT (MLO view) to ABUS registration.  
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6.4.4 Finite Element Analysis  
The constraints or boundary conditions for each external skin node are applied to the base 
DBT FE model. These boundary conditions are used as input to the FEA solver program, 
Optistruct, to generate and solve the differential equations to describe the model deformation 
based on the defined constraints. The boundary conditions are the nodal displacements of the 
external skin DBT mesh after skin deformation and marker corrections (if needed) subtracted 
from the nodal coordinates after being rigidly registered (or registered to the nipple when 
applicable) to the ABUS volume. The FEA is performed as a non-linear quasi-static analysis in 
a single step. The FEA was performed on a Windows 10 Intel® Core™ i7 CPU speed of 2.80 
GHz with 8 GB RAM and it takes approximately 30-60 minutes (dependent on model 
size/complexity) to complete.  
6.4.5 Lesion Registration  
After FEA is performed, the COM of lesions from the FEA-DBT model and the base FE 
ABUS model are determined. A lesion correlation algorithm determines if lesions are matched 
based off distances between COM, dCOM, being within a 25 mm distance (dCOM ≤ 25 mm). The 
lesion correlation algorithm also determines if lesions overlap and the distance between the 
overlap of corresponding lesions, dO, if lesions do not overlap. In our previous study that dealt 
with phantoms with multiple simulated lesions, we restricted the value of the dO and used it as 
part of corresponding lesion criteria. In this study, we do not use dO as part of correlation criteria 
but as supplemental information for a radiologist to aid in validating the registration.   
Previous studies, for deformable registration using FEM from breast MR to mammography 
CC views have shown mean registration errors between 10 - 20 mm 92. Additionally, from 
consulting with a radiologist (Dr. Marilyn Roubidoux) on this study we determined that 25 mm 
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was an acceptable bound, considering that DBT lesions appear elongated due to poor axial 
resolution.  
A radiologist verifies all results and views the original images from an in-house developed 
GUI software routine to show corresponding masses. The radiologist fills out a form to evaluate 
the performance of the algorithm, image quality using the external markers, segmentation quality 
of lesions, and any additional information that is necessary. This evaluation form can be found in 
the Appendix. 
6.5 Results  
 There were up to 7 total masses to be evaluated out of 5 patient datasets that were imaged in 
both the DBT (CC and MLO views) followed by a complete ABUS exam. An overview of 
subject criteria and additional findings from the study is summarized in Table 6.4. There is up to 
7 matched lesions as one patient dataset (Subject ID 7) was a case where 4 masses were seen in 
reconstructed DBT CC view. However, for this subject only 3 masses were found in 
reconstructed ABUS views and 2 in reconstructed DBT MLO views.   
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Table 6.4: Subject and lesion demographics. Compressed thickness is based on the DBT (CC view) 
RA=Retroareolar, LOQ= Lower Outer Quadrant, UOQ= Upper Outer Quadrant, LIQ= Lower Inner Quadrant, 
UIQ= Upper Inner Quadrant. A=Anterior depth P=Posterior depth M=Middle MP=Middle to Posterior depth 
*Indicates a mass has components of fibrocystic change, stromal fibrosis, and usual ductal hyperplasia 
Subject 
ID 
Lesion 
ID 
Compressed 
Thickness 
(mm) 
Quadrant/ 
Depth 
BI-RADS 
Density 
(Suspicion) 
Lesion Type 
(Size) 
Additional Findings 
1 1 59.9 RA/A 
Extremely 
Dense (4A) 
Fibroadenoma 
(13 mm) 
Two additional 
fibroadenomas 
(ABUS) 
2 2 48.1 LOQ/P 
Extremely 
Dense (4A) 
Papilloma 
(8 mm) 
Dilated Ducts 
(ABUS) 
3 3 52.2 UOQ/M 
Scattered 
Areas (4C) 
Invasive Ductal 
Carcinoma 
(16 mm) 
n/a 
4 4 65.3 LOQ/MP 
Scattered 
Areas(4B) 
Fibroadenoma 
(10 mm) 
n/a 
 
5  
5  UIQ/MP 
Scattered  
Areas (4) 
Fibroadenoma 
(13 mm) 
Four lesions shown 
in DBT (CC view) 
images only 3 found 
in ABUS, and 2 in 
DBT (MLO view) 
6 70.2 LIQ/M 
Fibroadenoma 
(6 mm) 
7  RA/A 
Other* 
(4 mm) 
 
6.5.1 Validation of deformable registration of DBT (CC view) mapped to ABUS  
 For DBT (CC view) to ABUS registration, 5 patients were imaged, and 7 masses were 
identified between image sets. An overview of the results for deformable registration of the DBT 
(CC view) to ABUS is illustrated in Table 6.5, where the various marker combinations are 
compared to a rigid registration. Using the deformable mapping technique without marker 
analysis there is up to 2.6 times improvement over rigid registration. Using the deformable 
mapping technique with marker analysis there is up to 4.8 times improvement over rigid 
registration. Using the deformable mapping technique without external marker analysis, all 7 
lesions were matched with a mean dCOM of 17.2 ± 4.3 mm. Using the deformable mapping 
technique with external marker analysis (best marker analysis cases), all 7 lesions were matched 
with a mean dCOM of 11.0 ± 4.9 mm.  
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Table 6.5: Deformable registration results compared to rigid registration for various marker combinations based on 
resulting dCOM values for DBT (CC view) mapped to ABUS. For Lesion ID #4, the lateral marker “G” (see Figure 
6.1(b)) was not seen in resulting ABUS views due to ABUS view misalignment therefore cases using 4 and 7 markers 
were not evaluated. For retroareolar lesions marker analysis using 1 marker is not evaluated. Best dCOM values are 
reported in bold. 
Lesion 
ID # 
Rigid 
dCOM (mm) 
Deformable Registration dCOM (mm) 
Number of Markers used in Analysis Best using Marker 
Analysis 0 1 3 4 6 7 
1 14.7 11.9 n/a 7.2 18.5 3.2 5.5 3.2 
2 21.1 19.6 21.9 18 20.9 20.1 21.2 18 
3 37.4 14.3 15.5 20.9 n/a 12.5 n/a 12.5 
4 11.1 14.7 13.6 8.4 8.3 10.9 11.4 8.3 
5 31 20.2 13.4 20.4 17.6 21.8 18.8 13.4 
6 30.8 23.3 16.8 19.1 16.9 14.9 13.6 13.6 
7 37.6 16.7 n/a 24.5 23.1 7.9 8.22 7.9 
Mean 26.2 17.2 16.20 16.9 17.6 13 13.1 11.0 
σ 10.7 4.0 2.50 6.6 5.1 6.6 6.0 4.9 
 
 A paired t-test and a signed Wilcoxon ranks tests of the dCOM’s was performed to compare 
the best marker analysis cases to the rigid registration values and resulted in p-values of 0.004 
and 0.016. Thus, indicating statistical improvement in lesion dCOM using the deformable method 
in comparison to a rigid registration. A paired t-test and a signed Wilcoxon ranks tests of the 
dCOM’s were performed to compare the deformable case without marker analysis to rigid 
registration and resulted in p-values of 0.06 and 0.08, indicating that the null hypothesis cannot 
be rejected. A paired t-test and a signed Wilcoxon ranks tests of the of dCOM’s were performed to 
compare the deformable case without marker analysis to the deformable case using marker 
analysis (best marker analysis cases) and resulted in p-values of 0.001 and 0.016; thus, showing a 
significant improvement in lesion dCOM using external fiducial markers within the deformable 
mapping method. 
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6.5.2 Validation of deformable registration of DBT (MLO view) mapped to ABUS  
 An overview of the results for registration of the DBT (MLO view) to ABUS is illustrated in 
Table 6.6 where they are compared to a rigid registration. Using the deformable mapping 
technique, we see up to 5 times improvement over rigid registration. Using the deformable 
mapping technique without external fiducial markers all 4 of the 6 lesions were matched within 
correlation bounds, a resulting mean dCOM of 19.6 ± 11.3 mm from all 6 lesions. Using the 
deformable mapping technique with the use of external fiducial markers (best marker analysis 
case), all 6 lesions were matched with a mean dCOM of 12.3 ± 4.8 mm. 
Table 6.6: Deformable registration results compared to rigid registration for various marker combinations based 
off resulting dCOM values for DBT (MLO view) mapped to ABUS. For Lesion ID #4, the lateral marker “G” (see 
Figure 6.1 (a) Ultrasound camisole for ABUS imaging (b) External fiducial marker locations (denoted by A-G) 
shown for marker placements on the left breast(b)) was not seen in resulting ABUS views due to ABUS view 
misalignment therefore cases using 4 and 7 markers could not be evaluated. For Lesion ID 7, was not seen in 
reconstructed DBT (MLO view) and therefore could not be registered due to lack on anterior compression.   
Lesion 
ID # 
Rigid 
dCOM (mm) 
Deformable Registration dCOM (mm) 
Number of Markers used in Analysis Best using Marker 
Analysis 0 1 3 4 6 7 
1 7.8 3.9 n/a 12.7 16.1 8.6 11.2 8.6 
2 43.9 33.9 33.7 26.12 27.6 18.6 14.8 14.8 
3 31 26.7 10.8 21.5 n/a 9.04 n/a 9.04 
4 92.9 19.7 24.1 22.8 18.9 22.3 22 18.9 
5 48.5 24.5 23.4 20.1 19 17.1 15.6 15.6 
6 35.6 9.1 16.0 11.3 10.7 6.8 8.3 6.8 
7 n/a n/a n/a n/a n/a n/a n/a n/a 
Mean 44.8 21.6 16.2 19.1 18.5 13.7 14.4 12.3 
σ 28.1 8.7 2.50 5.9 6.1 6.4 5.2 4.8 
  
 A paired t-test of the dCOM and a signed Wilcoxon ranks tests were performed to compare the 
best marker analysis case to the rigid registration values and resulted in p-values of 0.03 and 
0.06; thus, indicating significant improvement based off the t-test and that the null hypothesis 
cannot be rejected based off the Wilcoxon test. A paired t-test and a signed Wilcoxon ranks tests 
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of the dCOM’s were performed to compare the deformable case without marker analysis to rigid 
registration and resulted in p-values of 0.08 and 0.03, respectively. A paired t-test and a signed 
Wilcoxon ranks tests was performed on the dCOM values to compare the deformable case without 
marker analysis to the deformable case using marker analysis (best marker analysis cases). These 
tests resulted in p-values of 0.12 and 0.15; indicating that the null hypothesis cannot be rejected. 
However, for this case, it should be noted that the number of matched lesion improved from 4 to 
6 within the specified bounds thus, showing improvement with using marker analysis with the 
deformable mapping method. 
6.5.3 Elastic Modulus Sensitivity Analysis 
 A sensitivity analysis was performed on the deformable models without using marker 
analysis by varying the Young’s Moduli using the base, maximum, and minimum values as 
described in Table 6.2. These values are used to calculate the registration dCOM’s for the DBT to 
ABUS sets, by varying the lesion material properties (benign or malignant), fat, and glandular 
tissues. These were performed for benign and malignant lesion material properties with variation 
in the Young’s Moduli for adipose and glandular tissues for the DBT (CC view) mapped to 
ABUS using the deformable mapping method without marker analysis. The results (dCOM) using 
the variation of material properties for adipose, lesion (benign), and glandular tissues is shown in 
Figure 6.8 based on the base E values shown in Table 6.1 and the minimum and maximum E 
values shown in Table 6.2.    
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Figure 6.8: Sensitivity Analysis of variations in Young's Moduli, E, for registered dCOM for DBT (CC view) mapped 
to ABUS using the deformable mapping technique without marker analysis. Base values for E for lesion (benign), 
glandular tissue, and adipose tissue are shown in Table 6.1. The minimum and maximum E values for these tissues 
are shown in Table 6.2.  
 Assuming material properties of a malignant lesion, the results (dCOM) using the variation of 
material properties for adipose, lesion (malignant), and glandular tissues is shown in Figure 6.9 
based on the base E values shown in Table 6.1 and the minimum and maximum E values shown 
in Table 6.2. For most lesions, there is not a significant difference in lesion dCOM as a result of 
the variation in material properties. However, Lesion ID’s 4, 5, and 6 show dCOM differences up 
to 6 mm in the varied cases.  
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Figure 6.9: Sensitivity Analysis of variations in Young's Moduli, E, for registered dCOM for DBT (CC view) mapped 
to ABUS using the deformable mapping technique without marker analysis. Base values for E for lesion (malignant), 
glandular tissue, and adipose tissue are shown in Table 6.1. The minimum and maximum E values for these tissues 
are shown in Table 6.2. 
6.5.4 Algorithm Optimization Study 
 An optimization study was performed on Subject ID #4 (see Table 6.4) to determine the 
effect on resulting dCOM and algorithm run time. The Subject ID #4 (Lesion ID #4) dataset was 
chosen because the subject had the largest breast volume which would cause for increased 
runtimes for the FEA within the algorithm. Two cases were tested to be compared against the 
base case to show differences in using the deformable mapping method without external marker 
analysis for DBT (CC view) to ABUS registration. Case 1 uses all the same parameters except 
uses a less discretized meshing scheme by using the HyperMesh function “divide by nearest 
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diagonals” instead of the default “divide midpoint to triangular”. Case 2 resamples the 
segmented DBT volumes to a 0.3 mm length, 0.3 mm depth, and 1 mm slice thickness rather 
than the default resampling of 0.2 mm length, 0.2 mm depth, and 1 mm slice thickness. Results 
(dCOM) are shown in Table 6.7. These results indicate no change in lesion dCOM and reduction in 
run time by a factor of 2, approximately.  
Table 6.7: Variation in dCOM and FEA run time varying meshing parameters in Case 1 and resampling rates in Case 
2 in comparison to the base values 
Case 
dCOM 
(mm) 
FEA run time 
(minutes) 
Base 14.7 25 
1 14.9 15 
2 14.7 14 
 
6.6 Discussion  
 A novel deformable registration method has been described for providing a one-to-one 
correlation between corresponding lesions between two common DBT views (CC and MLO) to 
ABUS images based on 5 patient datasets and up to 7 lesions. For both analyzed cases there was 
a significant improvement in lesion dCOM in comparison to rigid registration using the 
deformable mapping method. This study extends upon our previous works by validating the 
algorithm to relate corresponding lesions on real patient datasets. 
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Figure 6.10: Registration results for Subject ID=2 Lesion ID=2 extremely dense breast tissue with presence of 
dilated ducts (a) registered lesion in DBT (CC view) (b) registered lesion in DBT (MLO view) (c) registered lesion 
in an ABUS image slice (d) presence of dilated ducts seen in a ABUS slice; These dilated ducts extended from ABUS 
Slices 180-215 
 We believe this method will be helpful for the one-to-one correlation of breast lesions and 
especially for women with dense breasts and multiple masses. Subject 2 of the study had very 
dense breast tissue and dilated ducts that can make it a more difficult case for a radiologist to 
find the corresponding mass between the DBT and ABUS modalities as shown in Figure 6.10. 
Additionally, since x-ray imaging has lower sensitivity for the imaging of dense breasts, ABUS 
imaging may find additional masses that are not seen in the DBT images as shown for Subject 1 
(see Table 6.4). Therefore, this method would be especially helpful to ensure that a mass seen in 
DBT is registered to the correct lesion in ABUS.  
 Likewise, for the case with multiple masses (Subject ID=5), the deformable registration 
algorithm was able to register and differentiate 3 of the 4 total masses. The fourth mass was 4 
mm in length in its widest dimension and could not be differentiated from other ultrasound 
structures and artifacts. However, 3 lesions were differentiated and matched using the 
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deformable mapping algorithm using the CC view as shown in Figure 6.11. Since the third lesion 
was superficial in-depth and located more anteriorly, the lack of compression anteriorly caused it 
to not be differentiable from other glandular structures in the DBT (MLO view).  
 
Figure 6.11: Corresponding lesions of multiple breast masses based on deformable registration results (a) a DBT 
(CC view) image slice showing Lesion ID=5 (b) a DBT (CC view) image slice showing Lesion ID=6 (red arrow) 
and Lesion ID=7 (yellow arrow) (c) the corresponding ABUS slice for Lesion ID=5 (d) the corresponding ABUS 
slice for Lesion ID=6 (e) the corresponding ABUS slice for Lesion ID=7 
 Based on the sensitivity analysis between material properties, the largest variation in dCOM 
values based on changes in Young’s moduli are shown for Lesion ID’s 4 and 5 using material 
properties of a benign lesion as shown in Figure 6.8. Both lesions are from subject’s who have 
scattered breast densities where the masses are located mid-to-posterior in depth. Similarly, the 
largest variation in resulting dCOM based on changes in Young Moduli are shown for Lesion ID’s 
4,5, and 6 using the material properties for a malignant lesion as shown in Figure 6.9. Here we 
see that using the minimum E values as described in Table 6.2 have the largest variation 
increasing the dCOM for Lesion’s 4 and 5 but the inverse effect for Lesion ID 6. This may indicate 
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that lesion depth can have an effect on the dCOM values. From these two figures, it can be 
observed that for the two cases of high breast density (Subjects ID’s 1 and 2) that there was not 
much variation in resulting dCOM values with changes in material properties which may be 
attributed to the abundance of dense breast tissue.   
 This study uses two statistical metrics, paired t-test and signed Wilcoxon ranks tests, to 
determine if lesion dCOM was significantly improved using the deformable technique in 
comparison to a rigid registration. In our previous study34, we only used t-tests to authenticate 
improvement of dCOM using the deformable case with and without external fiducial markers. 
However, we realize that due to the small sample size a normal distribution cannot be verified in 
order to use this test. Therefore, we decided to also include results from a non-parametric test 
(signed Wilcoxon ranks test) that is not based on a specific distribution in order to also evaluate 
the improvement in dCOM. There were several instances, when one statistical test indicated that 
there was significant improvement in dCOM (p ≤ 0.05) and the other did not. This is caused due to 
underlying differences in how p-values are calculated between the two statistical tests based off 
their respective differences in methodology. 
 Various marker combinations are tested and their corresponding dCOM results are compared. 
Overall results from Table 6.5, show that for DBT (CC) to ABUS registration marker analysis is 
not needed in order for lesions to be within correlation bounds (dCOM ≤ 25 mm). Corresponding, 
p-values based on both statistical tests show significant improvement using the deformable 
method with markers vs. without. Best marker results are shown for the use of 6 external 
markers. Using 1 external marker, was not performed for retroareolar breast masses. This is 
because the closest identifiable location is the nipple. A nipple correction is already being 
accounted for (if needed) by the algorithm. Therefore, modulating the next marker nearest to this 
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lesion will result in worse results since it is only correcting for that specific region in the breast. 
Using 1 marker for deformable analysis showed improved dCOM results for only Lesion ID 5. 
Similarly, for DBT (MLO) to ABUS registration as shown in Table 6.6, larger marker 
combinations (6 markers or greater) showed the largest improvement in dCOM results. Based on 
these results, we recommend that if marker analysis is being used, that at least 6 markers are 
needed to be placed at the indicated areas for the most optimal dCOM result.  
 Additionally, this methodology would work best if used adjunct to a computer-aided 
detection (CAD) program in order to detect breast masses and with a fully-automated 
segmentation program to segment those detected masses. In this study, masses were detected by 
the eye of a single viewer and segmented using semi-automated techniques. If the mass was not 
obvious, a radiologist was consulted in order to determine the lesion location and if the semi-
automated program did not segment the masses sufficiently, manual segmentation was 
performed.  
 One limitation to this registration technique is the fact that it registers DBT images to ABUS 
images and cannot do the inverse of registering ABUS images to DBT (FEA to deform the 
ABUS image to DBT). The latter would be helpful in the cases where additional ABUS findings 
can potentially indicate where in the DBT volume a lesion may be present (e.g. Subject 1 who 
had two additional masses found in the ABUS images with high breast density). Another 
limitation is that this technique only registers to the AP ABUS volume. Since up to 3 sweeps of 
the breast (central, medial, and lateral margins with some overlap) are taken in a typical ABUS 
exam for women with larger breasts the single AP sweep may not be enough to ensure full breast 
coverage. In the case of large breasts, the fusion of the ABUS volumes could be useful and 
would allow the deformable method to register to the stitched ABUS view. M. Costa 
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demonstrated the stitching of ABUS volumes using a homographic transfer model to render a 
stitch panorama view for areas within the AP and lateral ABUS views161.  
 Another limitation to this study is that it was not tested on lesions within the axillary tail and 
some lesions within the areolar region can be missed in ABUS images due to shadowing caused 
inferior to the nipple. Providing sufficient coupling to the axillary region is difficult for the large 
ABUS transducer. Often times HHUS is used in addition to ABUS to ensure there is sufficient 
imaging of the axillary region. Nipple offset pads could be used to reduce artifacts caused by the 
nipple in ABUS images to decrease signal fall out so that that retroareolar masses can be seen.  
 Additionally, using the external markers can be troublesome when translated into the clinic, 
especially with the use of the ABUS camisole. This can be minimized by assisting the patient in 
putting on the camisole, ensuring that enough time (at least 5 minutes) has passed before putting 
on the camisole after markers are glued, and by indicating locations on the breast (e.g. by using a 
washable marker) to reapply the external fiducial markers in case the external marker position is 
compromised. Additionally, if ABUS images are segmented to separate fat and glandular tissues. 
These segmentations could be used to provide internal landmarks for the deformable mapping 
algorithm which could allow less reliance for the methodology on external marker locations.  
 Criteria for volunteers in this study was restricted to women with masses within the breast 
(excluding axillary region) and masses ≥ 5 mm in size. Therefore, the validity of this technique 
was not tested on smaller masses or masses located in the axillary regions. Additionally, the 
algorithm was tested on a small sample size (5 subjects). Therefore, more patients would need to 
be scanned using this method to increase statistics. A larger sample size would allow for a more 
in-depth analysis to be performed to determine which marker combination yields optimal 
registration results based on lesion location and potentially breast density. It could also allow for 
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the investigation of the effect of lesion depth and density in vary the material properties used in 
the deformable registration analysis. Although this algorithm was tested on a small sample size, 
it should be noted that other studies were published that have used FEM based registration 
techniques to register lesions from breast MRI to mammography (CC and/or MLO views) that 
used 4 to 6 cases 86,90,162, 10 cases 85,163, 14 cases 87, and 79 cases 88.  
6.7 Conclusions 
 This work presents a validated deformable registration technique using FEM to register 
breast lesions between DBT and ABUS 3D image volumes. The results show 13 registrations 
between two common DBT views mapped to ABUS based on 5 patient datasets. This indicates 
this method could be a useful tool to aid in the detection and characterization of breast cancers 
and lesions between modalities. Our method is to our knowledge the first to show a direct 
correlation between DBT mapped to ABUS on patient datasets. The method uses nodal 
displacements in the FEA instead of simulating plate compressions which can be more expensive 
in computer run time. We assigned various material properties to the fibroglandular, adipose, and 
lesions to evaluate the differences in lesion accuracy and saw that in most cases there was no 
difference in the resulting dCOM. However, there were a few cases where there were larger 
differences in the resulting dCOM, which may be a result of breast density and lesion depth. Using 
the deformable mapping method, there is up to 5 times improvement in dCOM in comparison to a 
rigid registration and the use of external skin markers can aid in registration results. Future work 
will further validate this technique on a larger patient data set, where we can investigate which 
deformable analysis combination produces higher registration accuracy. We can also perform a 
more in depth analysis on dependence of the accuracy of the technique on breast density and 
lesion location. For the easy/obvious cases (e.g. one mass in a fatty breasts) this method would 
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only be beneficial in saving a radiologist time in navigating between the two 3D image volumes. 
However, for more difficult cases (e.g. multiple masses, dense breasts) this technique can be 
extremely useful in aiding a radiologist in determining corresponding lesion locations between 
DBT and ABUS images which can aid to the early detection of cancer masses. 
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Chapter 7  
Conclusions and Future Works 
 
 
7.1 Summary of Contributions 
 The work presented in this dissertation has demonstrated the efficacy and the diagnostic 
potential of using novel deformable registration methods to relate breast masses between 3D x-
ray (DBT and bCT) and 3D ultrasound (ABUS) breast modalities. For the phantom studies 
involved in this dissertation, this technique showed an improvement in lesion registration using 
external fiducial markers, including having more lesions within the specified correlation bounds 
(Chapter 3 and Chapter 5 (dCOM  15 mm) and Chapter 4 (dCOM  25 mm)). Based on the IRB-
approved patient study, this technique shows an improvement in lesion registration with the use 
of external fiducial markers. However, external markers are not mandatory in order to establish 
whether lesions correspond within the specified correlation bounds (dCOM  25 mm). Ultimately, 
the work in this dissertation demonstrates that this deformable mapping tool can be helpful for a 
radiologist by reducing the time spent navigating through 3D image volumes and provides a 
higher confidence between regions of interests between two modalities, especially for more 
difficult clinical cases, such as women with dense breasts or multiple lesions. Chapter 6 
illustrates a validation study tested on clinical datasets for DBT and ABUS images using the 
deformable registration methodology. A similar IRB-approved study is needed to quantify the
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effectiveness of this method for bCT to DBT and bCT to ABUS registration based on the 
deformable registration algorithm’s preliminary phantom results described in Chapter 5. 
7.2 Conclusions and Limitations  
7.2.1 Efficacy of Deformable Mapping Technique to relate lesions between DBT and ABUS 
images (Phantom Study) 
 Compressible multi-modality breast phantoms were used for studies in Chapter 3 and 
Chapter 4 to provide the foundation of the deformable registration algorithm for DBT to ABUS 
lesion registration. In Chapter 3, two breast phantoms (A and B) with varying stiffness properties 
are used to show the relationship of breast lesions using the FEM for DBT (CC view) to ABUS 
registration. This technique applies nodal displacements to the compressed DBT model in order 
to deform the breast for registration to the ABUS model using FEA. Without using external 
markers for Phantom A, results showed a mean lesion dCOM of 6.8 ± 2.8 mm. Using external 
markers, the average dCOM improved to 4.9 ± 2.4 mm. For Phantom B without external markers, 
the average lesion dCOM of 9.7 ± 3.5 mm improved to 8.5 ± 4.0 mm using marker analysis. 
Additionally, this study had more restrictive correlation bounds than used in Chapter 4 and 
Chapter 6 (patient study) of 15 mm (dCOM  15 mm) vs 25 mm (dCOM  25 mm). To our 
knowledge, this was the first published work to show registration between lesions in DBT and 
ABUS breast images. This study shows an improvement in the overall lesions’ correlation with 
the use of external fiducial markers during FEA.   
 The work presented in Chapter 4 performs deformable registration for the DBT (CC view) 
to ABUS view and incorporates deformable registration for the DBT (MLO view) for ABUS 
registration. The matching criterion was increased to 25 mm (dCOM  25 mm) from the 15 mm 
(dCOM  15 mm) used in Chapter 3 in order to account for translation of this technique to patients, 
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where the phantom is not representative of breast heterogeneity and complexity. For mapping of 
DBT (CC view) to ABUS without markers, the mean dCOM was 13.6 ± 6.3 mm. With markers the 
mean dCOM was 12.8 ± 6.0 mm. Without markers, 14 of 18 lesions were matched within 
correlation bounds and with markers this improved to 17 of 18 lesions matched. This resulted in 
a p-value of 0.04 (paired T-test) which shows a significant improvement in lesion registration. 
However, a p-value of 0.06 (Wilcoxon signed-rank test) indicated that not enough evidence is 
available to suggest that dCOM improves using external markers. For mapping of DBT (MLO 
view) to ABUS without markers, the mean dCOM was 9.3 ± 2.8 mm and which worsens to the 
mean dCOM was 12.3 ± 5.8 mm using external markers. Without markers, 8 of 18 lesions were 
matched which improved to 17 of 18 lesions matched. Based on these phantom studies, we see 
the largest improvement using external fiducial markers. A proof-of-concept study will need to 
be performed to validate this technique and specify its potential use to specific breast regions.  
 There are several limitations to these studies based on the fact that the phantoms are not 
anthropomorphic in that they used homogenous material and exhibit linear elastic behavior, 
whereas breasts are heterogeneous and exhibit non-linear elastic behavior. Additionally, the 
phantoms used in Chapter 3 and Chapter 4 do not contain an axillary attachment making it 
further difficult to resolve the implementation of this technique for lesions within the axillary 
region. Additionally, not having this axillary attachment may also contribute to the phantom’s 
linear elastic behavior under compression.  
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7.2.2 Efficacy of Deformable Mapping Technique to relate corresponding lesions between 
bCT to ABUS and DBT images (Phantom Study) 
 Chapter 5 describes the deformable mapping methodology for relating simulated bCT 
phantom images to DBT and ABUS images. The same phantom was used for this study as in 
Chapter 4 that contained 20 lesions. Anterior-to-posterior plate compression is simulated on the 
bCT model using FEA to relate the compressed bCT model to ABUS image volume. 
Additionally, CC and MLO compression is simulated on the bCT model using FEA to relate the 
compressed bCT model to the DBT image volumes. 
 For bCT to ABUS registration, without markers, 13 out of 20 lesions were matched and the 
mean dCOM was 8.6 ± 3.0 mm. With markers, 20 lesions were matched and the mean dCOM 
improved to 4.8 ± 2.4 mm. This resulted in p-values of 0.01 (paired T-test) and 0.02 (Wilcoxon 
signed-rank test); thus, indicating a significant improvement using external markers within the 
analysis. For registration of bCT to DBT (CC view), without using markers, 9 out of the 18 
lesions were matched and the mean dCOM was 11.6 ± 2.0 mm. With markers, all 18 lesions were 
matched and the mean dCOM was 5.0 ± 2.2 mm. This resulted in p-values of 0.00001 (paired T-
test) and 0.004 (Wilcoxon signed-rank test); thus, indicating a significant improvement using 
external markers within the analysis. For registration of bCT to DBT (MLO view), without using 
markers, 9 out of the 18 lesions were matched and the mean dCOM was 8.2 ± 3.1 mm. With 
markers, all 18 lesions were matched and the mean dCOM was 4.7 ± 2.5 mm. This resulted in p-
values of 0.002 (paired T-test) and 0.01 (Wilcoxon signed-rank test) thus indicating a significant 
improvement using external markers within the analysis.  
 Similar to Chapter’s 3 and 4, a major limitation to the bCT studies described in Chapter 5 is 
that the breast phantom has numerous inconsistencies in comparison to a real breast as described 
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in the previous section. These results indicate that the methodologies could be of potential use 
after validation with patient volunteers. Therefore, this method still needs to be validated with an 
IRB-approved proof of concept study for bCT to DBT and bCT to ABUS registration. 
Additionally, plate compression involved in this method is highly taxing in terms of 
computational time which may not make using this method applicable for medical centers that do 
not have access to super-computing capabilities. The time it took to run bCT to ABUS 
registration is approximately 13 hours, for bCT to DBT (CC view) registration approximately 30 
hours, and bCT to DBT (MLO view) registration approximately up to 45 hours. These high 
runtimes can be reduced by using parallel processors using super computers and larger graphics 
processing units.    
 Additionally, this method could be translated to uncompressed ultrasound CT for breast 
imaging provided by the Delphinus Medical Technologies (Novi, MI) for direct use to relate to 
DBT imaging. This will be discussed further within this chapter in Section 7.3.4 in Future 
Works.  
7.2.3 Design and Implementation of ABUS Camisole to Restrict Breast Motion  
 In Chapter 2, information was provided about the development and implementation of using 
an ABUS camisole to restrict breast motion during ABUS imaging which acquires multiples 
views for a complete ABUS examination. The overall results of this camisole design ensured that 
there was not degradation to the ultrasound beam penetration depth and minimal distortion. 
Several fabrics were tested, and a stretchable nylon mesh fabric was found to be superior. The 
camisole was tested on ten normal volunteers and was found to be helpful in restricting breast 
motion during ABUS imaging. Clinical translation of this camisole was used in the IRB-
approved study discussed in Chapter 6.  
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7.2.4 Implementation of Deformable Mapping Technique to relate corresponding lesions 
between DBT and ABUS images (Patient Study) 
 Chapter 6 discusses the results of the deformable mapping technique applied to clinical 
patient data sets and describes the minor modifications in the algorithm to relate corresponding 
lesions between DBT (CC and MLO views) to ABUS in clinical datasets. Up to 7 lesions were 
assessed from 5 patient datasets. This study compares the deformable registrations metrics (with 
and without using marker analysis) to a rigid registration and shows there was up to 5 times 
improvement using the deformable method over rigid registration.  
 For DBT (CC view) mapped to ABUS resulting p-values of 0.01 (paired T-test) and 0.02 
(Wilcoxon signed-rank test); thus, indicating a significant improvement in dCOM using the 
deformable mapping algorithm in comparison to rigid registration. Further analysis showed that 
using marker analysis has an insignificant affect in the number of total matched lesions in 
comparison to using the deformable mapping method without using marker analysis for lesion 
registration improvements. Thus, showing that markers increase the efficacy of the registration 
for DBT to CC views, however markers are not needed to ensure matched lesions are within 
correlation bounds.  
 For DBT (MLO view) mapped to ABUS resulting p-values of 0.03 (paired T-test) and 0.06 
(Wilcoxon signed-rank test) thus significant improvement based on the t-test using the 
deformable mapping algorithm in comparison to rigid registration. Improvements using the 
registration method ranged from 16% improvement over rigid registration to up to 5.2 times 
improvement. Further analysis showed that using marker analysis has a significant affect in the 
number of total matched lesions in comparison to using the deformable mapping method without 
using marker analysis for lesion registration improvements. Thus, showing that using marker 
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analysis is significant in improving lesion registration and the total number of matched lesions 
within correlation bounds based on the deformable mapping technique.  
 With such a small sample size, conclusive results on which breast regions the deformable 
registration has the most effect cannot be determined. However, based on the results presented, 
all breasts quadrants saw improvement using the deformable registration in comparison to a rigid 
registration. Lesions that had greater than twice the registration improvement included lesions in 
the retroareolar, medial, and upper outer breast regions for DBT (CC view) to ABUS 
registrations. For MLO view to ABUS registration, all breast mass locations except for one 
retroareolar case showed at least 2 times improvement over rigid registration. 
 Overall, it was mostly observed that when testing various ranges of material properties (i.e. 
Young’s modulus) there was not a significant difference in resulting dCOM. This is advantageous 
as it shows the method is mostly independent of material parameters which can widely vary. 
However, as shown for Lesions ID’s 4 and 5 further analysis into whether or not a lesion’s depth 
and breast density may explain the variation in dCOM using the varied elastic properties. To our 
knowledge, there are not any other studies that register breast lesions between two compressed 
states as shown in this study. However, uncompressed breast studies imaging with MRI or bCT 
often simulate the breast compression of mammography using FEM’s. A study by Hsu. et al. 
validated compression using a breast phantom by varying the relative Young’s modulus for the 
glandular, fat, and skin tissues of a breast and found it had a significant impact on the 
deformation of the breast under mammographic plate compression, even more so for less dense 
breasts.146 This may indicate why those lesions (Lesion ID’s 4, 5 and 6) show high differences. 
However, since this study applies FEA using nodal displacements to deform the DBT to ABUS 
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and not simulating the plate compression/decompression of the DBT image volume we suspect 
that this may reduce the mechanical property dependence.  
 Among the patient data sets there were cases of high breast density and multiple lesions 
within a breast. These are cases for which the algorithm would have the most impact. This 
deformable registration algorithm is also useful in reducing the time needed for a radiologist to 
navigate between large 3D image volumes. These results demonstrate the potential of the utility 
of the deformable registration technique to relate lesions between DBT and ABUS image 
volumes. Another advantage to this technique is that the FEA runs off nodal displacements the 
run times are about 30-60 minutes depending on breast volume. Thus, making the technique 
feasible to translate into the clinic. Although commercial FEA solvers are used within this 
dissertation, the methods can be translated to in-house or open source FEM packages for 
implementation.  
 A limitation of this technique is the fact that the deformable mapping algorithm relates DBT 
images to ABUS and not relate ABUS images to DBT. The latter would be helpful in the cases 
where additional ABUS findings can potentially indicate where in the DBT volume a lesion may 
be present, especially for dense breasts. Another limitation is that this technique only registers to 
the AP ABUS volume. Since up to 3 sweeps of the breast (AP, medial, and lateral margins with 
some overlap) are taken in a typical ABUS exam for women with larger breasts, the single AP 
sweep is not enough to ensure full breast coverage. Stitching of the ABUS volumes could be 
useful for this case in which then this method could use to register to the stitched ABUS view. 
M. Costa showed stitching of ABUS volumes using a homographic transfer model to render a 
stitch panorama view for areas within the AP and LAT views.161 Additionally, Chang et al. used 
a simple sum of absolute block-mean difference based registration technique to stitch 3D 
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ultrasound for women in pendant positioning and using ultrasound CT acquisition and validated 
the algorithm on 25 experimental cases.164 Nonetheless, stitching ABUS views would be very 
difficult due to the issues of alignment, a transducer tracking type of algorithm could be helpful 
in multi-view ABUS stitching to improve this alignment.  
 Criteria for volunteers in this study was restricted to women with masses within the breast 
(excludes axillary region) and masses (≥ 5 mm) in size. Therefore, the validity of this technique 
was not tested on smaller masses and masses located in the axillary regions. Additionally, the 
algorithm was tested on a small sample size (5 patient volunteers) therefore more patients would 
need to be scanned using this method to determine more accurate statistics. There was difficulty 
to recruit women to participate in the study due to the emotional distress associated with having a 
biopsy procedure and needing to come in before that procedure to receive additional imaging. 
We believe this software would be great to be used in adjunct to a computer aided diagnostic 
software in order to allow for automated detection of a breast lesion. Additionally, automated 
segmentation techniques would improve the pre-processing segmentation steps that can be 
directly fed into the algorithm for FE model generation.  
7.3 Future Works  
7.3.1 Extensive Proof-of-Concept study for DBT to ABUS Deformable Registration 
 As discussed previously, a more extensive study would be needed to gain proper statistics to 
determine the validity of this method with patient volunteers. With a more extensive study, we 
can more definitively quantify the improvement using marker analysis and determine which 
marker combination can provide optimal results based on lesion location/depth. The study results 
shown in Chapter 6 are based on up to 7 lesions from 5 clinical datasets. Although only 5 
subjects were imaged to validate this technique, other groups who used FEM based methods for 
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lesion registration for breast MRI and mammography (CC and/or MLO views) also had small 
sample sizes between 4 to 6 subjects.86,90,162. 
 With larger patient datasets some of the parameters that can be investigated are the quantity 
and location of the external fiducial markers and the effects on the deformable registration based 
on lesion location (breast quadrant), and depth. Additionally, more datasets will allow a more in 
depth analysis to determine if this technique improves a radiologist’s ability to better 
characterize lesions in dense breasts. 
7.3.2 Proof of Concept Study for bCT to DBT and bCT to ABUS Deformable Registration 
 Although promising results for bCT to DBT registration and bCT to ABUS registration are 
shown in Chapter 5, an IRB approved proof-of-concept study is still needed with patient 
volunteers to determine the validity of the technique. Within this study, investigations of quantity 
and location of fiducial markers can be assessed based on lesion location. Also, studies into the 
modeling the plate compression such as the friction coefficient can be analyzed along with a 
sensitivity analysis on the effects of using different material properties during the simulated plate 
compressions. A surprising finding within the patient study for DBT to ABUS registration 
showed that overall the lesion correlations (dCOM) are independent of changes in material 
properties (e.g. Young’s Moduli). Since this study does not model the actual decompression and 
plate compression of the breast for the deformable registration. I would hypothesize that 
modeling these mechanics would allow for more substantial changes to be seen in registration 
using material properties. Therefore, for the deformable registration techniques described in 
Chapter 5 that do simulate actual plate compression on the bCT model to register to ABUS and 
DBT models, I would expect changes in material properties to have a more significant impact 
based on results shown by a study by Hsu et al. that varied the elastic modulus of breast tissues 
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in a phantom model and found it had significant impact on the deformation of the breast under 
mammographic plate compression.146 Additionally, improved patient specific FE models can be 
generated with the isotropic spatial resolution provided in bCT imaging which can possibly show 
improvement in the deformable registration by accounting for breast heterogeneity.  
7.3.3 Relating Multiple ABUS Views into Singular 3D Volume 
 As mentioned in Chapter 6, one limitation to the deformable mapping algorithm is the fact 
that the DBT volume can only be registered to the AP ABUS projection. For women with larger 
breasts, the AP ABUS view may not acquire complete coverage for the breast when imaged. In 
these cases, creating a singular 3D ABUS volume based on all the views would be helpful. The 
use of FEMs could be used to apply deformation to the views based on the nipple location and 
relating the external fiducial markers to one another. There would need to be a correction for the 
medial and lateral views since the transducer is angled and positioned in a different orientation. 
We believe the use of the ABUS camisole can help reduce the amount of correction due to these 
effects by restricting breast motion.  
 Modeling the different views to create a solitary image volume could be simulated in FEA 
by modeling plate compression or by applying nodal displacements based on the nipple and/or 
marker locations. Additionally, if a lesion or other internal breast structures are seen between 
views this could provide an additional landmark in order to stitch views into one image volume. 
This is advantageous as the markers are only located at the breast surface and depth information 
can better relate internal breast structures.  
7.3.4 Deformable Registration to relate corresponding lesions from ABUS to DBT 
 As mention in Chapter 6, a limitation to the deformable registration algorithm described 
here is that it relates from DBT to ABUS and not ABUS to DBT. This can be especially limiting 
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for women with dense breasts. For dense breast cases where additional lesions are found in 
ABUS, the ability to map to a ROI within the original DBT location could be helpful to improve 
lesion characterization. The main reason this was not done is because ultrasound imaging can 
provide many artifacts and acoustic shadowing which makes it difficult to segment dense breast 
structures. Additionally, the breast surface is not as well defined as in DBT imaging and 
ultrasound has increased false positive findings13,14,165. There are also limited publications in 
automated segmentation methods to segment the dense breast structures from 3D ultrasound 
systems. Complete breast segmentation of the ABUS volume is essential for FEA to perform on 
the ABUS model for registration to DBT. Improvements in ABUS segmentation could allow for 
this technique to be implemented for ABUS to DBT registration.  
 Likewise, 3D ultrasound CT ultrasound systems (e.g. Delphinus Medical Systems) like bCT 
also acquire breast images in the prone geometry (unlike the ABUS supine geometry). Acquiring 
ultrasound images in the pendant configuration can allow for direct 3D models to be created 
using FEM of the breast in an uncompressed state. Therefore, the deformable registration method 
described in Chapter 5 could be implemented to use FEM to simulate plate compression on the 
uncompressed 3D ultrasound CT model to register with a reference DBT volume; thus, directly 
correlating and characterizing a lesion from ultrasound CT to DBT. This would be beneficial as 
ultrasound can decipher between solid and cystic lesions and that these determine and display 
ultrasound attenuation and ultrasound speed of sound images in addition to ultrasound B-mode 
reflection images. The disadvantage of this technique is the markers used within this study 
cannot be used since the adhesive used to attach the markers to the breast is not waterproof. 
Additional work would need to be completed to find an acceptable marker to be used between 
the two image sets if external markers would like to be analyzed for improved registration. 
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7.4 Final Thoughts  
 This dissertation presents validated methodologies to investigate the accuracy and 
performance of a novel deformable registration technique to relate corresponding lesions 
between 3D (DBT and bCT) x-ray and 3D ultrasound images. The methods described can save a 
radiologist time in navigating 3D volumes and provide higher confidence in relating the 
corresponding masses between the image sets. Implementation of this methodology could 
improve a radiologist’s characterizations of breast lesions, reduce negative biopsies, reduce 
patient callbacks and could be a useful tool for the early detection of breast cancers based on the 
direct localization of corresponding lesions between 3D x-ray and 3D ultrasound breast images.
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Appendix 
 
Clinical Protocol for ABUS Camisole Evaluation Study 
1. Research assistant will setup ABUS Machine in designated area. Research assistant will 
input the anonymized patient identification information into Invenia workstation. This 
includes putting a new ABUS mesh panel on ABUS transducer.  
2. The study coordinator, will consent the patient with the specified forms 
3. Research assistant will fit the patient for their camisole based on taking a band measurement 
(under the breast). Patient will try on camisole to ensure fit  
4. Research assist will denote fiducial marker areas on the patient’s breast with a magic marker 
attach the external markers at those locations.  
5. Ultrasound technologist will position patient and ensure that the ultrasound camisole is 
placed over the breast with the external markers underneath the camisole.  
6. Ultrasound technologist will place ultrasound lotion over the camisole. Performs the first 
anterior to posterior, AP, scan for the left breast. If needed a second scan of the lateral 
margins of the breast will be performed. If needed a third scan of the medial portions of the 
breast will be performed. Additional scans can be added to ensure complete coverage.  
7. Repeats Step 6 for the right side of the breast.  
8. Research assistant or Ultrasound technologist helps patients remove excess gel/lotion and 
markers from breast with alcoholic wipes. 
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9. Research assistant will dispose of the used Invenia mesh panel, camisoles, and external 
markers from patient  
10. Research assistant will save patient images on USB drive on Invenia, breakdown Invenia 
device, and perform any other cleaning involved with the room used for ABUS images.  
11. Patient redresses and signs form for gift card for participation in research study.  
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Procedures for Developing External Fiducial Markers 
1. Spread glass beads across a baking mini-cupcake baking sheet.  
2. Place 2-4 glass beads in each baking compartment. (Note: Use sufficient spacing between 
each glass bead as they will need to be cut into separate squares for each marker) 
3. Place the thermoplastic elastomer clear gel over glass beads in each baking compartment.  
4. Cover the top of the baking sheet in aluminum foil. (Note: Do not fold over the sides so 
that air bubbles can escape) 
5. Place in vacuum oven and heat to 130º C. (Note: Do NOT Preheat oven and then add 
sample tray. TPE must heat with oven to avoid voids within material.) 
6. Once oven reaches set temperature point turn on vacuum to reduce oven pressure to 1.5-2 
inHg. 
7. Close vacuum once pressure point is reached. Allow to sit at set temperature and pressure 
point for one hour.  
8. Turn off the oven temperature to allow it too cool down back to room temperature (Do 
Not release vacuum) this takes several hours to cool.  
9. Release vacuum and take out samples.  
10. Cut samples into square pieces with the glass bead as the center point.  
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Clinical Protocol for Proof-of Concept Study 
1. ABUS Machine setup in Ultrasound Imaging Room. She will input the anonymized 
Patient identification information into Invenia workstation. This includes putting a 
new ABUS mesh panel on ABUS transducer.  
2. Patient consented by study coordinator, or research assistant, and will verify which 
breast is being biopsied (right or left).  
3. Research assistant will fit the patient for their camisole based on taking a band 
measurement (under the breast). Patient will try on camisole to ensure fit. The 
camisole will not be used for x-ray imaging.  
4. Research assistant will use a washable magic marker to designate areas on the breast. 
Research assistant will attach the external fiducial markers to the breast at those 
locations using a commercial body adhesive. And place Tomospot sticker over each 
marker.  
5. Patient volunteer will be given a gown/robe and will be escorted to mammography 
room to prepare for the DBT examination.  
6. Research assistant will give mammography technologist the anonymized information 
for Patient study to input into the DBT machine.   
7. Mammography technologist will image the patients’ breast with DBT in the CC view 
and DBT in the MLO view. If attached markers come off during imaging they will be 
reattached before next image phase is performed.  
8. Patient will robe and be escorted to the ABUS imaging room (Research room). 
External fiducial markers will remain attached to the breast. 
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9. Patient will put on the ultrasound camisole above her breasts while sitting up on the 
bed. The patient will then lay down and with assistance of the research assistant or the 
ultrasound technologist for the camisole to be lowered across the breast for ABUS 
imaging.  
10. Ultrasound technologist will place ultrasound lotion over the camisole. The 
technologist will perform the first anterior to posterior, AP, scan of the indicated 
breast. A second scan of the lateral margins of the breast will be performed adding 
lotion if needed. Next, a third scan of the medial margins of the breast will be 
performed with added lotion if needed. Additional scans can be added to ensure 
complete coverage.  
11. Research assistant will cut the camisole off the patient from behind. Research 
assistant or Ultrasound technologist will help patient remove excess gel/lotion and 
markers from breast with towels. The patient will wash her breast to remove the 
magic marker ink. 
12. Research assistant will dispose of the used Invenia mesh panel, camisoles, and 
external markers from patient.  
13. Research assistant will save patient’s ultrasound images on an USB drive on the 
Invenia, shut down Invenia device, and perform any other cleaning involved with the 
room used for ABUS images.  
14. Patient dresses and signs form for gift card for participation in research study. 
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Parameters used for MiViewer Program  
 Table A.1 shows the parameter settings used for Lesion segmentation using the MiViewer 
program. It was found that two combination of parameters were most helpful in using the 
software, shown for Run 1 and Run 2 in Table A.1. For use of this software please contact the 
University of Michigan CAD laboratoryy.  
Table A.2:  Parameter setting used to Run MiViewer program on DBT and ABUS images 
 Run 1 Run 2 
Blur Kernel 0.2 0.2 
Diffusion Conductance 2 2 
Diffusion Timesteps 8 8 
Sample Width 3 3 
Ellipse Radius 0.8 1 
Sample Radius -1 -1 
Level-Set 1 Timesteps 150 150 
Level-Set 2 Timesteps 4 4 
Level-Set 3 Timesteps 10 10 
Level-Set 4 Timesteps 5 5 
Main Propagation Scaling 0.9 1.2 
Main Advection Scaling 4 4 
2D Propagation Scaling 0.9 1.2 
2D Advection Scaling 4 4 
2D Time-Steps 20 25 
curvscale -1 -1 
Zblur1 0.2 0.2 
timestep 0.045 0.045 
gradchopoff 1200 1200 
gradblursigma 0 0 
holerad1 2 2 
holerad2 2 2 
gradchop 0.5 0.5 
gaussianthresh 0.7 0.7 
priorsigma 4.5 4.5 
printseg 1 1 
printgrad 0 0 
 
                                                 
y https://medicine.umich.edu/dept/radiology/research/basic-radiological-sciences-brs/cad-research-laboratory  
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HyperMesh Scripting Optimization 
 
 Tcl/Tk scripting is used in order to create input files to run HyperMesh commands by a 
command prompt. Using HyperMesh the input files are generated to run for the specific FEA 
problem. For more information, on these built in commands for HyperMesh please see the 
following scripting documentationz as this entire process was automated using a MATLAB 
script. The script is used to build the models and export the 3D parameters to be analyzed to 
compute things such as the center of mass (COM) based on the nodal information. Additionally, 
information on how to use HyperMesh to generate the input files needed for FEA for Optistruct 
and ABAQUS can be found in the HyperMesh Solver Interfaces documentationaa.  
 Each segmentation should be housed in its own folder within the parent directory in order 
for the base FEM model file to be generated. An example of these directories are shown in 
Figure A.1. The original DICOM images should be in a separate folder within that directory (in 
Figure A.1 that folder is denoted as “Base_DCM”). Folder ‘1’ indicates the folder that contains 
the DICOM segmentation files for the lesion. If multiple lesions are used each lesion is separated 
(e.g. Folder “2” and Folder ‘3’). Mk1, Mk2, Mk3 etc. folders show the separate marker DICOM 
files. Folders for the segmented fat, glandular tissue, skin should also be housed as a separate 
folder in the directory.    
                                                 
z 
https://altairhyperworks.com/hwhelp/Altair/2017/help/hm_ref_guide/topics/chapter_heads/commands_and_function
s_scripts_r.htm  
aa https://altairhyperworks.com/hwhelp/Altair/2017/help/hm/hmbat.htm?HyperMesh_solver_interfaces_tutorials.htm  
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Figure A.1: Example of parent directory that houses all segmentation folders and base DICOM folder for base FE 
model generation 
 The Morfeus software is run on the segmented DICOM data to produce a resulting STL file. 
Therefore, all folders containing segmented data will have a Morfeus generated STL file. The 
STL file is the 3D object surface mesh based on the segmented DICOM information. These STL 
files are read into the HyperMesh program in order to mesh the base model. Base model 
generation can be described in the following pseudo-code for creating a BASE DBT file using 
HyperMesh shown in Figure A.2. The base templates contains the necessary components 
identifies and material properties for the run.  
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Figure A.2: Pseudo-code describing base FE model generation used within the deformable mapping algorithm 
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GUI Interface for relating corresponding lesions 
 A graphical user interface, GUI, was developed in order for a radiologist to view 
corresponding masses based on the deformable mapping registration results. The interface uses 
the slice information from the segmented DICOM files between modalities to determine lesion 
locations in the original DICOM images. It then takes the deformable mapping results to know 
which lesions are matched to the corresponding modality lesion. A user can pick from a drop 
down menu the Lesion ID number and the GUI will automatically change to the corresponding 
image slices for DBT and ABUS imaging.  
 First a user needs to indicate the specific parent folders that houses the base directory 
through a menu for each modality as shown in Figure A.3 for DBT and ABUS. 
 
Figure A.3: Selection Menu for GUI interface 
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 Additionally, the lateral (LAT) and medial (MED) ABUS views can also be shown. 
However, the deformable mapping program only registers to the ABUS AP view. Therefore, 
lesions will not be located to the LAT and MED views but can still be viewed as supplemental 
information. The resulting MATLAB file from the deformable mapping program will contain the 
folder information needed for the GUI to know which lesion segmentation folders to look in. 
This file also contains the dCOM values based off the algorithm results.  
 If only one mass was seen in corresponding views the User must select Lesion ID 1. Once 
the Lesion is displayed from the drop down menu the corresponding results can be viewed as 
shown in Figure A.4. A red cross hair will be shown on the middle slice for the corresponding 
lesions between views. 
 
Figure A.4 GUI Viewer results for a corresponding mass between the DBT (CC view) and ABUS view indicated by 
the red cross hair. 
The image window/level settings can be manually adjusted for the DBT and ABUS image views.  
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DBT/ABUS Study Radiologist Form 
Patient 
ID___________________________________________Date_____________________________ 
Radiologist Initials _________________ 
  Yes  No  Additional Comments  
DBT Image Quality 
Do the external fiducial markers 
affect the quality of DBT images?  
   
Can the lesion be clearly 
identified and is it sufficiently 
segmented? 
   
Are there any additional findings 
from the DBT images? 
   
ABUS Image Quality  
Do the external fiducial markers 
affect the quality of the ABUS 
images? 
   
Does the breast camisole affect 
the quality of the ABUS images? 
   
Can the lesion be clearly 
identified and is it sufficiently 
segmented? 
   
Are there any additional findings 
from the ABUS images? 
   
Comment on the image quality of 
the ABUS images in comparison 
to conventional ultrasound. 
 
Deformable Registration Algorithm         dCOM-CC=                                             dCOM-MLO= 
Does the algorithm correctly 
identify the corresponding lesion 
in the two modalities? 
   
Does the algorithm aid in lesion 
characterization between DBT 
and ABUS images? 
   
 
1) Do you have any recommendations for improving the display of the corresponding lesions in 
the ABUS and DBT images?    
 
2) Is the distance between the corresponding lesions sufficient? 
 
 
3) Do you have any suggestions for improving the interface for scrolling through the 
corresponding DBT and ABUS images? 
Additional Comments: 
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ABUS Camisole Form  
Patient ID___________________________________________ 
Date________________________________________________ 
Ultrasound Technologist/ Observer Initials _________________ 
 
  Yes  No  Additional Comments  
Were all external markers glued 
to breast before ABUS imaging?  
   
Did the glued external markers 
move when ultrasound gel/lotion 
is added over breast?  
   
Did the glued external markers 
move when patient puts on ABUS 
camisole? 
   
Was the camisole fitted to the 
breast? 
   
Does the camisole help restrict 
breast motion in comparison to if 
no camisole were not used? 
   
Do the external markers remain in 
the same position in between 
ABUS scans? 
   
Did the external fiducial markers 
have to repositioned at any time 
during ABUS exam  
   
Once breast camisole is removed 
were the external markers still in 
place? 
   
 
Additional Comments:  
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